



Duxin Sun, Ph.D.

Associate Dean for Research, College of Pharmacy
Charles R. Walgreen, Jr. Professor of Pharmacy and
Professor of Pharmaceutical Sciences

Department of Pharmaceutical Sciences
University of Michigan College of Pharmacy
North Campus Research Complex Building 520
1600 Huron Parkway, Ann Arbor, MI 48109
Tel: 734-615-8740 (Office); 734-615-8851 (Lab)
Email: duxins@umich.edu
<https://pharmacy.umich.edu/sun-lab>

Short Bios

Dr. Duxin Sun is the Associate Dean for Research, the Charles Walgreen Jr. Professor of Pharmacy and Pharmaceutical Sciences in the College of Pharmacy at the University of Michigan. He serves as the Director of the Pharmacokinetics (PK) Core. Dr. Sun also has a joint appointment in the Chemical Biology program, the Interdisciplinary Medicinal Chemistry program, and University of Michigan's Comprehensive Cancer Center.

Dr. Sun's research interests focus on drug development, cancer nanomedicine, cancer vaccine, and pharmacokinetics. Dr. Sun established the STAR system (Structure-Tissue/Cell Selectivity-Activity-Relationship) to enhance drug development success by addressing the 90% failure rate. He designed albumin based nanomedicines to enhance clinical efficacy of immuno-oncology drugs by targeting immune cells in the lymphatic system and tumors. He also developed SARS-CoV-2 B epitope-guided neoantigen peptide or mRNA cancer vaccine to enhance their anticancer efficacy by activating CD4/CD8 T cell immunity through B cell-mediated antigen presentation.

Dr. Sun earned his BS in Pharmacy, MS in Pharmacology, and PhD in Pharmaceutical Sciences, and has also received training in Molecular Biology as a visiting scientist. With research experience in both academia and the pharmaceutical industry, Dr. Sun has published over 280 papers, and has mentored 40 PhD students and 75 postdoctoral fellows/visiting scientists. Dr. Sun is an elected Fellow of both the American Association for the Advancement of Science (AAAS) and the American Association of Pharmaceutical Scientists (AAPS). He has served on the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee and participated in study sections for the NIH and FDA.

Education

- 1998-2002 Ph.D. in Pharmaceutical Sciences
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan
- 1994-1998 Visiting Scholar in Molecular Pharmacology
Department of Pharmacology, University of Pennsylvania (Philadelphia, PA) and Vanderbilt University (Nashville, TN)
- 1989-1992 Master of Pharmacology
School of Pharmacy, Second Military Medical University, Shanghai, China
- 1982-1986 Bachelor of Pharmacy
School of Pharmacy, Second Military Medical University, Shanghai, China

Appointments

- 2022- Associate Dean for Research, College of Pharmacy
- 2021- Charles R. Walgreen, Jr. Professor of Pharmacy

- 2017-2021 Department of Pharmaceutical Sciences, College of Pharmacy, The University of Michigan, Ann Arbor, MI 48109
J.G. Searle Endowed Professor
Department of Pharmaceutical Sciences, College of Pharmacy, The University of Michigan, Ann Arbor, MI 48109
- 2014-2017 William I. Higuchi Collegiate Professor
Department of Pharmaceutical Sciences, College of Pharmacy, The University of Michigan, Ann Arbor, MI 48109
- 2013- Professor
Department of Pharmaceutical Sciences, College of Pharmacy, The University of Michigan, Ann Arbor, MI 48109
Director of Pharmacokinetics Core, College of Pharmacy and Comprehensive Cancer Center, University of Michigan
Member, Interdepartmental Program in Medicinal Chemistry, College of Pharmacy, University of Michigan
Member, Comprehensive Cancer Center, University of Michigan Medical School
Member, Chemical Biology Program, University of Michigan
- 2008-2013 Associate Professor
Department of Pharmaceutical Sciences, College of Pharmacy, The University of Michigan, Ann Arbor, MI 48109
Member, Interdepartmental Program in Medicinal Chemistry, College of Pharmacy
Member, Comprehensive Cancer Center, University of Michigan Medical School
Member, Chemical Biology Program, University of Michigan
- 2003-2008 Assistant Professor
Div of Pharmaceutics, College of Pharmacy, Ohio State Univ. Columbus, OH 43210
Member, Comprehensive Cancer Center of The Ohio State University
Member, The Ohio State Biochemistry Program (OSBP), Ohio State University
Member, Molecular, Cellular, and Development Biology Program, Ohio State University
- 2002-2003 Research Investigator II
Bristol-Myers Squibb Company, One Squibb Drive, New Brunswick, NJ 08903
- 1994-1998 Senior Research Specialist and Visiting Scholar
Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104;
and Vanderbilt University, Nashville, TN 37232 (Same lab in two different universities due to PI's lab move)
- 1990-1994 Lecturer of Pharmacology
School of Pharmacy, Second Military Medical University, 101 Guo He Road, Shanghai 200433, China
- 1986-1990 Teaching Assistant of Pharmacology
School of Pharmacy, Second Military Medical University, 101 Guo He Road, Shanghai 200433, China

Current Research Programs - Drug Discovery, Cancer NanoMedicine, Cancer Vaccine, and Pharmacokinetics

1. Why 90% of drug development fails and how to improve it?

This project aims to enhance drug development success and efficiency through the STAR-guided drug design system (structure-tissue/cell selectivity-activity-relationship) for immunotherapy of cancer and autoimmune disease.

2. Why most anticancer nanomedicines do not enhance clinical efficacy and how to improve it?

This project develops albumin based anticancer nanomedicines to enhance clinical efficacy of immuno-oncology drugs by targeting immune cells in the lymphatic system and tumors for cancer immunotherapy.

3. How to improve anticancer efficacy of neoantigen mRNA or peptide cancer vaccines?

This project develops SARS-CoV-2 B epitope-guided neoantigen peptide or mRNA cancer vaccine to enhance their anticancer efficacy by activating CD4/CD8 T cell immunity through B cell-mediated antigen presentation.

4. What are the differences of microbiome, bile salts, and drug release in different regions of human GI tract?

This project investigates the differences of the microbiome, bile salts, and drug release among the human stomach, small intestine, and colon, as well as studies how these differences influence drug product development and disease states.

5. Pharmacokinetics Core

The pharmacokinetics and mass spectrometry (PKMS) core plays a pivotal role in advancing the drug discovery, clinical translation, and optimization of novel and existing therapeutics. The PKMS core supports: (1) quantitative LC-MS analysis of molecules and mass spectrometry imaging of spatial localization biomarkers in tissue section; (2) preclinical ADME and pharmacokinetics for lead compound optimization in drug discovery and development; (3) clinical pharmacokinetics and dosage regimen design for clinical trials. PKMS core has supported LC-MS analysis, pre-clinical ADME and PK of more than 7500 compounds; supported clinical pharmacokinetics of more than 55 compounds in clinical trials.

Current Grants

- | | |
|-----------|---|
| 2024-2029 | Development of chemical probe targeting NSD3 SET domain in breast cancer
NIH R01 CA285304, PI: Thomas Cierpicki, Co-I: Duxin Sun |
| 2024-2029 | Orally active CBP/p300 degraders
NIH R01 CA289013, PI: Shaomeng Wang, Co-I: Duxin Sun |
| 2024-2029 | Therapeutic Cancer NanoVaccine Promotes B/CD 4 T Cell Crosstalk for Durable Anticancer Efficacy
NIH R01 CA285790, Co-PI's: Duxin Sun, Wei Gao |
| 2024-2025 | Dual Functional Drug Overcomes STING Resistance by Eliminating Bregs for Long-term Efficacy in Pancreatic Cancer
U of M MTRAC Life Sciences, Co-PI's: Duxin Sun, Wei Gao |
| 2023-2028 | Targeting PRC1 in leukemia |

- NIH R01 CA282082, PI: Thomas Cierpick, Co-I: Duxin Sun
- 2023-2028 Small-molecule degraders of STAT5
NIH R01 CA282673, PI: Shaomeng Wang, Co-I: Duxin Sun
- 2023-2028 University of Michigan Rogel Cancer Center Support Grant
NIH P30 CA046592, PI: Eric Fearon, Co-I: Duxin Sun
- 2023-2024 Harnessing Gene Repression for New Targeted Drugs in Hematological Malignancies
UM Frankel Innovation Initiative, PI: Thomas Cierpicki, Co-I: Duxin Sun
- 2023-2028 Targeting Menin in Acute Leukemia with Upregulated HOX Genes
NIH R01 CA272561-01A1, PI: Jolanta Grembecka, Co-I: Duxin Sun
- 2022-2024 PARTNERSHIP: Developing a Dietary Approach in the Management of Inflammatory
Bowel Disease
USDA 2022-67017-36303, PI: Grace Chen, Co-I: Duxin Sun
- 2022-2026 The Microbiome and Aging in Clostridioides Difficile
NIH R01 AI162787-01-A1, PI: Vincent Young, Raymond Yung, Co-I: Duxin Sun
- 2022-2027 Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer
NIH R01 CA266513, PI: Nouri Neamati, Co-I: Duxin Sun
- 2022-2027 Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of
Pancreatic Cancer
NIH R01 CA272641-01, PI: Nouri Neamati, Co-I: Duxin Sun
- 2020-2025 Setting Patient-Centric Quality Standards (PCQS) for Modified Release (MR) Oral Drug
Products with Biopredictive *In Vitro* Dissolution Models
FDA BAA-20-00123-A2, Co-PIs: Duxin Sun, Amit Pai
- 2020-2025 Virus-Like Nanoparticles for Non-Capsid Antigen Delivery with Virus Structure/Functional
Mimicry to Activate B Cell Immunity
NIH R01 AI154072. PI: Duxin Sun
- 2019-2024 Development of ASH1L inhibitors for acute leukemia
NIH R01 CA244254, PI: Jolanta Grembecka, Co-I: Duxin Sun
- 2019-2024 Small-molecule STAT3 degraders
NIH R01 CA244509, PI: Shaomeng Wang, Co-I: Duxin Sun

Finished Grants

- 2019-2023 Hit-to-lead optimization for heart failure drug discovery
NIH R01 HL-148068-01, PI: Lennane Michel Espinoza-Fonseca, Co-I: Duxin Sun
- 2018-2023 Targeting NSD1 in leukemia

- NIH R01 CA-226759-01-A1, PI: Tomasz Cierpicki, Co-I: Duxin Sun
- 2020-2023 Tissue localization of Cyclosporine and related metabolite in CD-1 mouse models
Aurinia Pharmaceuticals Inc., PI: Duxin Sun
- 2021-2023 Development of Protein Degradors
Oncopia Therapeutics, Inc, co-I: Duxin Sun
- 2018-2023 Inhibiting Bcl-2 intestinal regulated intestinal fibrosis
NIH R01 DK-118154-01, PI: Peter Higgins, Co-I: Duxin Sun
- 2018-2023 University of Michigan Comprehensive Cancer Center support grant
NIH P30 CA-046592-29 PI: Eric Feiron, Co-I: Duxin Sun (PK SR Director)
- 2019-2023 New Strategy to Identify, Validate, and Eliminate Heterogeneity for Personalized Cancer
Therapy
Joint Institute UM/Peking Initiative J1 (UM-PKUHS), Co-PI: Duxin Sun, Ning Zhang,
Joseph Burnett
- 2018-2023 Development of a dual and selective small molecule inhibitor of EGFR and PI3 Kinase to
treat BRAF mutant colorectal cancer
NIH R01 CA-220199-01-A1, PI: Judith Leopold, Co-I: Duxin Sun
- 2018-2023 Develop a therapeutic nano-vaccine against head and neck cancer
NIH R01 DE-026728-01-A1, PI: Yu Lei, Co-I: Duxin Sun
- 2017-2022 Small-molecule MDM2 degraders
NIH R01 CA-219345, PI: Shaomeng Wang, Co-I: Duxin Sun
- 2018-2023 Targeting the menin-MLL complex for new therapeutics
NIH R01 CA-208267-01-A1, PI: Shaomeng Wang, Co-I: Duxin Sun
- 2019-2023 Development of first-in-class ST2 inhibitors for treating graft-versus-host disease
NIH 7R01 HL-141432-02, PI: Chao-Yie Yang, Co-I: Duxin Sun
- 2017-2022 Novel Mcl-1 inhibitors for overcoming therapeutic resistance in colorectal cancer
NIH R01 CA-217141, PI: Zaneta Nikolovska-Coleska, Co-I: Duxin Sun
- 2017-2022 Sputum microbial markers of type 2-low asthma
NIH R01 AI129958, PI: Yvonne Huang, Co-I: Duxin Sun
- 2017-2022 Development of novel anti-leukemia agents targeting the menin-MLL interaction
NIH R01 CA-160467-06, PI: Jolanta Grembecka, Co-I: Duxin Sun
- 2017-2022 Small-molecule degraders of BET proteins
NIH R01 CA-215758-01, PI: Shaomeng Wang, Co-I: Duxin Sun
- 2016-2021 Targeting the MLL complex in Castration Resistant Prostate Cancer
NIH R01 CA-200660-01-A1, PI: Jolanta Grembecka, Arul Chinnaiyan, Co-I: Duxin Sun

- 2019-2021 Nanoformulations of anticancer drugs to eliminate cancer stem cells
NanoMedicine Innovation Center LLC, PI: Duxin Sun
- 2019-2021 Drug Optimization altering tissue targeting to improve efficacy/safety
NanoMedicine Innovation Center LLC, PI: Duxin Sun
- 2018-2020 Precision guidance of germline B cells ex vivo for protective long-term immunity
University of Michigan MCubed fund, PI: Wei Cheng Co-I: Duxin Sun, Irina Grigorova
- 2015-2020 ROS-targeted therapy for pancreatic cancer
NIH R01-CA-188252-01-A1, PI: Nouri Neamati, Co-I: Duxin Sun
- 2015-2020 Efficacy of PDI inhibitors in glioblastoma
NIH R01 CA193690-01, PI: Nouri Neamati, Co-I: Duxin Sun
- 2015-2020 Wireless Pharmaceutical Analysis Device (WPAD) and computational model to determine *in vivo* drug dissolution in GI tract for distinguishing meaningful product differences and ensuring bioequivalence (BE)
FDA HHSF223201510146C, PI: Duxin Sun
- 2015-2020 Mechanisms of Mycobacterium tuberculosis pH-driven adaptation
NIH R01 AI116605, PI: Robert Abramovitch, Consultant: Duxin Sun
- 2019-2020 Enhancing CD8+ T-Cell Activation via Bispecific liposomes to Deliver PD-L1 mAb to TDLNs
UM Office of Research (UMOR), PI: Hongwei Chen, Co-I: Duxin Sun
- 2014-2019 SPORE in prostate cancer
NIH 1P50CA186786-01, PI: Arul Chinnaiyan, Co-I: Duxin Sun
- 2017-2020 Isozyme-selective ALDH inhibitors for sensitizing ovarian cancer stem-like cells to chemotherapy
NIH R01 CA-214567-01, PI: Scott Larsen, Co-I: Duxin Sun
- 2016-2019 Tissue distribution and pharmacokinetics of tyrosine kinase inhibitors (TKI)
Celgene Corporation, PI: Duxin Sun
- 2014-2019 Randomized controlled trial to improve oncology nurses' protective equipment use
CDC R01 OH010582-01, PI: Christopher Friese, Co-I Duxin Sun
- 2014-2018 Enhanced Oral Delivery of Low Solubility Drugs Using Cocrystal Design
NIH R01 GM107146-01-A1, PI: Nair Rodriguez-Hornedo, Co-I: Duxin Sun
- 2016-2018 Development of small-molecule degraders of BET proteins for triple-negative breast cancer. The Breast Cancer Research Foundation, PI: Shaomeng Wang, Co-I: Duxin Sun
- 2015-2018 The development of small molecule inhibitors for Gaucher Disease Type 3
NIH UH2-NS-092981-01, UH3-NS-092981-02, PI: James Shayman, Co-I: Duxin Sun

- 2012-2018 University of Michigan Comprehensive Cancer Center support grant.
NIH 2P30CA046592-24, PI: Eric Fearon, Co-I: Duxin Sun (PK Core director)
- 2013-2018 Targeted elimination of cancer stem cells for AML therapy
NIH R01 CA171972-01A1, PI: Yang Liu, Co-I: Duxin Sun
- 2017-2018 Development of small magnetic nanoparticles for cell isolation and DNA detection
IMRA America, Inc., PI: Hongwei Chen, Co-PI: Duxin Sun
- 2014-2018 Inhibition of the Rho/MRTF/SRF pathway as a new treatment for systemic sclerosis
NIH R01 AR066049, PI: Scott D Larsen, Co-I: Duxin Sun
- 2013-2018 Targeting the MLL-WDR5 protein-protein interaction
NIH R01 CA177307-01, PI: Shaomeng Wang, Yali Dou; Co-I: Duxin Sun
- 2014-2018 Discovering Novel Atypical PKC Inhibitors as in vivo Chemical Probes
NIH R01 EY023725, PI: David Antonetti, Co-I: Duxin Sun
- 2016-2017 Pharmacokinetics and tissue distribution of Abraxane
Celgene Corporation, PI: Duxin Sun
- 2015-2017 Drug tumor distribution impacts efficacy of tamoxifen analogs
Celgene Corporation, PI: Duxin Sun
- 2013-2017 Modernization of *in vivo-in vitro* oral bioperformance prediction and assessment
FDA HHSF223201310164C, Co-PI: Gordon Amidon, Co-PI: Duxin Sun
- 2014-2017 Targeting host deubiquitinases for broad spectrum anti-infective therapy
NIH R21/R33 AI102106-03, PI: Mary O’Riordan, Co-I: Duxin Sun
- 2016-2017 Mechanisms of epigenetic regulation of transcription – new targets for cancer
therapeutics. University of Michigan MCubed fund
PIs: Duxin Sun, Shaomeng Wang, Thomas Kerppola
- 2016-2016 Altered elimination and metabolism of Abraxane in comparison with taxol in FcRn
knockout and wild type mice
Celgene Corporation, PI: Duxin Sun
- 2012-2018 Mechanisms of motor neuron toxicity in Kennedy disease
NIH R01 NS055746-06A1, PI: Andrew Lieberman, Co-I: Duxin Sun
- 2015-2017 Menin-MLL Inhibitor Program
Kura Oncology, PI: Jolanta Grembecka, Co-I: Duxin Sun
- 2011-2017 Development of novel anti-leukemia agents targeting the menin-MLL interaction
NIH R01 CA160467-01. PI: Jolanta Grembecka, Co-I: Duxin Sun
- 2016-2016 Development of polymer-coated magnetic nanoparticles for in vitro diagnostics

IMRA America, Inc., PI: Hongwei Chen, Co-PI: Duxin Sun

- 2014-2016 Define and optimize tumor targeting properties to predict preclinical and clinical efficacy of anti-cancer agents
Celgene Corporation, PI: Duxin Sun
- 2013-2016 Investigation of Release Profiles of Bupropion and Pharmacogenomics of Metabolism Enzymes for Bioequivalence of Generic Bupropion Products in Healthy Volunteers
FDA HHSF223201310144C, PI: Duxin Sun
- 2013-2016 Novel Probes for Studying Treatment of CNS-based Lysosomal Storage Diseases
NIH R01 HD076004-01, PI: Scott D Larsen, Co-I: Duxin Sun
- 2012-2016 Potent and Highly Selective D3 Ligands for the Treatment of Cocaine Abuse.
NIH R01 DA032943. PI: Shaomeng Wang. Co-I: Duxin Sun
- 2014-2015 Pharmacokinetics and tumor distribution of different liposomal doxorubicin formulations
Celgene Corporation, PI: Duxin Sun
- 2010-2015 Correlation of mesalamine pharmacokinetics with local availability
FDA HHSF223201000082C, HHSF223201300460A, PI: Duxin Sun
- 2013-2015 Investigation of inequivalence of bupropion hydrochloride extended-release tablets: *In vitro* metabolism quantification
FDA HHSF223201310183C, PI: Duxin Sun
- 2014-2015 BET Bromodomain Inhibitors
Oncofusion Therapeutics, 145038, PI: Shaomeng Wang, Co-I: Duxin Sun
- 2012-2014 In vivo proof of efficacy studies for a novel glucosylceramide synthase inhibitor with central nervous system activity
NIH R21 NS079633-01, PI: James Shayman, Co-I: Duxin Sun
- 2010-2015 Menin-MLL Fusion Inhibitor Program
Lymphoma and Leukemia Society. UM347450 /N013134-03. PI: Jolanta Grembecka. Co-I: Duxin Sun
- 2011-2015 Receptor Na/K-ATPase antagonists as novel therapeutics for renal/cardiac diseases
NIH R01 HL109015-01. PI: ZiJian Xie. Co-I: Duxin Sun
- 2013-2014 Drug Discovery to block protein-protein interactions for cancer therapy
University of Michigan MCubed fund, PIs: Duxin Sun, Shaomeng Wang, Yali Dou.
- 2012-2014 Targeting breast cancer stem cells through combined PARP and Hsp90 inhibition
DOD W81XWH-12-1-0147. PI: Suling Liu, Co-I: Duxin Sun
- 2007-2013 An integrated system for both tumor imaging and targeted drug therapy of cancer
NIH R01 CA120023, PI: Duxin Sun.

- 2012-2013 DUB Inhibitors for Treatment of B-cell Malignancies
Lymphoma and Leukemia Society. PI: Nick Donato. Co-I: Duxin Sun
- 2012-2013 CDNM pilot funds for drug discovery (Pharmacokinetics support)
University of Michigan CDNM pilot funds. PI: Rick Neubig, Margaret Gnegy, Haoming Zhang. Co-I: Duxin Sun
- 2011-2013 Characterization, conjugation, and application of laser-generated gold nanoparticles for targeted drug delivery and tumor imaging.
IMRA America Inc. N014096, PI: Duxin Sun
- 2012-2012 Targeting PDGF signaling in traumatic brain Injury. MICHR Pilot RD9.
MICHR, PI: Dan Lawrence. Co-I: Duxin Sun
- 2009-2011 New molecular target and its inhibitors for use against pancreatic cancer
NIH R21 CA143474, PI: Duxin Sun
- 2010-2011 Chaperones and Small Molecules
NIH R01 NS059690-S1, Jason Gestwicki (PI), Duxin Sun (Co-I)
- 2009-2010 Novel inhibitors that disrupt the Hsp90-Cdc37 interaction for use against pancreatic cancer
UM Comprehensive Cancer Center Research Grant UM 314174, PI: Duxin Sun
- 2007-2008 Targeted delivery of microbubble encapsulated fluorophores for cancer imaging
Department of Defense (DOD) Concept Award BC062867, PI: Ronald Xu, Co-I: Duxin Sun
- 2006-2008 Chemical glycobiology of anthracyclines
NIH R01 CA118208, PI: PG Wang, Co-I: Duxin Sun
- 2007-2008 Electrical measurements of gold nanoparticles in biological tissue for cancer detection, Institute for Materials Research (IMR) Interdisciplinary Materials Research Grant of OSU PI: Joseph Heremans, Co-I: Duxin Sun.
- 2005-2007 Targeted prodrug delivery for cancer therapy
Ohio Cancer Research Associate (20020750), New Investigator Award, PI: D Sun
- 2006-2007 An integrated system for tumor detection and targeted drug therapy
American Cancer Society (ACS) Institutional Research Grant (Seed grant) #IRG-67-003-44, PI: Duxin Sun
- 2004-2006 Site-specific activation of geldanamycin prodrug to target Hsp90 in cancer therapy
PhRMA Foundation (20012144), Research Starter Grant for New Investigators, PI: Duxin Sun
- 2005-2006 In vitro cell systems and in vivo animal models to evaluate BA/BE and drug absorption for inhalation drug formulation

FDA HHSF223200530511P, PI: Duxin Sun

2004-2005 Effect of excipients on permeability of transporter substrates for BCS class III compounds
FDA D3921804, PI: Duxin Sun

2004-2005 Glucose transporters and targeted drug delivery for chemotherapeutic compounds in cancer therapy.
AACP New Investigator Program (NIP, 20020001), PI: Duxin Sun

2004-2005 Targeted Drug Delivery for cancer treatment
American Cancer Society (ACS) institutional grant (OSU Comprehensive Cancer Center Seed Grant), PI: Duxin Sun

Honors and Awards

2022 Fellow, American Association for the Advancement of Science (AAAS)
2014 Fellow, American Association of Pharmaceutical Scientists (AAPS)
2014 Marquis Who's Who in America (2015 Edition)
2004 2004 AAPS meritorious Manuscript Award
2003 Triumph Award for innovative formulation prototypes and screening to overcome pH-interaction *in vivo* of a weak base compound. Pharmaceutical Research Institute, Bristol-Myers Squibb Company.
2002 Highlight Poster Award in 29th International Symposium on Controlled Release of Bioactive Materials. July 20-25, 2002. Seoul, Korea
2002 Bristol-Myers Squibb on the Spot Award for establishment of canine absorption model for bioequivalence/bioavailability and formulation strategies studies in Biopharmaceutics R&D
2001 CRS Cygnus Graduate Student Award for outstanding work in drug delivery. 28th International Symposium on Controlled Release of Bioactive Materials. June 23-27, 2001. San Diego, CA
2001 Poster Award in XXXIII Annual Pharmaceutics Graduate Student Research Meeting (PGSRM), June 14-16, 2001. University of Wisconsin, Madison, Wisconsin
2001 AFPE Fellowship Award (American Foundation of Pharmaceutical Education)
2000 Fred Lyons Jr. Fellowship Award in the College of Pharmacy, University of Michigan
1999 Merck Fellowship Award in the College of Pharmacy, University of Michigan
1991 Young Investigator Outstanding Paper Award in the National Conference of Cardiovascular Pharmacology (first place)

Review for Grant Agencies and Other Invited Reviews

2024 NCI Clinical & Translational Cancer Research, SEP-3 (ZCA1SRB-8 (O1)), ad hoc member, NIH
2024 NCI Cancer Center Site Visit, 2024/05 NCI-A RTRB-G (K1), ad hoc member, NIH
2023 Workforce Diversity in Basic Cancer Research, Center for Scientific Review Special Emphasis Panel Center for Scientific Review (ZRG1BTC-M (55)), ad hoc member, NIH
2023 FDA/M-CERSI Physiologically Based Biopharmaceutics Modeling, PBBM Best Scientific Practices to Drive Drug Product Quality: Latest Regulatory and Industry Perspectives, ad hoc member

2023 NCI Cancer Center Site Visit, 2023/10 NCI-A RTRB-G (E1), ad hoc member, NIH
2022 NCI Cancer Center Study Section A, NCI-A RTRB-0 (R1), ad hoc member, NIH
2022 Ontario Research Fund, Ontario Canada, guest proposal reviewer
2022 UMB MS Regulatory Science Program, Graduate School & School of Pharmacy, University of Maryland, Baltimore, virtual program review
2021 NCI Cancer Center Study Section A, NCI-A RTRB-G (K1), ad hoc member, NIH
2021 Joint Institute for Translational and Clinical Research, JI RFP Review
2021 NCI WFBCCC, ad hoc member, NIH
2021 NCI Alliance for Nanotechnology in Cancer, Special Emphasis Panel (ZRG1IMST-M (55)), ad hoc member, NIH
2020 Cancer Nanotechnology Study Section (ZRG1IMST-M (55)), ad hoc member, NIH
2020 Gene and Drug Delivery Systems Study Section, ad hoc member, NIH
2020 NCI Oncology Sciences Fellowship (ZRG1 F09B-M (20) L), ad hoc member, NIH
2019 Joint Institute for Translational and Clinical Research Symposium
2019 NCI The Experimental Therapeutics Clinical Trials Network (ZCA1 RPRB-N (J1)), ad hoc member, NIH
2018 Cancer Biotherapeutics and Development (ZRG1 OTC-E (10)), ad hoc member NIH
2018 NCI Omnibus Review R03 and R21 (ZCA1 TCRB-V (J1)), ad hoc member, NIH
2018 NCI Cancer Biotherapeutics Development Study Section, ad hoc member, NIH
2018 NANO Review panel, ad hoc member, NIH
2017 NIBIB Career Development (K) and Conference (R13) Applications panel, ad hoc member, NIH
2016 Mentored Career Development Award (K) Applications panel, ad hoc member, NIH
2016 NCI Special Emphasis Panel R50 (ZCA1 SRB-V (A1)), ad hoc member, NIH/NCI
2016 NCI Omnibus Review R02 and R21 (ZCA1 SRB-V (J1)), ad hoc member, NIH/NCI
2015 NCI Omnibus Exploratory (R21) and Small Grants (R03) Program – Cancer Biology (ZCA1 SRB-V (J1)), ad hoc member, NIH/NCI
2015 Prevent ToxPharm (ZCA1 TCRB-U (C3) B), ad hoc member, NIH/NCI
2014 Cancer Biology 3 study section (NCI Omnibus R21, ZCA1 SRLB-V (M1)), ad hoc member, NIH/NCI
2013 Development therapeutics study section, ad hoc member, NIH/NCI
2013 Omnibus Exploratory (R21) and Small Grants (R03) Program – Drug Development and Delivery (ZCA1 SRLB-2 (01)), ad hoc member, NIH
2013 NCI Omnibus and Cancer Developmental Therapeutics (ZCA1 SRLB-X (M1)), ad hoc member, NIH
2012 Developmental Therapeutics/Omnibus Review Committee (ZCA1 SRLB-D(J1)), ad hoc member, NIH
2012 Gene and drug delivery study section, ad hoc member, NIH
2012 University of Michigan OVRP program, ad hoc member
2011 Development therapeutics study section, ad hoc member, NIH/NCI
2011 Ohio Cancer Research Associate, Member
2011 Cancer Therapeutics (Special Emphasis Panel, ZRG1 OTC-K (05)), ad hoc member
2011 Innovative Technology Development (ZCA1 SRLB-Q (M1)), ad hoc member, NIH
2010 Health and Technologies Research, Department of Innovation, Italian Ministry of Health, Member, grant review
2010 Preclinical pharmacokinetic and pharmacological studies (ZCA1 SRLB-V (C1)), member, NIH
2010 Gene and drug delivery study section, ad hoc member, NIH
2010 French National Research Agency (JCJC SVSE5), reviewer, France

- 2010 Development of anticancer agents (ZCA1 SELB-D (C1)), ad hoc member, NIH
2009 Ohio Cancer Research Associates, Member.
2009 Development of anticancer agents SBIR (topic 251), ad hoc member, NIH
2008 Cancer Research UK, external grant reviewer
2008 Multidisciplinary Research Grant (MRG) Program, North Carolina Biotechnology Center, Science & Technology Development Program
2008 Cancer Drug Development and Therapeutics SBIR/STTR Study Section ONC-X (14), ad hoc member, NIH
2008 Development of anticancer agents SBIR (topic 251, ZCA1 SRRB-D), ad hoc member, NIH
2008 FDA Office of Women's Health intramural scientific program, member, FDA
2007 Cancer Drug Development and Therapeutics SBIR/STTR Study Section, ad hoc member, NIH
2007 New Investigators Program for Pharmacy Faculty, AACP, member
2006 Xenobiotic and Nutrient Disposition and Action (XNDA) study section, ad hoc member, NIH
2006 FDA Office of Women's health intramural scientific program, member, FDA
2005 AIDS therapeutics study section, ad hoc member, NIH
2005 Cancer Drug Development and Therapeutics SBIR/STTR study section, ad hoc member, NIH
2004 National Cooperative Drug Discovery Groups for Cancer (NCDDG) study section, ad hoc member, NIH

Professional Affiliations

- 2024- American Chemical Society (ACS), member
2023- Asian American Scholar Forum, member
2020-2021 American Society of Clinical Oncology (ASCO), member
2014- American Association for the Advancement of Science (AAAS), fellow
2003- American Association of Cancer Research (AACR), member
2003- American Association of Colleges of Pharmacy (AACP), member
1998- American Association of Pharmaceutical Scientists (AAPS), member

Professional Association and Agency Service

- 2023-2024 Chair, Nomination/Leadership Subcommittee, Section S Steering Committee, AAAS
2016-2019 Member, Pharmaceutical Science and Clinical Pharmacology Advisory Committee, US Food and Drug Administration
2012-2012 Co-chairs, 47th Arden Conference, March 2012, West Point, New York, NY
2011-2011 Co-chairs, roundtable: Current technologies in protein and peptide delivery. Oct. 2011, AAPS Annual Meeting, Washington DC.
2011-2011 Co-chairs, sunrise session: miRNA and SiRNA delivery. Oct 2011, AAPS Annual Meeting, Washington DC.
2011-2011 Co-Chairs, workshop: Emerging Oral Delivery and Technologies to Enable Biopharmaceutical Performance of BCS II, III and IV Molecules. April 2011, Baltimore, MD
2010-2010 Co-Chairs of a round table, Can nanoparticle be simultaneously used for tumor imaging and targeted drug delivery, 2010 AAPS annual meeting, Nov 2010, New Orleans, LA
2011-2012 Chair, Physical Pharmacy and Biopharmaceutics (PPB) Section, AAPS

- 2009-2010 Chair-Elect, Physical Pharmacy and Biopharmaceutics (PPB) Section, AAPS
2009-2009 Vice President, Chinese American Pharmaceutical Association (ACPA)
2009-2009 Organizing committee for 45th Annual Pharmaceutical Technologies Arden
Conference Formulation Strategies for Poorly Soluble Drugs
2009-2009 AAPS Meritorious Manuscript Award selection committee
2009-2009 AAPS Annual meeting program committee for 2010
2009-2009 Co-chairs for two roundtables in 2009 AAPS annual meeting: (1) Latest
developments of drug targeting to cancer stem cells. (2) Tumor targeting using
nanotechnology-based drug delivery systems.
2009-2009 Co-chairs, AAPS Workshop on Evolving Science and Technology in Physical
Pharmacy and Biopharmaceutics, May 2009
2008-2008 Vice Chair, Physical Pharmacy and Biopharmaceutics (PPB) Section, AAPS
2008-2008 Program committee for five symposia in 2008 AAPS annual meeting: (1) Tumor
Imaging and Targeted Drug Delivery (sunrise session); (2) The World Within and
Beyond P-gp: Do we Underestimate or Overestimate P-gp (roundtable); (3) Prodrug
Approaches for Organ Specific Targeted Therapy (roundtable); (4) Rational Drug
and Prodrug Design Via Computational Modeling (sunrise session); (5)
Transporters as Prodrug Carriers for Oral Drug Delivery (roundtable)
2007-2008 Chair, Prodrug focus group, AAPS
2007-2007 Co-chairs, Tumor-activated prodrug and tumor-targeting technologies roundtable in
2007 AAPS annual meeting
2007-2007 Program committee, Prodrug approaches for site-specific cellular targets roundtable
in 2007 AAPS annual meeting
2007-2007 Program committee, BE, BCS and Beyond, AAPS workshop
2006-2007 Chair-elect, Prodrug focus group, AAPS
2005-2007 Prodrug focus group steering committee, AAPS
2003-2006 Sub-chair, AAPS annual meeting abstract review committee (PDD section)
2004-2004 Organizing committee, Advances in biopharmaceutics and oral delivery, University
of Michigan.
2003-2003 Co-chairs, Targeted Drug Delivery Symposium in 2003 AAPS Annual Meeting

Journal Editorial Board

AAPS Journal

AAPS Journal Guest Editors (Duxin Sun & Simon Zhou) for special issue: "Revisit Drug
Absorption and Elimination in Design and Evaluation of Oral Modified Release Drug
Products," November 2016.

Molecular Pharmaceutics, Advisory Board Member

Molecular Pharmaceutics, Guest Editor of theme issue: Nanotheranostics Theranostics

Acta Pharmaceutica Sinica B

University Committee Service

2008- University of Michigan

2023- Member, Advisory Group to the ARPA-H Initiative, University of Michigan

2023- Chair, Strategic Planning Concept Team – Research and Scholarship,
Pharmaceutical Sciences, College of Pharmacy

2023-2024 Member, Promotions Committee (Cheng), Pharmaceutical Science, College of
Pharmacy

2023- Chair, Website, Marketing, and PharmD/PhD Program, College of Pharmacy,

University of Michigan
2023- Member, Research Cores Office (RCO) Advisory Committee, University of Michigan
2023-2024 Member, Academic Leadership Program (ALP) in the Big Ten Experience, University of Michigan
2023- Chair, DATA Research Committee, Accelerating Impact through Partnerships Industry-University Cooperative Research Centers, University of Michigan
2023- Member, Research Administration Advisory Council (RAAC) Faculty Advisory Council, Office of Research and Sponsored Projects, University of Michigan.
2023-2024 Executive Director of Development Search Committee, College of Pharmacy
2023-2024 Member, Pharmaceutical Sciences Department Chair Search Committee, Pharmaceutical Science, College of Pharmacy
2023-2023 Member, Proposal of Medchem 741 Committee, College of Pharmacy
2023-2023 Member, Martin Clasby Faculty Launch Committee, Faculty Development Office, Michigan Medicine
2022- Dean of Record, Research Resources and Shared Equipment Committee, College of Pharmacy
2022- Chair, Search Committee (PK faculty), Pharmaceutical Science, College of Pharmacy
2022-2022 Member, Promotions Committee (Zhu), Pharmaceutical Science, College of Pharmacy
2022-2022 Member, Promotions Committee (Hertz), Pharmaceutical Science, College of Pharmacy
2022-2022 Member, Computational Faculty Search Committee, Department of Medicinal Chemistry, College of Pharmacy
2022- Dean of Record, Safety Committee, College of Pharmacy, University of Michigan
2022-2023 Member, Space Committee, College of Pharmacy, University of Michigan
2022- Member, Executive Committee, College of Pharmacy, University of Michigan
2022- Member, Administrative Operations Committee, College of Pharmacy, University of Michigan
2021-2022 Member, Dean Search Committee, College of Pharmacy
2020-2025 Member, NPDC/CCG Joint Advisory Committee, University of Michigan
2019-2021 President, Association of Chinese Professors (ACP)
2019-2022 PharmD Curriculum and Assessment, College of Pharmacy, University of Michigan
2019-2020 Chair, Strategic Planning Committee, College of Pharmacy, University of Michigan
2019- Member, Pharmacy Building Workshop for Shared Instrumentation Space, University of Michigan, College of Pharmacy
2019-2021 Member, Michigan Drug Discovery Core Directors, University of Michigan
2019-2020 Member, Predoctoral Fellowship Decision Committee, University of Michigan
2019- Member, Pharmacological Sciences Training Program (PSTP) Executive Committee, Dept of Pharmacology, UofM Medical School, Michigan Medicine
2017-2017 Member, U-M Faculty Grievance Panel
2016-2022 Member, Research Resources & Shared Equipment Committee, College of Pharmacy
2016-2018 Member, Graduate Recruitment and Admissions Committee, Department of Pharmaceutical Sciences, College of Pharmacy
2015-2016 Member, Graduate Education Committee, College of Pharmacy
2013-2014 Member, Dean Search Committee, College of Pharmacy
2012-2014 Member, Executive Committee, College of Pharmacy
2012-2019 Member, Core Leadership Team, Center for Discovery of New Medicines

- 2012-2016 Member, Faculty Search Committee, Department of Clinical, Social, and Administrative Sciences, College of Pharmacy
- 2012-2016 Member, Adjunct Faculty Appointments Committee, College of Pharmacy, Department of Pharmaceutical Sciences
- 2012-2016 Member, Strategic Planning and Leadership Committee, Department of Pharmaceutical Sciences
- 2011-2012 Member, Searle Professorship Search Committee, College of Pharmacy
- 2010-2011 Member, Operating Committee, Program in Chemical Biology
- 2009-2014 Member, Faculty Development Committee, College of Pharmacy
- 2009-2012 Member, Senate Assembly Representative
- 2009-2011 Member, Academic Standing Committee, College of Pharmacy

2003-2008 The Ohio State University

- 2003-2007 Member, Strategic Planning Committee, College of Pharmacy
- 2005-2008 Member, Pharm D. Program Committee, College of Pharmacy
- 2003-2005 Member, Bachelor of Science of Pharmaceutical Science (BSPS) Program Committee, College of Pharmacy
- 2003-2008 Member, Faculty Advisor of AAPS student chapter at the Ohio State University
- 2003-2008 Member, Faculty Advisor of Biotechnology Focus Group

Teaching

2008- University of Michigan

- 2024 PharmSci 608, Basic and Clinical Pharmacokinetics
- 2023 PharmSci 760, Advanced Pharmacokinetics
PharmSci 608, Basic and Clinical Pharmacokinetics
- 2022 PharmSci 608, Basic and Clinical Pharmacokinetics
- 2021 PharmSci 760, Advanced Pharmacokinetics & Biopharmaceutics
- 2020 PharmSci 718, Biopharmaceutics & Pharmacogenomics
PharmSci 608, Basic and Clinical Pharmacokinetics
- 2019 PharmSci 760, Advanced Pharmacokinetics
PharmSci 718, Biopharmaceutics & Pharmacogenomics
PharmSci 608, Basic and Clinical Pharmacokinetics
- 2018 PharmSci 718, Biopharmaceutics & Pharmacogenomics
PharmSci 718, Biopharmaceutics & Pharmacogenomics
PharmSci 700, Biopharmaceutics & Drug Disposition
PharmSci 718, Biopharmaceutics & Pharmacogenomics
- 2015 PharmSci 563, Biopharmaceutics & Pharmacogenomics
- 2014 PharmSci 700, Biopharmaceutics & Drug Disposition
- 2013 PharmSci 464, Pharmacokinetics & Biopharmaceutics
- 2012 PharmSci 464, Pharmacokinetics & Biopharmaceutics
- 2012 PharmSci 700, Biopharmaceutics and Drug Disposition
- 2011 PharmSci 464, Pharmacokinetics & Biopharmaceutics
- 2011 PharmSci 465, Biopharmaceutics and Pharmacogenomics
- 2011 PharmSci 702, Pharmaceutical Design, Delivery, and Targeting (PDDT): Biological-Molecular Concepts in PDDT
- 2011 ChemBio 602, Critical Analysis in Chemical Biology
- 2010 PharmSci 700, Biopharmaceutics and Drug Disposition
- 2010 PharmSci 464, Pharmacokinetics & Biopharmaceutics

2010 BME 321, Bioreaction Engineering and Design
 2009 PharmSci 464, Pharmacokinetics & Biopharmaceutics
 2009 PharmSci 762, Fundamentals of Drug Delivery
 2009 PharmSci 757, Drug Transport
 2009 BME 321, Bioreaction Engineering and Design

2003-2008 The Ohio State University

2003-2008 Pharmacy 804, Drug transport
 2003-2008 Pharmacy 622, Drug delivery II
 2003-2008 Pharmacy 732, Pharmacogenomics
 2003-2008 Pharmacy 694, Drug discovery and development
 2003-2008 Pharmacy 850, Ph.D student seminar for Pharmaceutics program
 2006 OSBP 760, Ph.D. student seminar for Ohio Sate Biochemistry Program
 2007 MCDB 800/890, Ph.D. student seminar for MCDB Program

Current PhD Graduate Students

2019-	Luchen Zhang	Ph.D. student
2020-	Zera Montmayor	Ph.D. student
2022-	Natalie Jusko	Ph.D. student
2022-	Hanning Wen	Ph.D. student
2024-	Hannah Myatt	Ph.D. student
2024-	Neha Karekar	Ph.D. student

Current Postdoctoral Research Fellows, Research Associates, and Visiting Scientists

2012-	Bo Wen	Postdoctoral research fellow 2012-2013; Research lab specialist 2013-2019, Assistant Director 2019-2024 Associate Research Scientist 2024-
2014-	Miao He	Visiting research investigator, 2013-2018; Research lab specialist associate, 2018-
2017-	Lu Wang	Postdoctoral research fellow, 2017-2021, Research Lab Specialist Inter 2021-
2017-	Wei Gao	Postdoctoral research fellow, 2017-2022, Asst Research Scientist 2022-
2018-	Aleksas Matvekas	Laboratory tech general assoc, 2018-2021, Research Lab Tech Lead 2021-
2021-	Meilin Wang	Visiting research Scientist, 2021-2023 Research Lab Specialist, 2023-
2022-	Hong-Yi Zhao	Postdoctoral research fellow
2022-	Jinsong Tao	Postdoctoral research fellow
2022-	Qiuxia Li	Laboratory tech general assoc
2023-	Shengan Duan	Postdoctoral research fellow
2023-	Weijia Zheng	Postdoctoral research fellow
2023-	Djibo Mahamadou	Postdoctoral research fellow 2023-2024 Research Lab Specialist Inter 2024-
2024-	Chengyi Li	Postdoctoral research fellow
2024-	Fang Ke	Research Investigator
2024-	Zerick Dill	Laboratory Tech General Associate

2024- Ching-Hua Kua Visiting Asst Research Scientist

Past Ph.D. Graduate Students (Year of graduation, their Current Positions)

2003-2007	Xianhua Cao	Ph.D. 2007, Senior Scientist, Abbott Labs
2003-2007	Lanyan (Lucy) Fang	Ph.D. 2007, Scientist reviewer, FDA
2004-2007	Seth Gibbs	Ph.D. 2008, Senior Scientist, Battelle, Columbus, OH
2005-2010	Tao Zhang	Ph.D. 2010, Assistant Professor, Husson University
2005-2010	Yanyan Li	Ph.D. 2010, Co-advised with Steven Schwartz. Assistant Professor, Montclair State University
2008-2010	Yiqun Jiang	Ph.D. 2010, Thesis research. Associate Professor, Jilin University
2008-2010	Zhenkun Zhu	Ph.D. 2010, Thesis research. Lecturer, Shandong University
2008-2010	Mancang Gu	Ph.D. 2010, Thesis research. Lecturer, Zhejiang Traditional Chinese Medicine University
2006-2011	Yanke Yu	Ph.D. 2011, Senior Scientist, Eisai Co. Ltd
2006-2011	Peng Zou	Ph.D. 2011, Scientist, FDA
2006-2008	Shuwen Yu	Ph.D. 2012, Thesis research. Director of Pharmacy, Shandong University
2009-2011	Yiling Liu	Visiting Ph.D. student for thesis research; Jilin University
2005-2012	Hsiu-Fang (Sarah) Lee	Ph.D. 2012, Project Manager, Trialynx Inc.
2006-2012	Bryan Newman	Ph.D. 2012, FDA
2012-2014	Xiaoqing Ren	Visiting Ph.D. student for thesis research; Fudan University
2014-2014	Yue Liu	Visiting Ph.D. student for thesis research; Second Military Medical University
2014-2014	Chun Tao	Visiting Ph.D. student for thesis research; Second Military Medical University
2009-2015	Joseph Burnett	Ph.D. 2015; Assistant research scientist, University of Michigan College of Pharmacy
2010-2015	Jamie Connarn	Ph.D. 2015; Scientist I, Celgene Corporation
2010-2015	Hayley Paholak	Ph.D. 2015; Medical Writer II, MMS Holdings
2015-2016	Xin Luan	Visiting Ph.D. student for thesis research, 2015-2016; postdoctoral research fellow, University of Michigan College of Pharmacy
2011-2016	Rebecca Moody	Ph.D. 2016, Chief Scientific Officer, NanoMedicine Innovation Center
2013-2017	Ila Myers	Ph.D. student, 2013-2017, University of Michigan
2011-2017	Kanokwan Sansanaphongpricha	Ph.D. 2017, Researcher, National Science and Technology Development Agency, Thailand
2017-2018	Ling Zhang	Visiting Ph.D. student for thesis research, 2017-2018
2013-2018	Alex Yu	Ph.D. 2018, Johnson and Johnson
2012-2018	Mari Gasparyan	Ph.D. 2018
2012-2018	Chang-Ching (Albert) Lin	Ph.D. 2018, Postdoctoral Researcher, UT Southwestern Medical Center
2017-2019	Ryan Clauson	Ph.D. 2019, Research Scientist, Torigen Pharmaceutical
2014-2020	Nathan Truchan	Ph.D. 2020, Research Scientist, NMIC
2015-2020	Jamie Do	Ph.D. 2020, Patent Agent, Singular Genomics

2015-2020	Garrett Johnson	Ph.D. 2020, Postdoctoral Fellow, University of Michigan
2016-2022	Hongxiang Hu	Ph.D. 2022, Research Investigator, BMS in Summit, NJ
2019-2023	Yingzi Bu	Ph.D. 2023, Scientist Reviewer, FDA
2020-2024	Chengyi Li	Ph.D. 2024, Postdoctoral Fellow, University of Michigan

Past Postdoctoral Research Fellows, Research Associates, and Visiting Scientists

2020-2024	Mohamed Abdelnabi	Clinical studies coordinator
2021-2024	Zhongwei Liu	Postdoctoral research fellow
2022-2024	Farzad Sarkari	Laboratory tech general assoc
2022-2024	Jia Yi	Postdoctoral research fellow
2022-2024	Shuai Mao	Visiting assoc research scientist
2024-2024	Yingzi Bu	Postdoctoral research fellow
2020-2024	John Takyi-Williams	Postdoctoral research fellow
2022-2023	Ankhabayar Lkhagva	Postdoctoral research fellow
2022-2023	Wenjing Zhang	Postdoctoral research fellow
2018-2023	Krishani Rajanayake	Postdoctoral research fellow Research Lab Specialist Assoc
2017-2023	Mady Traore	Postdoctoral research fellow, 2017-2022 Research Investigator 2022-2023
2021-2022	Alejandra Duran	Laboratory tech general assoc
2019-2022	Ruiting Li	Postdoctoral research fellow
2022-2022	Hamidreza Ardalani	Postdoctoral research fellow
2021-2022	Nathan Truchan	Postdoctoral research fellow, 2021-2022, Research Investigator 2022-2022
2020-2022	Djibo Mahamadou	Postdoctoral research fellow
2019-2022	Yudong Song	Postdoctoral research fellow
2014-2021	Hebao Yuan	Assistant research scientist, 2014-2019; Research Lab Specialist Senior, 2020-2021
2021-2021	Garrett Johnson	Postdoctoral research fellow
2015-2021	Joseph Burnett	Postdoctoral research fellow, 2015-2017; Assistant research scientist, 2017-2021
2021-2021	Xiang Gao	Research associate II
2016-2020	Jeremy Felton	Postdoctoral research fellow
2018-2020	Cai Liu	Postdoctoral research fellow
2016-2020	Lipeng Dai	Postdoctoral research fellow
2019-2020	Cao Yan	Visiting research scientist
2019-2020	Langdong Chen	Visiting research scientist
2018-2020	Yang Chen	Postdoctoral research fellow
2011-2019	Hongwei Chen	Postdoctoral research fellow, 2011-2012; Assistant research scientist, 2012-2018; Research assistant Professor, 2018-2019
2018-2020	Jizhao Xie	Visiting research scientist
2017-2019	Praveen Kumar	Postdoctoral research fellow
2019-2019	Hongjuan Bi	Visiting research scientist
2015-2019	Yanyan Han	Research associate, 2015-2018 Research Lab specialist intermediate 2018-2019
2017-2019	Inkyung Jung	Postdoctoral research fellow
2018-2018	Qingshan Chen	Visiting research scientist
2015-2018	Jinhui Liao	Research associate

2015-2018	Pan Shu	Postdoctoral research fellow
2016-2018	Xin Luan	Postdoctoral research fellow
2014-2018	Miao-Chia Lo	Assistant research scientist
2014-2018	Mark Koenigsnecht	Postdoctoral research fellow, 2014-2016 Senior research fellow, 2016-2018
2014-2017	Siwei Li	Postdoctoral research fellow
2015-2017	Feng Li	Postdoctoral research fellow
2013-2017	Ann Fioritto	Clinical study coordinator
2016-2017	Nicholas Stevers	Lab technician
2016-2017	Takahiro Iwao	Visiting research scientist
2016-2017	Rebecca Moody	Postdoctoral research fellow
2016-2016	Jinhua He	Visiting research scientist
2015-2016	Hongwei Guo	Visiting research scientist
2015-2016	Yongtai Zhang	Visiting research scientist
2015-2016	Hongyan Zhu	Visiting research scientist, 2015-2016
2015-2016	Jianjun Zou	Visiting research scientist
2015-2016	Qingfa Tang	Visiting research scientist
2016-2016	Yanyan Li	Visiting research scientist
2015-2016	Tao Zhang	Visiting research scientist
2013-2016	Ruijuan Luo	Research associate
2015-2015	Anjie Dong	Visiting research scientist
2014-2015	Fangying Xu	Visiting research scientist
2014-2015	Jun Liao	Visiting research scientist
2014-2018	Huixia Zhang	Visiting MS student, 2014-2015; Visiting research scientist, 2015-2018
2011-2015	Ting Zhao	Research associate
2014-2015	Ying Wang	Visiting research scientist, 2014; Postdoctoral research fellow, 2014-2015
2014-2015	Jiao Yang	Visiting research scientist
2014-2014	Yanqiang Zhong	Visiting research scientist
2014-2014	Liang Zhao	Visiting research scientist
2013-2014	Yi Wei	Research associate
2013-2014	Feng Ni	Visiting research scientist
2013-2014	Li Qiu	Visiting research scientist
2013-2014	Changhong Wang	Visiting research scientist
2011-2014	Mike Bly	Research lab specialist intermediate
2013-2014	Meng Lei	Visiting research scientist
2012-2014	Honglin Ren	Visiting scientist
2012-2013	Lichao Sun	Postdoctoral research fellow
2012-2013	Hao Zou	Visiting scientist
2012-2013	Min Li	Visiting scientist
2012-2013	Masayuki Ito	Visiting scientist
2012-2013	Yuki Ichikawa	Visiting scientist
2010-2013	Xiaoqin Li	Postdoctoral research fellow
2011-2012	Lei Duan	Visiting scientist
2011-2011	Hai Zhang	Visiting scientist
2011-2012	Yasuhiro Tsume	Postdoctoral research fellow
2010-2011	Yiqun Jiang	Postdoctoral research fellow
2009-2011	Wenpeng Zhang	Postdoctoral research fellow

2009-2010	Young Ho Seo	Postdoctoral research fellow
2007-2008	Bin Wang	Postdoctoral research fellow
2006-2007	Huifei Cui	Visiting scholar
2004-2006	Guisheng Zhang	Postdoctoral research fellow
2003-2005	Hao Cheng	Postdoctoral research fellow

Master Students and Undergraduate Students for Thesis Research

2003-2005	Heather Miller (MS)	MS, Ohio State University
2005-2005	Josephine Aimiwu (BS)	Honor thesis, Ohio State University
2005-2007	Robert Battisti (BS)	Honor thesis, Ohio State University
2010-2010	Anna Jenks (BS)	Research credit, University of Michigan
2011-2011	Maya Kalyan (BS)	Research credit, University of Michigan
2011-2011	Aditya Bharadwaj (BS)	Research credit, University of Michigan
2011-2011	Jimmy Li (BS)	Summer Research, University of Michigan
2011-2011	Vivian Pang (BS)	Research credit, Eastern Michigan University
2011-2011	Neha Kaushal (MS)	Research credit, University of Michigan
2012-2012	Jian Zhong (BS)	Summer Research, Xian Jiao Tong University
2012-2012	Jiwan Gurung (MS)	Visiting student, University of Bath, UK
2013-2015	Nicholas Stevers	Undergraduate student research assistant
2013-2014	Sara Brown	Undergraduate student research assistant
2014-2015	Huixia Zhang	Visiting MS student
2019-2019	Rachel O'Rourke	Research Credit, University of Michigan
2023-2023	Nicholas Yang	Research Credit, University of Michigan
2023-2023	Shalaka Abhyankar	Research Credit, University of Michigan
2023-2023	Albert Cao	Visiting BS student, Univ of Maryland Baltimore

Ph.D. Students for Lab Rotation

2024-	Lyucheng Huang	PharmD student
2024-2024	Deepika Tripu	ChemBio student
2023-2024	Hannah Myatt	Pharm Sci student
2023-2023	Gyulee Park	PharmD student
2023-2023	Neha Kerekar	Pharm Sci student
2023-2023	Yao Fu	MedChem student
2023-2023	Xinyao Wang	Biomedical Engineering
2022-2022	Julia Catalano	Pharm Sci student
2022-2022	Natalie Jusko	Pharm Sci student
2022-2022	Alexander Meyer	Pharm Sci student
2022-2022	Cecilia Specia	Pharm Sci student
2021-2021	Zhixin Yu	Pharm Sci student
2021-2021	Hanning Wen	Pharm Sci student
2021-2021	Namir Khalasawi	Pharm Sci student
2021-2021	Yunxuan Xie	Pharm Sci student
2021-2021	Vivian Juang	Pharm Sci student
2021-2021	Adaeze Eneli	Pharm Sci student
2021-2021	Andrea Villarreal	ChemBio student
2020-2020	Hannah Naldrett	Pharm Sci student
2020-2020	Mary Villarreal	ChemBio student
2020-2020	Zera Montemayor	Pharm Sci student
2020-2020	Antonela Rodriguez	Pharm Sci student

2019-2019	Fang Xie	Pharm Sci student
2019-2019	Chengyi Li	Pharm Sci student,
2019-2019	Sunny Min	PharmD student
2019-2019	Ziyun Xia	Pharm Sci student
2019-2019	Yinzhe Liu	Pharm Sci student, Illinois University
2019-2019	Manali Sawant	Pharm Sci student
2019-2019	Xin Ju	PharmD student
2019-2019	Mery Vet George De la Rosa	Pharm Sci student
2018-2018	Kristen Hong	Pharm Sci student
2018-2018	Cameron White	Pharm Sci student
2018-2019	Junius Thomas	Chem Bio student
2018-2018	Xiao Liu	PharmD student
2018-2018	Andrew Willmer	PharmD student
2018-2018	Emily Makowski	Pharm Sci student
2017-2017	Jung Won Kwon	PharmD student
2016-2017	Alyssa Loecher	PharmD student
2013-2013	Khoa Nguyen	PharmD student
2012-2012	Hsiao Ng	PharmD student
2005--2005	Nancy Pham	PharmD student
2003-2006	Sulk Chan	PharmD student

Graduate Student Thesis Committee

2003-2003	Liang Zhao	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2003-2003	Minoli Perera	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2004-2004	Jongham Kim	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2004-2004	Jiyun (Sunny) Chen	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2004-2004	Adam Ogden	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2004-2004	Greg Lyness	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2004-2004	Scott Fisher	MS, Div. of Pharmaceutics, College of Pharmacy, OSU
2005-2005	Eun Joo Hurh	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2005-2005	Jun Yang	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2005-2005	Casey Bohl	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2005-2005	Na Guan	MS, Div. of Pharmaceutics, College of Pharmacy, OSU
2006-2006	Yan Xin	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2006-2006	Dan Lu	Ph.D. Div. of Pharmaceutics, College of Pharmacy, OSU
2006-2006	Jing Song	Ph.D. Department of Microbiology, Shandong University
2006-2006	Xiaogang Pan	Ph.D. College of Pharmacy, OSU
2006-2006	Ju-Ping Lai	Ph.D. candidate, College of Pharmacy, OSU
2006-2008	Qing Liu	Ph.D. candidate, College of Pharmacy, OSU
2007-2007	Weiping Ye	Ph.D. College of Veterinary Medicine, OSU
2006-2008	Jacqqeline Lieblein	Ph.D. candidate, OSBP, OSU
2007-2008	Jianning Yang	Ph.D. candidate, College of Pharmacy, OSU
2007-2008	Liuqing Yang	Ph.D. candidate, College of Pharmacy, OSU
2007-2008	Robbie Kidd	Ph.D. candidate, College of Pharmacy, OSU
2007-2007	Kimberly N. Becker	Undergrad honors Thesis, College of Pharmacy, OSU
2006-2008	Ran Zhao	Ph.D. candidate, OSBP, OSU
2007-2008	Ling Cen	Ph.D. OSBP, OSU
2007-2007	Jie Shen	Ph.D. Chemistry, OSU

2007-2008	Jian Yang	Ph.D. candidate, Med Chem, College of Pharm, OSU
2008-2008	Xiaojuan Yang	Ph.D. candidate, Pharmaceutics, College of Pharm, OSU
2008-2008	Amada Jones	Ph.D. candidate, Pharmaceutics, College of Pharm, OSU
2008-2008	Sunjoo Ahn	Ph.D. candidate, Pharmaceutics, College of Pharm, OSU
2008-2008	Jackie Ji	Ph.D. candidate, Pharmaceutics, College of Pharm, OSU
2008-2008	Chien-Ming Li	Ph.D. candidate, Pharmaceutics, College of Pharm, OSU
2008-2010	Shu Pei Wu	Ph.D. candidate, Pharm Science, College of Pharm, UM
2009-2009	Kefeng Sun	Ph.D. candidate, Pharm Science, College of Pharm, UM
2009-2009	Shweta Urva	External reviewer of PhD dissertation, School of Pharm & Pharmaceutical Science, Univ Buffalo
2009-2009	Bei Yang	Ph.D. candidate, Pharm Science, College of Pharm, UM
2009-2009	Maria Posada	Ph.D. candidate, Pharm Science, College of Pharm, UM
2009-2009	Kyoung Ah Min	Ph.D. candidate, Pharm Science, College of Pharm, UM
2009-2009	Lily Roy	Ph.D. candidate, Pharm Science, College of Pharm, UM
2009-2011	Cara Hartz	Ph.D. candidate, Pharm Science, College of Pharm, UM
2009-2011	Hugo Fung	Ph.D. candidate, Chemical Biology, UM
2010-2015	Oluseyi Adeniyi	Ph.D. candidate, Pharm Science, College of Pharm, UM
2010-2010	Anne Gillies	Ph.D. candidate, Chemical Biology, UM
2010-2010	Fardokht Abulwerdi	Ph.D. candidate, Chemical Biology, UM
2010-2010	Yehua Xie	Ph.D. candidate, Pharm Science, College of Pharm, UM
2012-2012	Sharan Shrinivasan	Ph.D. candidate, Chemical Biology, UM
2012-2015	Brian Larsen	Ph.D. candidate, Chemical Biology, UM
2012-2016	Xiaomei Chen	Ph.D. candidate, Pharm Science, College of Pharm, UM
2013-2016	Ahmed Mady	Ph.D. candidate, Med Chem, Medical Ctr., UM
2013-2013	Max Mazzara	Ph.D. candidate, Pharm Science, College of Pharm, UM
2013-2015	Yongjun Hu	Ph.D. candidate, Pharm Science, College of Pharm, UM
2013-2016	Fengjuan Cao	Ph.D. candidate, Pharm Science, College of Pharm, UM
2013-2017	Stephanie Gates	Ph.D. candidate, Chemical Biology, UM
2013-2013	Chris Holt	Ph.D. candidate, Med Chem, UM
2014-2017	Rui Kuai	Ph.D. candidate, Pharm Science, College of Pharm, UM
2014-2017	Morgan Giles	Ph.D. candidate, Pharm Science, College of Pharm, UM
2014-2017	Xiaoxing Wang	Ph.D. candidate, Pharm Science, College of Pharm, UM
2014-2018	James Song	Ph.D. candidate, Chemical Biology, UM
2014-2017	Jae Min Shin	D.D.S./Ph.D. School of Dentistry, UM
2015-2015	Shuai Hu	Ph.D. candidate, Med Chem, UM
2015-2019	Zhilin Chen	Ph.D. candidate, Pharm Science, College of Pharm, UM
2015-2019	Daniel Epling	Ph.D. candidate, Pharm Science, College of Pharm, UM
2015-2020	Chengcheng Zhang	Ph.D. candidate, Chemistry, UM
2015-2015	Dan Li	Ph.D. candidate, Pharm Science, College of Pharm, UM
2015-2020	Nicholas Waltz	Ph.D. candidate, Pharm Science, College of Pharm, UM
2015-2019	Yuchen Fan	Ph.D. candidate, Pharm Science, College of Pharm, UM
2015-2019	Patrick Sinko	Ph.D. candidate, Pharm Science, College of Pharm, UM
2015-2016	Joseph Labuz	Ph.D. Biomedical Engineering, College of Engineering, UM
2015-2017	Yu Sui	Ph.D. EECS, College of Engineering, UM
2016-2019	Sang Yeop Kim	Ph.D. candidate, Pharm Science, College of Pharm, UM
2016-2019	Mikhail Murashov	Ph.D. candidate, Pharm Science, College of Pharm, UM
2016-2020	Lindsay Scheetz	Ph.D. candidate, Pharm Science, College of Pharm, UM
2016-2016	Lindsey Drake	Ph.D. candidate, Pharm Science, College of Pharm, UM
2016-2016	David Mertz	Ph.D. Biomedical Engineering, College of Engineering, UM

2016-2019	Karson Kump	Ph.D. candidate, Chemical Biology, UM
2017-2019	Deanna Montgomery	Ph.D. candidate, Med Chem, UM
2017-2020	Brian Thompson	Ph.D. candidate, Pharm Science, College of Pharm, UM
2017-2021	Chang Lee	Ph.D. candidate, Chemistry, LSA, UM
2018-2022	Minzhi Yu	Ph.D. candidate, Pharm Science, College of Pharm, UM
2018-2022	Xiaoqi Sun	Ph.D. candidate, Pharm Science, College of Pharm, UM
2018-2022	Matt Schnizlein	Ph.D. candidate, Michigan Medicine, UM
2017-2018	Jiqing Jiang	Ph.D. College of Engineering, UM
2018-2022	Dan Li	Ph.D. candidate, Pharm Science, College of Pharm, UM
2018-2022	James Song	Ph.D. Chemical Biology, UM
2019-2023	Jingcheng Xiao	Ph.D. candidate, Pharm Science, College of Pharm, UM
2019-2023	Glory Velazquez	Ph.D. candidate, Medicinal Chemistry, UM
2019-2021	Kai Wang	Ph.D. candidate, Pharm Science, College of Pharm, UM
2019-2023	Junius Thomas	Ph.D. candidate, Chemical Biology, UM
2019-2023	Mery Vet George De la Rosa	Ph.D. candidate, Pharm Science, College of Pharm, UM
2020-2023	Jin Xu	Ph.D. student, Pharm Sciences, UM
2020-2023	Emily Briggs	Ph.D. student, Pharm Sciences, UM
2020-2021	Lucy Her	Ph.D. candidate, Pharm Science, College of Pharm, UM
2021-2024	Tao Zheng	Ph.D. student, Pharm Sciences, UM
2021-2024	Ziyun Xia	Ph.D. student, Pharm Sciences, UM
2021-	Sunny Jung	Ph.D. student, PharmD, UM
2021-2024	Jaylen Mans	Ph.D. student, Pharm Sciences, UNTHSC
2022-	Ruheng Zhao	Ph.D. student, Med Chem, UM
2022-	Shuhan Liu	Ph.D. candidate, Clinical Pharm, UM
2022-2023	Andrew Willmer	Ph.D. candidate, Pharm Science, College of Pharm, UM
2022-2024	Hanrui Zhang	Ph.D. student, Bioinformatics, UM
2022-	Xingwu Zhou	Ph.D. student, Pharm Sciences, UM
2022-2024	Fang Xie	Ph.D. student, Pharm Sciences, UM
2022-	Adaeze Eneli	Ph.D. student, Pharm Sciences, UM
2022-	April Kim	Ph.D. student, Pharm Sciences, UM
2022-	Swetha Kodamasimham	Ph.D. student, Pharm Sciences, UM
2023-2023	Yu-Ting Kao	Ph.D. student, Med Chem, UM
2023-	Nishant Shah	Ph.D. student, Pharm Sciences, UM
2023-	Mariana Romero-Gonzalez	Ph.D. student, Pharm Sciences, UM
2023-	Namir Khalasawi	Ph.D. student, Pharm Sciences, UM
2023-	Bhanuz Dechayont	Ph.D. student, Pharm Sciences, UM
2023-	Alexander Meyer	Ph.D. student, Pharm Sciences, UM

High School Students for Summer Research

2011-2012	Yuxuan Chen	Summer Research
2012-2012	Jimmy Li	Summer Research
2012-2012	Connie Yang	Summer Research
2019-2019	Daeun Nam	Summer Research
2022-2022	David Chen	Summer Research

Patents

Issued

- 1 Duxin Sun, Hongwei Chen, Hongxiang Hu, Kanokwan Sansanaphongpricha, Yee Sun Tan, Yu Lei. *Complexes for Delivery of Antigenic Peptides*. Filed for US provisional patent 06/01/18. Application number: 16/619,802. US patent number 11701433 issued 07/18/23.
- 2 Duxin Sun, Yogesh Gianchandani, Tao Li, Jinhui Liao, Qisen Cheng, Johnathan Lewis, Ryan Meredith, Jeremy Felton. *Sampling Device for Drug Development and Diagnosis of Gastric-Intestinal Diseases*. Filed for US provisional patent 06/26/20. Application number: 16/958,165. US patent number 11647959 issued 05/16/23.
- 3 Hongwei Chen, Duxin Sun. *Core-Satellite Nanocomposites for MRI and Photothermal Therapy*. Filed for US provisional patent 11/25/19. Application number: 16/694,715. US patent number 10485886 issued 11/26/19 and 10898595 issued 01/26/21.
- 4 Shaomeng Wang, Yujun Zhao, Bing Zhou, Angelo Aguilar, Liu Liu, Longchuan Bai, Donna McEachern, Duxin Sun, Bo Wen, Ruijuan Luo, Ting Zhao, Arul Chinnaiyan, Irfan Asangani, Jeanne Stuckey, Jennifer Meagher, Xu Ran, Yang Hu. *9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors*. Filed for US provisional patent 2017, US patent application 15/443,336 filed 02/27/17. US patent number 10253044 issued 04/09/19.
- 5 Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollack, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu. *Thienopyrimidine and thienopyridine compounds and methods of use thereof*. US patent application 15/509,989 filed 03/09/17. US patent number 10246464 issued 04/02/19. Re-issued patent number RE049687 issued 10/10/23.
- 6 Scott D. Larsen, Akira Abe, Liming Shu, Michael William Wilson, Richard F. Keep, Duxin Sun, James A. Shayman. *Glucosylceramide synthase inhibitors and therapeutic methods using the same*. Filed for US provisional patent 2015; US patent application 15/546,320 filed 07/26/17. US patent number 10202340 issued 02/12/19.
- 7 Vishwanath Subramaniam, Joseph West, Jennifer McFerran-Brock, Emily Sequin, Duxin Sun, Peng Zou, Travis Hamilton Jones. *Electromagnetic system and method*. US Patent application 13/210,293 filed 8/15/11; US patent application 14/257,200 filed 04/21/14. US patent number 9844347 issued 12/19/17.
- 8 Shaomeng Wang, Xu Ran, Yujun Zhao, Chao-Yie Yang, Liu Liu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Jennifer Lynn Meagher, Duxin Sun, Xiaoqin Li, Bing Zhou, Hacer Karatas, Ruijuan Luo, Arul Chinnaiyan, Irfan A. Asangani. *BET bromodomain inhibitors and therapeutic methods using the same*. US patent number 9675697 issued 06/14/17. US patent application 15/619,671 filed 06/12/17.
- 9 Shaomeng Wang, Yujun Zhao, Bing Zhao, Angelo Aguilar, Liu Liu, Longchuan Bai, Donna McEachern, Duxin Sun, Bo Wen, Ruijuan Luo, Ting Zhao, Arul Chinnaiyan, Irfan A. Asangani, Jeanne Stuckey, Jennifer Lynn Meagher, and Xu Ran. *9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors*. US patent number 9580430 issued 02/28/17.
- 10 Hongwei Chen and Duxin Sun. *Photothermal therapy using magnetic nanoparticles*. US patent number 9533045 issued 01/03/17.
- 11 Duxin Sun, Hongwei Chen, Wei Qian, Yong Che, Masayuki Ito, Hayley Paholak, Kanokwan Sansanaphongpricha. *ivingPEGylation to Control PEG-R Density and Composition on Gold Nanoparticles*. US patent number 9234078 issued 01/12/16. US patent number 9587071 issued 03/07/17.
- 12 Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay L. Hess, Duxin Sun, Xiaoqin Li. *Compositions and Methods for Treatment of Leukemia*. US patent number 9216693 issued

- 12/22/15. US patent number 9505781 issued 11/29/16. US patent number 9505782 issued 11/29/16.
- 13 Shaomeng Wang, Jianfang Chen, Donna McEachern, Longchuan Bai, Liu Liu, Duxin Sun, Xiaoqin Li, Angelo Aguilar. *BCL-2/BCL-XL Inhibitors and therapeutic methods using the same*. US patent number 9096625 issued 07/15/15. US patent number 9403856 issued 08/02/16.
- 14 Shaomeng Wang, Haibin Zhou, Jianfang Chen, Angelo Aguilar, Jennifer Meagher, Duxin Sun, Chao-Yie Yang, Liu Liu, Longchuan Bai, Donna J. McEachern, Jeanne A. Stuckey-Cupp, Xiaoqin Li. *BCL-2/BCL-XL Inhibitors and therapeutic methods using the same*. US patent number 8691184 issued 04/08/14.
- 15 Shaomeng Wang, Shanghai Yu, Wei Sun, Sanjeev Kumar Shangary, Duxin Sun, Peng Zou, Donna McEachern, Yujun Zhao. *Spiro-oxindole MDM2 antagonists*. US patent number 9079913 issued 06/24/15. US patent number 8877796 issued 11/04/14. US patent number 8518984 issued 08/27/13.
- 16 Guisheng Zhang, Lanyan Fang, Peng George Wang, Duxin Sun. *Multidrug resistant anticancer anthracyclines*. US patent number 7737123 issued 06/15/10.

Submitted

- 1 Duxin Sun, Alejandra Duran, Chengyi Li, Jia Yi, Wei Gao, Zera Montemayor. *Vaccine Compositions, Component, and Methods of Use*. Filed for US provisional patent 06/16/23. Application number: 18/210,980.
- 2 Duxin Sun, Chengyi Li, Mahamadou Djibo, Wei Gao. *Sting Agonists, Formulations, and Uses Thereof*. Filed for US provisional patent 04/25/23. PCT/US2023/019815.
- 3 Duxin Sun, Mahamadou Djibo, Mohamed Dit Mady Traore, Wei Gao. *Lipids, Formulations, and Uses Thereof*. Filed for US provisional patent 04/25/23. PCT/US2023/019809.
- 4 Duxin Sun, Chengyi Li, Mahamadou Djibo, Mohamed Dit Mady Traore, Shuai Mao, Wei Gao, Zhongwei Liu. *Dual Functioning Immune Modulating Compounds, Formulations, and Uses Thereof*. Filed for US provisional patent 04/25/23. PCT/US2023/019804.
- 5 Duxin Sun, Lu Wang, Mohamed Dit Mady Traore, Yingzi Bu, Zhongwei Liu. *Jak Inhibitor Analogs, Formulations, and Uses Thereof*. Filed for US provisional patent 04/14/23. PCT/US2023/018658.
- 6 Duxin Sun, Wei Gao, Fei Wen, Ruiting Li, Hongxiang Hu, Luke K. Bugada, Yudong Song Mahamadou Djibo. *Pi3k inhibitors, nanoformulations, and uses thereof*. Filed for US provisional patent 04/20/22. PCT number: PCT/US2022/025520.
- 7 Duxin Sun, Hongwei Chen, Ryan Clauson, Brett Dallas Hill, Fei Wen, Syed Rizvi, Wei Gao, Luke Francesco Bugada, Chengyi Li. *Nano-satellite complexes*. Filed for US provisional patent 04/16/21. Application number: 17/232,751.
- 8 Duxin Sun, Wei Gao, Hongxiang Hu, Mohamed Dit Mady Traore, Yudong Song, Bo Wen. *Remdesivir and Remdesivir Analog Nanoparticle, Liposomal, and Microparticle Composition for treating viral infections*. Filed for US provisional patent 04/02/20. PCT number: PCT/US2021/025427.
- 9 Duxin Sun, Kanokwan Sansanaphongpricha, Yee Sun Tan, Yu Lei. *Nanoparticle Vaccine Formulations Against Human Papillomavirus-Positive Cancer*. Filed for US provisional patent 12/05/19. PCT number: PCT/US2018/035623.
- 10 Duxin Sun, Wei Gao, Hongxiang Hu. *Compositions and Methods for Systemic Delivery of BCL-2 and BCL-XL Antagonists*. Filed for US provisional patent 12/11/19. PCT number: PCT/US2020/064530.

Peer-Reviewed Publications (Google Scholar H-Index 66)Google Scholar: <https://scholar.google.com/citations?user=Ufab1aYAAAAJ&hl=en>

- 1 Chen Z, Wang M, Wu D, Zhao L, Metwally H, Jiang W, Wang Y, Bai L, McEachern D, Luo J, Wang M, Li Q, Matvekas A, Wen B, **Sun D**, Chinnaiyan AM, Wang S. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degradator for the Treatment of Advanced Prostate Cancer. *J Med Chem*. 2024 Apr 11;67(7):5351-5372. Epub 2024 Mar 26. PubMed PMID: 38530938.
- 2 Chen Z, Wang M, Wu D, Bai L, Xu T, Metwally H, Wang Y, McEachern D, Zhao L, Li R, Takyi-Williams J, Wang M, Wang L, Li Q, Wen B, **Sun D**, Wang S. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degradator Capable of Achieving Tumor Regression. *J Med Chem*. 2024 Apr 11;67(7):5275-5304. Epub 2024 Mar 13. PubMed PMID: 38477974.
- 3 Li C, Clauson R, Bugada LF, Ke F, He B, Yu Z, Chen H, Jacobovitz B, Hu H, Chuikov P, Hill BD, Rizvi SM, Song Y, Sun K, Axenov P, Huynh D, Wang X, Garmire L, Lei YL, Grigorova I, Wen F, Cascalho M, Gao W, **Sun D**. Antigen-Clustered Nanovaccine Achieves Long-Term Tumor Remission by Promoting B/CD 4 T Cell Crosstalk. *ACS Nano*. 2024 Apr 2;18(13):9584-9604. Epub 2024 Mar 21. PubMed PMID: 38513119.
- 4 Cussa J, Juarez J, Gomez Costa M, Anunziata O. Successful controlled release of cyclophosphamide from tert-butylamine-functionalized large-pore SBA-15. *Composite Interfaces*, 1–25. 21 Mar 2024. <https://doi.org/10.1080/09276440.2024.2331329>
- 5 Zhou H, Wu D, Bai L, Acharyya R, Hoda M, McEachern D, Wen B, **Sun D**, Wang S. Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression. *Cancer Res* 15 March 2024; 84 (6_Supplement): 3881. <https://doi.org/10.1158/1538-7445.AM2024-3881>.
- 6 Acharyya R, Bai L, Zhao H, Wu D, Hoda M, McEachern D, Wen B, **Sun D**, Wang S. Discovery of potent and highly efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression. *Cancer Res* 15 March 2024; 84 (6_Supplement): 4509. <https://doi.org/10.1158/1538-7445.AM2024-4509>.
- 7 Chen Z, Wang M, Wu D, Zhao L, Xu T, Hoda M, Wang Y, McEachern D, Jiang W, Bai L, Luo J, Wang M, Li R, Takyi-Williams J, Wang L, Li Q, Wen B, **Sun D**, Chinnaiyan A, Wang S. Discovery of CBPD-409 and CBPD-268 as highly potent and orally efficacious CBP/p300 PROTAC degraders for the treatment of castration-resistant prostate cancer. *Cancer Res* 15 March 2024; 84 (6_Supplement): 4504. <https://doi.org/10.1158/1538-7445.AM2024-4504>.
- 8 Bai L, Zhou H, Zhou J, Wu D, Kumar Acharyya R, Metwally H, McEachern D, Wen B, Sun D, Zou W, Wang S. Evaluation of a highly potent and selective STAT3 degrader as a new class of immunotherapy. *Cancer Res* 15 March 2024; 84 (6_Supplement): 6057. <https://doi.org/10.1158/1538-7445.AM2024-6057>.
- 9 Leng L, Yang L, Tu W, Rej R, Allu S, Huang L, Jiang W, Wang Y, Stuckey J, Sarkari F, Wang M, Wang L, Wen B, **Sun D**, Wang S. Discovery of potent, highly selective and orally efficacious SMARCA2 degraders. *Cancer Res* 15 March 2024; 84 (6_Supplement): 4506. <https://doi.org/10.1158/1538-7445.AM2024-4506>.
- 10 Zhou H, Wu D, Bai L, Acharyya R, Metwally H, McEachern D, Wen B, **Sun D**, Wang S. Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving complete tumor regression. *Cancer Res* 15 March 2024; 84 (6_Supplement): 4519. <https://doi.org/10.1158/1538-7445.AM2024-4519>.

- 11 Rej R, Chen Z, Acharyya R, Wu D, Hu B, Xu G, Nagilla R, Metwally H, Wang Y, Wen B, **Sun D**, Bai L, Wang S. Potent and orally efficacious PROTAC degraders of estrogen receptor α (ER α). *Cancer Res* 15 March 2024; 84 (6_Supplement): 4510. <https://doi.org/10.1158/1538-7445.AM2024-4510>.
- 12 Li C, Mao S, Zhao H, He M, Wang M, Liu Z, Wen W, Yu Z, Wen B, Mahamadou D, Tao J, Bu Y, Gao W, **Sun D**. Dual Targeting of STING and PI3K γ Eliminates Regulatory B Cells to Overcome STING Resistance for Pancreatic Cancer Immunotherapy. *bioRxiv* 2024.02.14.580378; doi: <https://doi.org/10.1101/2024.02.14.580378>.
- 13 Takyi-Williams J, Leino AD, Li R, Downes KJ, Zuppa AF, Bwint A, Wen B, **Sun D**, Scheetz MH, Pai MP. Bioanalysis of six antibiotics from volumetric microsamples: a new tool for precision dosing in critically ill children. *Bioanalysis*. 2024 Jan;16(1):19-31. Epub 2023 Nov 22. PMID: 37991215; PMCID: PMC10718164.
- 14 Bu Y, Traore MDM, Zhang L, Wang L, Liu Z, Hu H, Wang M, Li C, **Sun D**. A gastrointestinal locally activating Janus kinase inhibitor to treat ulcerative colitis. *J Biol Chem*. 2023 Dec;299(12):105467. Epub 2023 Nov 17. PMID: 37979913; PMCID: PMC10755797.
- 15 Xiang W, Zhao L, Han X, Xu T, Kregel S, Wang M, Miao B, Qin C, Wang M, McEachern D, Lu J, Bai L, Yang CY, Kirchhoff PD, Takyi-Williams J, Wang L, Wen B, **Sun D**, Ator M, Mckean R, Chinnaiyan AM, Wang S. Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degradator with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer. *J Med Chem*. 2023 Sep 28;66(18):13280-13303. Epub 2023 Sep 8. PMID: 37683104.
- 16 Chen Z, Hu B, Rej RK, Wu D, Acharyya RK, Wang M, Xu T, Lu J, Metwally H, Wang Y, McEachern D, Bai L, Gersch CL, Wang M, Zhang W, Li Q, Wen B, **Sun D**, Rae JM, Wang S. Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degradator with Strong Antitumor Activity. *J Med Chem*. 2023 Sep 14;66(17):12559-12585. Epub 2023 Aug 30. PMID: 37647546.
- 17 Yuan X, Jiang H, Fu D, Rech JC, Robida A, Rajanayake K, Yuan H, He M, Wen B, **Sun D**, Liu C, Chinnaswamy K, Stuckey JA, Paczesny S, Yang CY. Prophylactic Mitigation of Acute Graft versus Host Disease by Novel 2-(Pyrrolidin-1-ylmethyl)pyrrole-Based Stimulation-2 (ST2) Inhibitors. *ACS Pharmacol Transl Sci*. 2023 Sep 8;6(9):1275-1287. 2023 Sep 8. PMID: 37705593; PMCID: PMC10496145.
- 18 Yang L, Tu W, Huang L, Miao B, Kaneshige A, Jiang W, Leng L, Wang M, Wen B, **Sun D**, Wang S. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degradator with Strong in vivo Antitumor Activity. *J Med Chem*. 2023 Aug 10;66(15):10761-10781. Epub 2023 Jul 31. PMID: 37523716.
- 19 Wang K, Marciani L, Amidon GL, Smith DE, **Sun D**. Stochastic Differential Equation-based Mixed Effects Model of the Fluid Volume in the Fasted Stomach in Healthy Adult Human. *AAPS J*. 2023 Jul 27;25(5):76. PMID: 37498389.
- 20 Han X, Zhao L, Xiang W, Miao B, Qin C, Wang M, Xu T, McEachern D, Lu J, Wang Y, Metwally H, Yang CY, Kirchhoff PD, Wang L, Matvekas A, Takyi-Williams J, Wen B, **Sun D**, Ator M, Mckean R, Wang S. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degradator of Androgen Receptor for the Treatment of Advanced Prostate Cancer. *J Med Chem*. 2023 Jul 13;66(13):8822-8843. Epub 2023 Jun 29. PMID: 37382562; PMCID: PMC10568492.
- 21 Zhou S, Rajanayake K, He M, Wen B, Lkhagva A, Yap E, Sun D, Cross J, Engelke K, Huizinga, R. Selective Renal Disposition of The Calcineurin Inhibitors Voclosoprin, Cyclosporine, and Tacrolimus. *Nephrology Dialysis Transplantation*, Volume 38, Issue Supplement_1, June 2023, gfad063b_2989, https://doi.org/10.1093/ndt/gfad063b_2989.

- 22 Zhang T, Holman J, McKinstry D, Trindade BC, Eaton KA, Castrejon JM, Ho S, Wells E, Yuan H, Wen B, **Sun D**, Chen GY, Li Y. Corrigendum to "A steamed broccoli sprout diet preparation that reduces colitis via the gut microbiota" [J Nutr Biochem 2023;112:109215]. J Nutr Biochem. 2023 Jul;117:109340. Epub 2023 Apr 12. PMID: 37059606.
- 23 Thomas JE 2nd, Wang M, Jiang W, Wang M, Wang L, Wen B, **Sun D**, Wang S. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degradors of CBP and p300 Proteins. J Med Chem. 2023 Jun 22;66(12):8178-8199. Epub 2023 Jun 5. PMID: 37276143.
- 24 Qu P, Rom O, Li K, Jia L, Gao X, Liu Z, Ding S, Zhao M, Wang H, Chen S, Xiong X, Zhao Y, Xue C, Zhao Y, Chu C, Wen B, Finney AC, Zheng Z, Cao W, Zhao J, Bai L, Zhao S, **Sun D**, Zeng R, Lin J, Liu W, Zheng L, Zhang J, Liu E, Chen YE. DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates. Cell Metab. 2023 May 2;35(5):742-757.e10. Epub 2023 Apr 10. PMID: 37040763.
- 25 Zhang T, Holman J, McKinstry D, Trindade BC, Eaton KA, Castrejon JM, Ho S, Wells E, Yuan H, Wen B, **Sun D**, Chen GY, Li Y. Corrigendum to "A steamed broccoli sprout diet preparation that reduces colitis via the gut microbiota" [J Nutr Biochem 2023;112:109215]. J Nutr Biochem. 2023 Apr 12;109340. [Epub ahead of print] PMID: 37059606.
- 26 Bu Y, Gao R, Zhang B, Zhang L, **Sun D**. CoGT: Ensemble Machine Learning Method and Its Application on JAK Inhibitor Discovery. ACS Omega. 2023 Apr 11;8(14):13232-13242. eCollection 2023 Apr 11. PMID: 37065046; PMCID: PMC10099439.
- 27 He B, Xiao Y, Liang H, Huang Q, Du Y, Li Y, Garmire D, **Sun D**, Garmire LX. ASGARD is A Single-cell Guided Pipeline to Aid Repurposing of Drugs. Nat Commun. 2023 Feb 22;14(1):993. PMID: 36813801; PMCID: PMC9945835.
- 28 Roy J, Kyani A, Hanafi M, Xu Y, Takyi-Williams J, **Sun D**, Osman EEA, Neamati N. Design and Synthesis of Orally Active Quinolyl Pyrazinamides as Sigma 2 Receptor Ligands for the Treatment of Pancreatic Cancer. J Med Chem. 2023 Feb 9;66(3):1990-2019. Epub 2023 Jan 24. PMID: 36692906.
- 29 Kaneshige A, Bai L, Wang M, McEachern D, Meagher JL, Xu R, Kirchhoff PD, Wen B, **Sun D**, Stuckey JA, Wang S. Discovery of a Potent and Selective STAT5 PROTAC Degradator with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia. J Med Chem. 2023 Feb 3;. [Epub ahead of print] PMID: 36735833.
- 30 Kaneshige A, Bai L, Wang M, McEachern D, Meagher JL, Xu R, Wang Y, Jiang W, Metwally H, Kirchhoff PD, Zhao L, Jiang H, Wang M, Wen B, **Sun D**, Stuckey JA, Wang S. A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo. Nat Chem Biol. 2023 Feb 2;. PMID: 36732620.
- 31 Zhang T, Holman J, McKinstry D, Trindade BC, Eaton KA, Mendoza-Castrejon J, Ho S, Wells E, Yuan H, Wen B, **Sun D**, Chen GY, Li Y. A steamed broccoli sprout diet preparation that reduces colitis via the gut microbiota. J Nutr Biochem. 2023 Feb;112:109215. Epub 2022 Nov 9. PMID: 36370930.
- 32 Begley LA, Opron K, Bian G, Kozik AJ, Liu C, Felton J, Wen B, **Sun D**, Huang YJ. Effects of Fluticasone Propionate on Klebsiella pneumoniae and Gram-Negative Bacteria Associated with Chronic Airway Disease. mSphere. 2022 Dec 21;7(6):e0037722. Epub 2022 Nov 7. PMID: 36342141; PMCID: PMC9769713.
- 33 Wu F, Mousa Y, Raines K, Bode C, Tsang YC, Cristofolletti R, Zhang H, Heimbach T, Fang L, Kesisoglou F, Mitra A, Polli J, Kim MJ, Fan J, Zolnik BS, **Sun D**, Zhang Y, Zhao L. Regulatory utility of physiologically-based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report. CPT Pharmacometrics Syst Pharmacol. 2022 Dec 18. PMID: 36530026. PMCID: PMC10196428.

- 34 Yang CY, Yuan X, Jiang H, Rech J, Fu D, Robida A, Rajanayake K, Yuan H, Wen B, **Sun D**, Chinnaswamy K, Stuckey J, Paczesny S. Novel Chemical Series of Anti-ST2 Small Molecules Suppress Allogeneic T Cells Proliferation While Increasing Treg Cells and Improve Gvhd and Survival In Vivo. *Blood* 2022; 140 (Supplement 1): 10675–10677. doi: <https://doi.org/10.1182/blood-2022-163374>.
- 35 Leino AD, Takyi-Williams J, Wen B, **Sun D**, Pai MP. Application of a new volumetric microsampling device for quantitative bioanalysis of immunosuppression. *Bioanalysis*. 2022 Sep;14(17):1141-1152. Epub 2022 Oct 8. PMID: 36208082; PMCID: PMC9644239.
- 36 Yuan X, Jiang H, Fu D, Robida A, Rajanayake K, Yuan H, Wen B, **Sun D**, Watch BT, Chinnaswamy K, Stuckey JA, Paczesny S, Rech JC, Yang CY. Structure-Activity relationship of 1-(Furan-2ylmethyl)Pyrrolidine-Based Stimulation-2 (ST2) inhibitors for treating graft versus host disease. *Bioorg Med Chem*. 2022 Oct 1;71:116942. PMID: 35930851; PMCID: PMC9451522.
- 37 Hongxiang H, Traore M, Li R, Yuan H, He M, Wen B, Gao W, Jonsson C, Fitzpatrick EA, **Sun D**. Optimization of The Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. *J Med Chem*. 2022 Sep 22;65(18):12044-12054. PMID: 36070561.
- 38 Wang K, Li Y, Chen B, Chen H, Smith DE, **Sun D**, Feng MR, Amidon GL. In Vitro Predictive Dissolution Test Should Be Developed and Recommended as a Bioequivalence Standard for the Immediate-Release Solid Oral Dosage Forms of the Highly Variable Mycophenolate Mofetil. *Mol Pharm*. 2022 Jul 4;19(7):2048-2060. Epub 2022 May 23. PMID: 35603895.
- 39 Li Y, Zhang T, Holman J, McKinsty D, Trindade BC, Mendoza-Castrejon J, Ho S, **Sun D**, Wells E, Chen G. A Specific Broccoli Sprout Preparation Reduces Chemically Induced Colitis Via Gut Microbiota. *Current Developments in Nutrition*, 2022 Jun; 6(Suppl 1): 307. PMCID: PMC9193678.
- 40 Song Y, Bugada L, Li R, Hu H, Zhang L, Li C, Yuan H, Rajanayake KK, Truchan NA, Wen F, Gao W, **Sun D**. Albumin nanoparticle containing a PI3Ky inhibitor and paclitaxel in combination with α -PD1 induces tumor remission of breast cancer in mice. *Science Translational Medicine*, 2022 May 4;14(643):eabl3649. PMID: 35507675. PMCID: PMC9589917.
- 41 Rom O, Liu Y, Finney AC, Ghayeb A, Zhao Y, Shukha Y, Wang L, Rajanayake KK, Das S, Rashdan NA, Weissman N, Delgadillo L, Wen B, Garcia-Barrio MT, Aviram M, Kevil CG, Yurdagul A Jr, Pattillo CB, Zhang J, **Sun D**, Hayek T, Gottlieb E, Mor I, Chen YE. Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis. *Redox Biol*. 2022 Jun;52:102313. PMID: 35447412. PMCID: PMC9044008.
- 42 Xue D, Xu Y, Kyani A, Roy J, Dai L, **Sun D**, Neamati N. Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer. *J Med Chem*. 2022 Feb 24;65(4):3404-3419. PMID: 35167303. PMCID: PMC9165018.
- 43 **Sun D**, Gao W, Hu H, Zhou S. Why 90% of Clinical Drug Development Fails and How to Improve It? *Acta Pharm Sin B*. 2022 Jul;12(7):3049-3062. PMID: 35865092; PMCID: PMC9293739.
- 44 Gao W, Hu H, Dai L, He M, Yuan H, Zhang H, Liao J, Wen B, Li Y, Palmisano M, Traore M, Zhou S, **Sun D**. Structure-Tissue Exposure/Selectivity Relationship (STR) Correlates with Clinical Efficacy/Safety. *Acta Pharmaceutica Sinica B*, 2022, 12, 2462-2478. Epub 2022 Feb 23. PMID: 35646532. PMCID: PMC9136610.
- 45 Xue D, Xu Y, Kyani A, Roy J, Dai L, **Sun D**, Neamati N. Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors. *J Med Chem*. 2022 Jan 13;65(1):343-368. PMID: 34982568. PMCID: PMC9164994.

- 46 Luo Y, Guo Y, Wang H, Yu M, Hong K, Li D, Li R, Wen B, Hu D, Chang L, Zhang J, Yang B, **Sun D**, Schwendeman AS, Eugene Chen Y. Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. *EBioMedicine*. 2021 Dec;74:103725. PMID: 34879325 PMCID: PMC8654800.
- 47 Rej RK, Wang C, Lu J, Wang M, Petrunak E, Zawacki KP, McEachern D, Yang CY, Wang L, Li R, Chinnaswamy K, Wen B, **Sun D**, Stuckey JA, Zhou Y, Chen J, Tang G, Wang S. Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression. *J Med Chem*. 2021 Oct 14;64(19):14540-14556. PMID: 34613724. PMCID: PMC8862192.
- 48 He B, Xiao Y, Liang H, Huang Q, Du Y, Li Y, Garmire D, **Sun D**, Garmire LX. ASGARD: A Single-cell Guided pipeline to Aid Repurposing of Drugs. *ArXiv*. 2021 Sep 14. PMID: 34545335; PMCID: PMC8452105.
- 49 Xiang W, Zhao L, Han X, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Kirchhoff PD, Wang L, Matvekas A, He M, Wen B, **Sun D**, Wang S. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degradator of Androgen Receptor for the Treatment of Advanced Prostate Cancer. *J Med Chem*. 2021 Sep 23;64(18):13487-13509. PMID: 34473519. PMCID: PMC8855934.
- 50 Han X, Zhao L, Xiang W, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Wang L, Matvekas A, Wen B, **Sun D**, Wang S. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degradators of Androgen Receptor for the Treatment of Prostate Cancer. *J Med Chem*. 2021 Sep 9;64(17):12831-12854. PMID: 34431670. PMCID: PMC8880306.
- 51 Chen H, Chengalvala V, Hu H, **Sun D**. Tumor-derived exosomes: Nanovesicles made by cancer cells to promote cancer metastasis. *Acta Pharm Sin B*. 2021 Aug;11(8):2136-2149. PMID: 34522581 PMCID: PMC8424275.
- 52 Luan X, Yuan H, Song Y, Hu H, Wen B, He M, Zhang H, Li Y, Li F, Shu P, Burnett JP, Truchan N, Palmisano M, Pai MP, Zhou S, Gao W, **Sun D**. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. *Biomaterials*. 2021 Aug;275:120910. PMID: 34144373. PMCID: PMC8883361.
- 53 Liu Y, Zhao Y, Shukha Y, Lu H, Wang L, Liu Z, Liu C, Zhao Y, Wang H, Zhao G, Liang W, Fan Y, Chang L, Yurdagul A Jr, Pattillo CB, Orr AW, Aviram M, Wen B, Garcia-Barrio MT, Zhang J, Liu W, **Sun D**, Hayek T, Chen YE, Rom O. Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis. *Cell Rep*. 2021 Jul 27;36(4):109420. PMID: 34320345 PMCID: PMC8363062.
- 54 Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, **Sun D**, Deng J, Zhang J. Author Correction: Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3 β signaling. *Sci Rep*. 2021 Jul 20;11(1):15201. PMID: 34285337 PMCID: PMC8292357.
- 55 Zhou H, Bai L, Xu R, McEachern D, Chinnaswamy K, Li R, Wen B, Wang M, Yang CY, Meagher JL, **Sun D**, Stuckey JA, Wang S. SD-91 as A Potent and Selective STAT3 Degradator Capable of Achieving Complete and Long-Lasting Tumor Regression. *ACS Med Chem Lett*. 2021 Jun 10;12(6):996-1004. PMID: 34141084 PMCID: PMC8201759.
- 56 Rogawski DS, Deng J, Li H, Miao H, Borkin D, Purohit T, Song J, Chase J, Li S, Ndoj J, Klossowski S, Kim E, Mao F, Zhou B, Ropa J, Krotoska MZ, Jin Z, Ernst P, Feng X, Huang G, Nishioka K, Kelly S, He M, Wen B, **Sun D**, Muntean A, Dou Y, Maillard I, Cierpicki T, Grembecka J. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. *Nat Commun*. 2021 May 14;12(1):2792. PMID: 33990599 PMCID: PMC8121805.

- 57 Wang H, Ong E, Kao JY, **Sun D**, He Y. Reverse Microbiomics: A New Reverse Dysbiosis Analysis Strategy and Its Usage in Prediction of Autoantigens and Virulent Factors in Dysbiotic Gut Microbiomes from Rheumatoid Arthritis Patients. *Front Microbiol.* 2021;12:633732. PMID: 33717026 PMCID: PMC7947680.
- 58 Wang Y, Xie Y, Niu Y, Song P, Liu Y, Burnett J, Yang Z, **Sun D**, Ran Y, Li Y, Sun L. Carboxypeptidase A4 negatively correlates with p53 expression and regulates the stemness of breast cancer cells. *Int J Med Sci.* 2021;18(8):1753-1759. PMID: 33746592 PMCID: PMC7976593.
- 59 Ali R, Gandhi A, Dai L, Weiner J, Estes S, Yalvarthi S, Gockman K, **Sun D**, Knight J. Antineutrophil properties of natural gingerols in models of lupus. *JCI Insight.* 2021 Feb 8;6(3):138385. PMID: 33373329 PMCID: PMC7934838.
- 60 Huddle B, Grimley E, Chrcherbinine M, Buchman C, Takahashi C, Debnath B, McGonigal S, Mao S, Li S, Felton J, Pan S, Wen B, **Sun D**, Neamati N, Buckanovich R, Hurley T, Larsen S. Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A. *Eur J Med Chem.* 2021 Feb 5;211:113060. PMID: 33341649. PMCID: PMC7855449.
- 61 Liu Y, Hur J, Chang WKB, Wang Z, Xie J, **Sun D**, Handelman S, Sexton J, Yu H, He Y. Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection. *Sci Data.* 2021 Jan 13;8(1):16. PMID: 33441564. PMCID: PMC7806933.
- 62 Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, Villacorta L, Fan Y, Chang L, Wang L, Liu C, Yang D, Song J, Rech JC, Guo Y, Wang H, Zhao G, Liang W, Koike Y, Lu H, Koike T, Hayek T, Pennathur S, Xi C, Wen B, **Sun D**, Garcia-Barrio MT, Aviram M, Gottlieb E, Mor I, Liu W, Zhang J, Chen YE. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. *Sci Transl Med.* 2020 Dec 2;12(572):eaaz2841. PMID: 33268508. PMCID: PMC7982985.
- 63 Chen J, Zhou Y, Dong X, Liu L, Bai L, McEachern D, Przybranowski S, Yang CY, Stuckey J, Li X, Wen B, Zhao T, Sun S, **Sun D**, Jiao L, Jing Y, Guo M, Yang D, Wang S. Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. *J Med Chem.* 2020 Nov 25;63(22):13994-14016. PMID: 33185101. PMCID: PMC8855370.
- 64 Wilson MW, Shu L, Hinkovska-Galcheva V, Jin Y, Rajeswaran W, Abe A, Zhao T, Luo R, Wang L, Wen B, Liou B, Fannin V, Sun D, Sun Y, Shayman JA, Larsen SD. Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3. *ACS Chem Neurosci.* 2020 Oct 21;11(20):3464-3473. PMID: 33035424. PMCID: PMC7919060.
- 65 **Sun D**, Zhou S, Gao W. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right. *ACS Nano.* 2020 Oct 27;14(10):12281-12290. PMID: 33021091.
- 66 Hu S, Sechi M, Singh PK, Dai L, McCann S, Sun D, Ljungman M, Neamati N. A Novel Redox Modulator Induces a GPX4-Mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species. *J Med Chem.* 2020 Sep 10;63(17):9838-9855. PMID: 32809827. PMCID: PMC8082945.
- 67 **Sun D**. Correction to: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit. *AAPS J.* 2020 Aug 2;22(5):102. PMID: 32743771. PMCID: PMC7396203.
- 68 Bailey CM, Liu Y, Peng G, Zhang H, He M, **Sun D**, Zheng P, Liu Y, Wang Y. Liposomal formulation of HIF-1 α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer. *Nanomedicine.* 2020 Oct;29:102278. PMID: 32738299. PMCID: PMC7508926.

- 69 Li Y, Palmisano M, **Sun D**, Zhou S. Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies. *Clin Pharmacol*. 2020 Jul 1;12:83-96. PMID: 32669879. PMCID: PMC7335848.
- 70 Rej RK, Wang C, Lu J, Wang M, Petrunak E, Zawacki KP, McEachern D, Fernandez-Salas E, Yang CY, Wang L, Li R, Chinnaswamy K, Wen B, **Sun D**, Stuckey J, Zhou Y, Chen J, Tang G, Wang S. EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development. *J Med Chem*. 2020 Jul 9;63(13):7252-7267. PMID: 32580550. PMCID: PMC8859984.
- 71 Yuan H, Guo H, Luan X, He M, Li F, Burnett J, Truchan N, **Sun D**. Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer. *Mol Pharm*. 2020 Jul 6;17(7):2275-2286. PMID: 32485107. PMCID: PMC8829889.
- 72 Gasparyan M, Lo MC, Jiang H, Lin CC, **Sun D**. Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer. *J Biol Chem*. 2020 Aug 21;295(34):12188-12202. PMID: 32467227. PMCID: PMC7443492.
- 73 **Sun D**. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit. *AAPS J*. 2020 May 26;22(4):77. PMID: 32458279. PMCID: PMC7250281.
- 74 Liu X, Wilson MW, Liu K, Lee P, Yeomans L, Hagen SE, Lin CM, Wen B, **Sun D**, White AD, Showalter HD, Antonetti DA. Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidines as atypical protein kinase C inhibitors to control retinal vascular permeability and cytokine-induced edema. *Bioorg Med Chem*. 2020 Jun 1;28(11):115480. PMID: 32327351. PMCID: PMC7318885.
- 75 Lin CC, Lo MC, Moody R, Jiang H, Harouaka R, Stevers N, Tinsley S, Gasparyan M, Wicha M, **Sun D**. Corrigendum to "Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer" [*Canc. Lett.* 438 (2018, Dec 1) 165-173]. *Cancer Lett*. 2020 Jun 28;480:51. PMID: 32229161.
- 76 Ji X, Xie S, Jiao Y, Zhang X, **Sun D**, Yang VC, Wang M, He H, Sun L. MT1-MMP activatable fluorogenic probes with enhanced specificity via high-affinity peptide conjugation for tumor imaging. *Biomater Sci*. 2020 Apr 21;8(8):2308-2317. PMID: 32186291. PMCID: PMC8859983.
- 77 Wang Y, Liu Y, Bailey C, Zhang H, He M, **Sun D**, Zhang P, Parkin B, Baer MR, Zheng P, Malek SN, Liu Y. Therapeutic targeting of TP53 mutated acute myeloid leukemia by inhibiting HIF-1 α with echinomycin. *Oncogene*. 2020 Apr;39(14):3015-3027. PMID: 32060420. PMCID: PMC7291851.
- 78 Liu X, Wilson MW, Liu K, Lee P, Yeomans L, Hagen SE, Lin CM, Wen B, **Sun D**, White AD, Showalter HD, Antonetti DA. Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidines as atypical protein kinase C inhibitors to control retinal vascular permeability and cytokine-induced edema. *Bioorg Med Chem*. 2020 Apr 3:115480. PMID: 32327351. PMCID: PMC7318885.
- 79 Ji X, Xie S, Jiao Y, Zhang X, **Sun D**, Yang VC, Wang M, He H, Sun L. MT1-MMP activatable fluorogenic probes with enhanced specificity via high-affinity peptide conjugation for tumor imaging. *Biomater Sci*. 2020 Apr 21;8(8):2308-2317. PMID: 32186291. PMCID: PMC8859983.

- 80 Zwicker JD, Smith D, Guerra AJ, Hitchens JR, Haug N, Vander Roest S, Lee P, Wen B, **Sun D**, Wang L, Keep RF, Xiang J, Carruthers VB, Larsen S Discovery and Optimization of Triazine Nitrile Inhibitors of Toxoplasma gondii Cathepsin L for the Potential Treatment of Chronic Toxoplasmosis in the CNS. ACS Chem Neurosci. 2020 Feb 18. PMID: 32027110. PMCID: PMC7431380.
- 81 Chen H, Luan X, Paholak HJ, Burnett JP, Stevers NO, Sansanaphongpricha K, He M, Chang AE, Li Q, **Sun D**. Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy. Nanomedicine (Lond). 2020 Jan;15(1):77-92. PMID: 31868112. PMCID: PMC7132783.
- 82 Wang Y, Zhao L, Han X, Wang Y, Mi J, Wang C, **Sun D**, Fu Y, Zhao X, Guo H, Wang Q. Saikosaponin A Inhibits Triple-Negative Breast Cancer Growth and Metastasis Through Downregulation of CXCR4. Front Oncol. 2020 Jan 28;9:1487. PMID 32047724. PMCID: PMC6997291.
- 83 Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, Linhares BM, Chen **D**, Jih G, Perkey E, Huang H, He M, Wen B, Wang Y, Yu K, Lee SC, Danet-Desnoyers G, Trotman W, Kandarpa M, Cotton A, Abdel-Wahab O, Lei H, Dou Y, Guzman M, Peterson L, Gruber T, Choi S, **Sun D**, Ren P, Li LS, Liu Y, Burrows F, Maillard I, Cierpicki T, Grembecka J. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020 Jan 21. PMID: 31855575. PMCID: PMC6997291.
- 84 Zhou H, Bai L, Xu R, Zhao Y, Chen J, McEachern D, Chinnaswamy K, Wen B, Dai L, Kumar P, Yang CY, Liu Z, Wang M, Liu L, Meagher JL, Yi H, **Sun D**, Stuckey JA, Wang S. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degradator of STAT3 Protein. J Med Chem. 2019 Dec 26;62(24):11280-11300. PMID: 31747516. PMCID: PMC8848307.
- 85 Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, Chen J, Yang CY, Liu Z, Wang M, Liu L, Jiang H, Wen B, Kumar P, Meagher JL, **Sun D**, Stuckey JA, Wang S. A Potent and Selective Small-Molecule Degradator of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 2019 Nov 11;36(5):498-511.e17. PMID: 31715132. PMCID: PMC6880868.
- 86 Yu A, Koenigsnecht MJ, Hens B, Baker JR, Wen B, Jackson TL, Pai MP, Hasler W, Amidon GL, **Sun D**. Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. AAPS J. 2019 Nov 11;22(1):3. PMID: 31712917.
- 87 Das NK, Schwartz AJ, Barthel G, Inohara N, Liu Q, Sankar A, Hill DR, Ma X, Lamberg O, Schnizlein MK, Arqués JL, Spence JR, Nunez G, Patterson AD, **Sun D**, Young VB, Shah YM. Microbial Metabolite Signaling Is Required for Systemic Iron Homeostasis. Cell Metab. 2020 Jan 7;31(1):115-130.e6. PMID: 31708445.
- 88 Shu P, Zhao T, Wen B, Mendelsohn-Victor K, **Sun D**, Friese CR, Pai MP. Application of an innovative high-throughput liquid chromatography-tandem mass spectrometry method for simultaneous analysis of 18 hazardous drugs to rule out accidental acute chemotherapy exposures in health care workers. J Oncol Pharm Pract. 2019 Sep 4:1078155219870591. PMID: 31483750.
- 89 Chen H, Hu H, Tao C, Clauson RM, Moncion I, Luan X, Hwang S, Sough A, Sansanaphongpricha K, Liao J, Paholak HJ, Stevers NO, Wang G, Liu B, **Sun D**. Self-Assembled Au@Fe Core/Satellite Magnetic Nanoparticles for Versatile Biomolecule Functionalization. ACS Appl Mater Interfaces. 2019 Jul 10;11(27):23858-23869. PMID: 31245984.
- 90 Li F, Yuan H, Zhang H, He M, Liao J, Chen N, Li Y, Zhou S, Palmisano M, Yu A, Pai M, **Sun D**. Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel. Mol Pharm. 2019 Jun 3;16(6):2385-2396. PMID: 31002261.

- 91 Gan X, Wilson MW, Beyett TS, Wen B, **Sun D**, Larsen SD, Tesmer JJG, Saltiel AR, Showalter HD. Synthesis of deuterium-labelled amlexanox and its metabolic stability against mouse, rat, and human microsomes. *J Labelled Comp Radiopharm*. 2019 May 15;62(5):202-208. PMID:30828860.
- 92 Kahl DJ, Hutchings KM, Lisabeth EM, Haak AJ, Leipprandt JR, Dexheimer T, Khanna D, Tsou PS, Campbell PL, Fox DA, Wen B, **Sun D**, Bailie M, Neubig RR, Larsen SD. 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. *J Med Chem*. 2019 Apr 18. PMID:30951312.
- 93 Dai W, Samanta S, Xue D, Petrunak EM, Stuckey JA, Han Y, **Sun D**, Wu Y, Neamati N. Structure-Based Design of N-(5-Phenylthiazol-2-yl) acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors. 2019 Mar 28;62(6):3068-3087. PMID: 30735370.
- 94 Seekatz AM, Schnizlein MK, Koenigsknecht MJ, Baker JR, Hasler WL, Bleske BE, Young VB, **Sun D**. Spatial and Temporal Analysis of the Stomach and Small-Intestinal Microbiota in Fasted Healthy Humans. *mSphere*. 2019 Mar 13;4(2). PMID: 30867328.
- 95 Baker JR, Dickens JR, Koenigsknecht M, Frances A, Lee AA, Shedden KA, Brasseur JG, Amidon GL, **Sun D**, Hasler WL. Propagation Characteristics of Fasting Duodeno-Jejunal Contractions in Healthy Controls Measured by Clustered Closely spaced Manometric Sensors. *Journal Neurogastroenterol Motility*. 2019 Jan 31;25(1):100-112. PMID: 30646481.
- 96 Sun L, Yuan H, Burnett J, Gasparyan M, Zhang Y, Zhang F, Yang Z, Ran Y, **Sun D**. MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung Cancer. *International Journal of Medical Sciences*. 2019 Jan 1;16(1):68-74. PMID: 30662330.
- 97 Paixao P, Bermejo M, Hens B, Tsume Y, Dickens J, Shedden K, Salehi N, Koenigsknecht MJ, Baker JR, Hasler WL, Lionberger R, Fan J, Wysocki J, Wen B, Lee A, Frances A, Amidon GE, Yu A, Benninghoff G, Lobenberg R, Talattof A, **Sun D**, Amidon GL. Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 2: Fed State. *Molecular Pharmceutics*. 2018 Dec 3;15(12):5468-5478. PMID: 30417648.
- 98 Bermejo M, Paixao P, Hens B, Tsume Y, Koenigsknecht MJ, Baker JR, Hasler WL, Lionberger R, Fan J, Dickens J, Shedden K, Wen B, Wysocki J, Lobenberg R, Lee A, Frances A, Amidon GE, Yu A, Salehi N, Talattof A, Benninghoff G, **Sun D**, Kuminek G, Cavanagh KL, Rodriguez-Hornedo N, Amidon GL. Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions. *Molecular Pharmaceutics*. 2018 Dec 3;15(12):5454-5467. PMID: 30372084.
- 99 Li YF, Zhang C, Zhou S, He M, Zhang H, Chen N, Li F, Luan X, Pai M, Yuan H, **Sun D**, Li Y. Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans. *Clinical Pharmacology*. 2018 Nov 8;10:165-174. PMID: 30519122.
- 100 Yu J, Chen J, Zhao H, Gao J, Li Y, Li Y, Xue J, Dahan A, **Sun D**, Zhang G, Zhang H. Integrative proteomics and metabolomics analysis reveals the toxicity of cationic liposomes to human normal hepatocyte cell line L02. *Mol Omics*. 2018 Oct 8;14(5):362-272. PMID: 30247494.
- 101 Li F, Zhang H, He M, Liao J, Chen N, Li Y, Zhou S, Palmisano M, Yu A, Pai MP, **Sun D**. Different nanoformulations alter the tissue distribution of paclitaxel, which aligns with reported distinct efficacy and safety profiles. *Molecular Pharmaceutics*. 2018 Oct 1;15(10):4505-4516. PMID: 30180593.

- 102 Huddle BC, Grimley E, Buchman CD, Chtcherbinine M, Debnath B, Mehta P, Yang K, Morgan CA, Li S, Felton J, **Sun D**, Mehta G, Neamati N, Buchanovich RJ, Hurley TD, Larsen SD. Structure-based optimization of a novel class of aldehyde dehydrogenase 1A (ALDH1A) subfamily-selective inhibitors as potential adjuncts to ovarian cancer chemotherapy. *J Med Chem*. 2018 Sep 28. PMID: 30221940.
- 103 Lin CC, Lo MC, Moody R, Jiang H, Harouaka R, Stevers N, Tinsley S, Gasparyan M, Wicha M, **Sun D**. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer. *Cancer Lett*. 2018 Sep 15;438:165-173. PMID: 30227220.
- 104 Tsume Y, Patel S, Fotaki N, Bergstrom C, Amidon GL, Brasseur JG, Mudie DM, **Sun D**, Bermejo M, Gao P, Zhu W, Sperry DC, Vertzoni M, Parrott N, Lionberger R, Kambayashi A, Hermans A, Lu X, Amidon GE. In vivo predictive dissolution and simulation workshop report: facilitating the development of oral drug formulation and the prediction of oral bioperformance. *AAPS Journal*. 2018 Sep 6;20(6):100. PMID: 30191341.
- 105 Luan X, Guan YY, Liu HJ, Lu Q, Zhao M, **Sun D**, Lovell JF, Sun P, Chen HZ, Fang C. A tumor vascular-targeted interlocking trimodal nanosystem that induces and exploits hypoxia. *Advanced Science*. 2018 May 28;5(8):1800034. PMID: 30128230.
- 106 Paixao P, Bermejo M, Hens B, Tsume Y, Dickens J, Shedden K, Salehi N, Koenigsnecht MJ, Baker JR, Hasler WL, Lionberger R, Fan J, Wysocki J, Wen B, Lee A, Frances A, Amidon GE, Yu A, Benninghoff G, Lobenberg R, Talattof A, **Sun D**, Amidon GL. Gastric Emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. *Eur J Pharm Biopharm*. 2018 Aug;129:162-174. PMID:29857136.
- 107 Zhao Y, Zhou B, Bai L, Liu L, Yang CY, Meagher JL, Stuckey JA, McEachern D, Przybranowski S, Wang M, Ran X, Aguilar A, Hu Y, Kampf JW, Li X, Zhao T, Li S, Wen B, **Sun D**, Wang S. Structure-Based Discover of CF53 as a Potent and Orally Bioavailable Bromodomain and extra-Terminal (BET) Bromodomain Inhibitor. *J Med Chem*. 2018 Jul 26;61(14):6110-6120. PMID: 30015487.
- 108 Chong Q, Hu Y, Zhou B, Fernandez-Salas E, Yang C, Liu L, McEachern D, Przybranowski S, Wang M, Stuckey J, Meagher J, Bai L, Chen Z, Lin M, Yang J, Ziazadeh D, Xu F, Hu J, Huang L, Siwei L, Wen B, **Sun D**, Wang S. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degradar of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. *Journal of Medicinal Chemistry*. 2018, July 18. PMID: 30019901
- 109 Hens B, Sinko P, Job N, Dean M, Al-Gousous J, Salehi N, Ziff RM, Tsume Y, Bermejo M, Paixao P, Brasseur JG, Yu A, Talattof A, Benninghoff G, Langguth P, Lennernas H, Hasler WL, Marciani L, Dickens J, Shedden K, **Sun D**, Amidon GE, Amidon GL. Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded '21st century BA/BE' project. *Int J Pharm*. 2018 Sep 5;548(1):120-127. PMID: 29944899
- 110 Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, Wei S, Zhao L, Vatan L, Wen B, **Sun D**, Klier C, Wicha M, Sabel M, Tao K, Wang G, Zou W. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEPBP isoform in triple-negative breast cancer. *Cell Metabolism*. 2018 Jul 3;28(1):87-103.e6. PMID: 29805099.
- 111 Luan X, Guan Y, Liu Q, Zhao M, **Sun D**, Lovell JF, Sun P, Chen H, Fang C. A Tumor Vascular-Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia. 2018 May28;5(8):1800034. PMID: 30128230.

- 112 Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, Zhao X, Bellile EL, Hu H, Chen H, Polverini PJ, Chen Q, Young S, Carey TE, Nör JE, Ferris RL, Wolf G, Sun D, Lei YL. Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine. *Clin Cancer Res*. 2018 May 16. PMID: 29769207.
- 113 Borkin D, Klossowski S, Pollock J, Miao H, Linhares BM, Kempinska K, Jin Z, Purohit T, Wen B, He M, **Sun D**, Cierpicki T, Grembecka J. Complexity of blocking bivalent protein-protein interactions: Development of a highly potent inhibitor of the menin-mixed-lineage leukemia interaction. *J Med Chem*. 2018 May 23. PMID: 29738674.
- 114 Madak JT, Cuthbertson CR, Miyata Y, Tamura S, Petrunak EM, Stuckey JA, Han Y, He M, **Sun D**, Showalter HD, Neamati N. Design, synthesis, and biological evaluation of 4-quinoline carboxylic acids as inhibitors of dihydroorotate dehydrogenase. *J Med Chem*. 2018 May 14. PMID: 29727569.
- 115 Lin C-C, Lo M-C, Moody RR, Stevers NO, Tinsley SL, **Sun D**. Doxycycline targets aldehyde dehydrogenase-positive breast cancer stem cells. *Oncology Reports*. 2018 Jun;39(6):3041-3047. PMID: 29620216.
- 116 Tan YS, Sansanaphongpricha K, Prince MEP, **Sun D**, Wolf GT, Lei YL. Engineering vaccines to reprogram immunity against head and neck cancer. *J Dent Res*. 2018 Jun;97(6):627-634. PMID: 29533731.
- 117 Zwicker JD, Diaz NA, Guerra AJ, Kirchoff PD, Wen B, **Sun D**, Carruthers VB, Larsen SD. Optimization of dipeptidic inhibitors of cathepsin L for improved *Tosoplasma gondii* selectivity and CNS permeability. *Bioorg Med Chem Lett*. 2018 Jun 1;28(10):1972-1980. PMID: 29650289.
- 118 Moody RR, Lo MC, Meagher JL, Lin CC, Stevers NO, Tinsley SL, Jung I, Matvekas A, Stuckey JA, **Sun D**. Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epeigenetic complexes. *J Biol Chem*. 2018 Feb 9;293(6):2125-2136. PMID: 29263092.
- 119 Ye G, Jiang Y, Yang X, Hu H, Wang B, Sun L, Yang VC, **Sun D**, Gao W. Smart nanoparticles undergo phase transition for enhanced cellular uptake and subsequent intracellular drug release in a tumor microenvironment. *ACS Appl Mater Interfaces*. 2018 Jan 10;10(1):278-289. PMID: 29260563.
- 120 Conner TM, Nikolian VC, Georgoff PE, Pai MP, Alam HB, **Sun D**, Reed RC, Zhang T. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex. *Eur J Pharm Sci*. 2018 Jan 1;111:465-481. PMID: 29030176.
- 121 Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, To K, Watcharotone K, Parameswaran A, Luo R, **Sun D**, Alam HB. Safety and tolerability of intravenous valproic acid in healthy subjects: A phase I dose-escalation trial. *Clin Pharmacokinet*. 2018 Feb;57(2):209-219. PMID: 28497259.
- 122 Koenigsnecht MJ, Baker JR, Wen B, Frances A, Zhang H, Yu A, Zhao T, Tsume Y, Pai MP, Bleske BE, Zhang X, Lionberger R, Lee A, Amidon GL, Hasler WL, **Sun D**. In vivo dissolution and systemic absorption of immediate release ibuprofen in human gastrointestinal tract under fed and fasted conditions. *Mol Pharm*. 2017 Dec 4;14(12):4295-4304. PMID: 28937221.
- 123 Hens B, Tsume Y, Bermejo M, Paixao P, Koenigsnecht MJ, Baker JR, Hasler WL, Lionberger R, Fan J, Dickens J, Shedden K, Wen B, Wysocki J, Loebenberg R, Lee A, Frances A, Amidon G, Yu A, Benninghoff G, Salehi N, Talattof A, **Sun D**, Amidon GL. Low buffer capacity and alternating motility along the human gastrointestinal tract: Implications for in vivo dissolution and absorption of ionizable drugs. *Mol Pharm*. 2017 Dec 4;14(12):4281-4294. PMID: 28737409.

- 124 Yu A, Jackson T, Tsume Y, Koenigsknecht M, Wysocki J, Marciani L, Amidon GL, Frances A, Baker JR, Hasler W, Wen B, Pai A, **Sun D**. Mechanistic fluid transport model to estimate gastrointestinal fluid volume and its dynamic change over time. *AAPS J*. 2017 Nov;19(6):1682-1690. PMID:28980204.
- 125 Connarn JN, Flowers S, Kelly M, Luo R, Ward KM, Harrington G, Moncion I, Kamali M, McInnis M, Feng MR, Ellingrod V, Babiskin A, Zhang X, **Sun D**. Pharmacokinetics and pharmacogenomics of bupropion in three different formulations with difference release kinetics in healthy human volunteers. *AAPS J*. 2017 Sep;19(5):1513-1522. PMID: 28685396.
- 126 Kick BL, Shu P, Wen B, **Sun D**, Taylor DK. Pharmacokinetic profiles of nalbuphine after intraperitoneal and subcutaneous administration to C57BL/6 mice. *J Am Assoc Lab Anim Sci*. 2017 Sep 1;56(5):534-538. PMID: 28903824.
- 127 Yu J, Zhang H, Li Y, Sun S, Gao J, Zhong Y, **Sun D**, Zhang G. Metabolomics revealed the toxicity of cationic liposomes in HepG2 cells using UHPLC-Q-TOF/MS and multivariate data analysis. *Biomed Chromatogr*. 2017 Dec;31(12). PMID: 28664536.
- 128 Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S. Discovery of a small-molecule degrader of Bromodomain and Extra-Terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. *J Med Chem*. 2018 Jan 25;61(2):462-481. PMID: 28339196.
- 129 Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, **Sun D**. Engineering exosomes as refined biological nanoplatfoms for drug delivery. *Acta Pharmacol Sin*. 2017 Jun;38(6)754-763. PMID: 28392567.
- 130 Sun L, Cao J, Guo C, Burnett J, Yang Z, Ran Y, **Sun D**. Associations of carboxypeptidase 4 with ALDH1A1 expression and their prognostic value in esophageal squamous cell carcinoma. *Dis Esophagus*. 2017 Jun 1; 30(6):1-5. PMID: 28475748.
- 131 Sun L, Guo C, Cao J, Burnett J, Yang Z, Ran Y, **Sun D**. Over-expression of alpha-enolase as a prognostic biomarker in patients with pancreatic cancer. *Int J Med Sci*. 2017 Jun 22;14(7):655-661. PMID: 28824297.
- 132 Karatas H, Li Y, Liu L, Ji J, Lee S, Chen Y, Yang J, Huang L, Bernard D, Xu J, Townsend EC, Cao F, Ran X, Li X, Wen B, **Sun D**, Stuckey JA, Lei M, Dou Y, Wang S. Discovery of a highly potent, cell-permeable macrocyclic peptidomimetic (MM-589) targeting the WD repeat domain 5 protein (WDR5)-mixed lineage leukemia (MLL) protein-protein interaction. *J Med Chem*. 2017 Jun 22;60(12):4818-4839. PMID: 28603984.
- 133 Zhao Y, Bai L, Liu L, McEachern D, Stuckety JA, Meagher JL, Yang CY, Ran X, Zhou B, Hu Y, Li X, Wen B, Zhao T, Li S, **Sun D**, Wang S. Structure-based discovery of 4-(6-methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a potent and orally bioavailable BET bromodomain inhibitor. *J Med Chem*. 2017 May 11;60(9):3887-3901. PMID: 28463487.
- 134 Wang M, Xie F, Wen X, Chen H, Zhang H, Liu J, Zhang H, Zou H, Yu Y, Chen Y, Sun Z, Wang X, Zhang G, Yin C, **Sun D**, Gao J, Jiang B, Zhong Y, Lu Y. Therapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cells. *Nanomedicine (Lond)*. 2017 May;12(9):1025-1042. PMID: 28440698.
- 135 Tsume Y, Matsui K, Searls AL, Takeuchi S, Amidon GE, Sun D, Amidon GL. The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS). *Eur J Pharm Sci*. 2017 May 1; 102:126-139. PMID: 28263914.

- 136 Hutchings KM, Lisabeth EM, Rajeswaran W, Wilson MW, Sorenson RJ, Campbell PL, Ruth JH, Amin A, Tsou PS, Leipprandt JP, Olson SR, Wen B, Zhao T, **Sun D**, Khanna D, Fox DA, Neubig RR, Larsen SD. Pharmacokinetic optimization of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. *Bioorg Med Chem Lett*. 2017 Apr 15;27(8):1744-1749. PMID: 28285914.
- 137 Aguilar A, Lu J, Liu L, Du D, Bernard D, McEachern D, Przybranowski S, Li X, Luo R, Wen B, **Sun D**, Wang H, Wen J, Wang G, Zhai Y, Guo M, Yang D, Wang S. Discovery of 4-((3'R,4'S,5'R)-6'' -Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2'' -oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3'' -indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. *J Med Chem*. 2017 Apr 13;60(7):2819-2839. PMID: 28339198.
- 138 Patel TS, Cinti S, **Sun D**, Li S, Luo R, Wen B, Gallagher BA, Stevenson JG. Oseltamivir for pandemic influenza preparation: Maximizing the use of an existing stockpile. *Am J Infect Control*. 2017 Mar 1;45(3):303-305. PMID: 27816215.
- 139 Burnett JP, Lim G, Shah RB, Lim R, Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, Wicha MS, **Sun D**, Zhang T. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells. *Cancer Lett*. 2017 May 28;394:52-64. PMID: 28254410.
- 140 Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, **Sun D**, Meagher JL, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Targeted degradation of BET proteins in triple-negative breast cancer. *Cancer Res*. 2017 May 1; 77(9):2476-2487. PMID: 28209615.
- 141 Sansanaphongpricha K, DeSantis MC, Chen H, Cheng W, Sun K, Wen B, **Sun D**. Multibuilding block Janus synthesized by seed-mediated self-assembly for enhanced photothermal effects and colored Brownian motion in an optical trap. *Small*. 2017 Feb;13(6):1603569. PMID: 27873448.
- 142 Yu A, Baker JR, Fioritto AF, Wang Y, Luo R, Li S, Wen B, Bly M, Tsume Y, Koenigsnecht MJ, Zhang X, Lionberger R, Amidon GL, Hasler WL, **Sun D**. Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. *Mol Pharm*. 2017 Feb 6;14(2):345-358. PMID: 28009518.
- 143 Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, **Sun D**, Deng J, Zhang J. Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3 β signaling. *Sci Rep*. 2017 Jan 30;7:41656. PMID: 28134352.
- 144 Dahl JU, Gray MJ, Bazopoulou D, Beaufay D, Beaufay F, Lempart J, Koenigsnecht MJ, Wang Y, Baker JR, Hasler WL, Young VB, **Sun D**, Jakob U. The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation. *Nat Microbiol*. 2017 Jan 23;2:16267. PMID: 28112760.
- 145 Luo R, LI Y, He M, Zhang H, Yuan H, Johnson M, Palmisano M, Zhou S, **Sun D**. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. *Int J Pharm*. 2017 Jan 4;519(1-2):1-10. PMID: 28063903.
- 146 Chen D, Xie F, **Sun D**, Yin C, Gao J, Zhong Y. Nanomedicine-mediated combination drug therapy in tumor. *Open Pharmaceutical Science Journal*. 2017 Jan;4:1-10. DOI:10.2174/1874844901704010001.
- 147 Mahran RI, Hagra MM, **Sun D**, Brenner DE. Bringing curcumin to the clinic in cancer prevention: A review of strategies to enhance bioavailability and efficacy. *AAPS J*. 2017 Jan;19(1):54-81. PMID: 27783266.

- 148 Sun L, Guo C, Burnett JP, Pan J, Yang Z, Ran Y, **Sun D**. Association between expression of Carboxypeptidase 4 and stem cell markers and their clinical significance in liver cancer development. *Journal of Cancer*. 2017 Jan 1;8(1):111-116. PMID: 28123604.
- 149 Connarn JN, Luo R, Windak J, Zhang X, Babiskin A, Kelly M, Harrington G, Ellingrod VL, Kamali M, McInnis M, and **Sun D**. Identification of non-reported bupropion metabolites in human plasma. *Biopharm Drug Disposition*. 2016 Dec;37(9):550-560. PMID: 27723114.
- 150 Wagner D, Caraballo M, Waldvogel J, Peterson Y, **Sun D**. In vitro effects of an extracorporeal membrane oxygenation circuit on the sequestration of ϵ -aminocaproic acid. *Perfusion*. 2017 Apr;32(3):226-229. PMID: 27815558.
- 151 Sun L, Guo C, Burnett JP, Yang Z, Ran Y, **Sun D**. Serum carboxypeptidaseA4 levels predict liver metastasis in colorectal carcinoma. *Oncotarget*. 2016 Nov 29;7(48):78688-78697. PMID: 27780921.
- 152 Sun L, Guo C, Yuan H, Burnett JP, Pan J, Yang Z, Ran Y, Myers I, **Sun D**. Overexpression of carboxypeptidase A4 (CPA4) is associated with poor prognosis in patients with gastric cancer. *American Journal of Translational Research*. 2016 Nov 15;8(11):5071-5075. eCollection 2016. PMID: 27904708.
- 153 Zhang H, Lauver DA, Wang H, **Sun D**, Hollenberg PF, Chen YE, Osawa Y, Eitzman DT. Significant improvement of antithrombotic responses to clopidogrel by use of a novel conjugate as revealed in an arterial model of thrombosis. *J Pharmacol Exp Ther*. 2016 Oct;359(1):11-7. PMID: 27511819.
- 154 Sun L, Burnett JP, Zou H, **Sun D**. Overexpression of ALDH1A1 is associated with poor prognosis and therapeutic effects of sulforaphane in esophageal cancer. *Int J Clin Exp Pathol*. 2016;9(11):11670-11675.
- 155 Costa MD, Ashraf NS, Fischer S, Yang Y, Schapka E, Joshi G, McQuade TJ, Dharia RM, Dulchavsky M, Ouyang M, Cook D, **Sun D**, Larsen MJ, Gestwicki JE, Todi SV, Ivanova MI, Paulson HL. Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3. *Brain*. 2016 Nov 1;139(11):2891-2908. PMID: 27645800.
- 156 Jia T, Sun Z, Lu Y, Gao J, Zou H, Xie F, Zhang G, Xu H, **Sun D**, Yu Y, Zhong Y. A dual brain-targeting curcumin-loaded polymersomes ameliorated cognitive dysfunction in intrahippocampal amyloid- β 1-42-injected mice. *Int J Nanomedicine*. 2016 Aug 5;11:3765-75. eCollection 2016. PMID: 27540290.
- 157 Paholak HJ, Stevers NO, Chen H, Burnett JP, He M, Korkaya H, McDermott SP, Deol Y, Clouthier SG, Luther T, Li Q, Wicha MS, **Sun D**. Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy. *Biomaterials*. 2016 Oct;104:145-57. PMID: 27450902.
- 158 Sun L, Wang Y, Yuan H, Burnett JP, Pan J, Yang Z, Ran Y, Myers I, **Sun D**. CPA4 is a novel diagnostic and prognostic marker for human non-small-cell lung cancer. *J Cancer*. 2016;7(10):1197-1204. PMID: 27390594.
- 159 Sun L, Burnett JP, Gasparyan M., Xu F, Jiang H, Lin C-C, Myers I, Korkaya H, Liu Yajing, Connarn J, He H, Zhang N, Wicha MS, **Sun D**. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer. *Oncotarget*. 2016 Aug 9;7(32):51408-51422. PMID: 27285982.
- 160 Passalacqua KD, Charbonneau ME, Donato N, Showalter H, **Sun D**, Wen B, He M, Sun H, O'Riordan M, Wobu C. Anti-infective activity of 2-cyano-3-acrylamide inhibitors with improved drug-like properties against two intracellular pathogens. *American Society for Microbiology*. 2016 Jul;60(7):4183-96. PMID: 27139470.

- 161 Huang J, Tao C, Yu Y, Yu F, Zhang H, Gao J, Wang D, Chen Y, Gao J, Zhang G, Zhou G, Liu J, Sun Z, **Sun D**, Zou H, Xu H, Lu Y, Zhong Y. Simultaneous targeting of differentiated breast cancer cells and breast cancer stem cells by combination of docetaxel- and sulforaphane-loaded self-assembled poly(D,L-lactide-co-glycolide)/hyaluronic acid block copolymer-based nanoparticles. *J Biomed Nanotechnol.* 2016 Jul;12(7):1463-77. PMID: 29337484.
- 162 Ren Y, Wang R, Gao L, Li K, Zhou X, Guo H, Liu C, Han D, Tian J, Ye Q, Hu YT, **Sun D**, Yuan X, Zhang N. Sequential co-delivery of miR-21 inhibitor followed by burst release doxorubicin using NIR-responsive hollow gold nanoparticle to enhance anticancer efficacy. *J Controlled Release.* 2016 Apr 28; 228:74-86. PMID: 26956593.
- 163 Hsu E, Kulp SK, Huang H, Tu H, Chao M, Tseng Y, Yang M, Salunke SB, Sullivan NJ, Chen W, Zhang J, Teng C, Fu W, **Sun D**, Wicha MS, Shapiro CL, and Chen C. Integrin-linked kinase as a novel molecular switch of the IL-6-NF- κ B signaling loop in breast cancer. *Carcinogenesis.* 2016 Apr;37(4):430-42. PMID: 26905583.
- 164 Yu F, Huang J, Yu Y, Lu Y, Chen Y, Zhang H, Zhou G, Sun Z, Liu J, **Sun D**, Zhang G, Zhong Y. Glutathione-Responsive Multilayer Coated Gold Nanoparticles for Targeted Gene Delivery. *Journal of Biomedical Nanotechnology.* 2016 Mar;12(3):503-15. PMID: 27280248.
- 165 Borkin D, Pollock JW, Kempinska K, Purohit T, Li X, Wen B, Zhao T, Miao H, Shukla S, He M, **Sun D**, Cierpicki T, Grembecka J. Property focused structure-based optimization of small molecule inhibitors of the protein-protein interaction between Menin and Mixed Lineage Leukemia (MLL). *J Med Chem.* 2016 Feb 11;59(3):892-913. PMID: 26744767.
- 166 Ya-di Yang, Xue-mei Cheng, Wei Liu, Zh-zhen Han, Gui-xin Chou, Ying Wang, **Duxin Sun**, Zheng-tao Wang, and Chang-hong Wang. Peganumine B-I and two enantiomers: New alkaloids from the seeds of *Peganum harmala* Linn. and their potential cytotoxicity and cholinesterase inhibitory activities. *RSC Advances.* 2016;6:15976. DOI: 10.1039/c6ra00086j.
- 167 Yan Li, **Duxin Sun**, Maria Palmisano, and Simon Zhou. Slow drug delivery decreased total body clearance and altered bioavailability of immediate- and controlled-release oxycodone formulations. *Pharmacology Research and Perspectives.* 2016 Jan 22;4(1):e00210. PMID: 26977300.
- 168 Lichao Sun, Joseph P. Burnett, ChunGuang Guo, Yibin Xie, Jian Pan, Zhihua Yang, Yuliang Ran, **Duxin Sun**. CPA4 is a promising diagnostic serum biomarker for pancreatic cancer. *Am J Cancer Res.* 2015 Dec 15;6(1):91-96. PMID: 27073726.
- 169 Burnett JP, Korkaya H, Ouzounova MD, Jiang H, Conley SJ, Newman BW, Sun L, Connarn JN, Chen CS, Zhang N, Wicha MS, **Sun D**. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options. *Sci Rep.* 2015;5:15821. PMID: 26522776.
- 170 Zhang H, Sun S, Chen Q, Zhang G, Zhang Z, **Sun D**, Zhang W. A screening method for potential anti-pancreatic cancer candidate compounds based on Hsp90-Cdc37 interaction model in vitro. *Letters in Drug Design and Discovery.* 2015;12(1):66-71.
- 171 Hsu E, Kulp SK, Huang H, Tu H, Salunke SB, Sullivan NJ, **Sun D**, Wicha MS, Shapiro CL, Chen C-S. Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6–Abundant Breast Cancer Cells by Regulating γ -Secretase–Mediated Notch1 Activation in Caveolae. *Neoplasia.* 2015;17(6):497-508.
- 172 Friese, CR, Mendelsohn-Victor K, Wen B, **Sun D**, Sutcliffe K, Yang JJ, Ronis DL, McCullagh MC, DEFENS Study investigators. DEFENS - Drug Exposure Feedback and Education for Nurses' Safety: study protocol for a randomized controlled trial. *Trials.* 2015 Apr 17;16:171. PMID: 25928792.

- 173 Chen H, Ren X, Paholak HJ, Burnett J, Ni F, Fang X, **Sun D**. Facile fabrication of near-infrared-resonant and magnetic resonance imaging-capable nanomediators for photothermal therapy. *ACS Appl Mater Interfaces*. 2015 Jun 17;7(23):12814-23. PMID: 26010660.
- 174 Connarn JN, Zhang X, Babiskin A, **Sun D**. Metabolism of bupropion by carbonyl reductases in liver and intestine. *Drug Metabolism and Disposition*. 2015 Jul;43(7):1019-27. PMID: 25904761.
- 175 Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, **Sun D**, Jakubowiak A, Malek SN, Talpaz M, Donato NJ. Targeting deubiquitinase activity with a novel small molecule inhibitor as therapy for B-cell malignancies. *Blood*. 2015 Jun 4;125(23):3588-97. PMID: 25814533.
- 176 Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, **Sun D**, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J. Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo. *Cancer Cell*. 2015 Apr 13;27(4):589-602. PMID: 25817203.
- 177 Wang Y, Liu Y, Liu Y, Zhou W, Wang H, Wan G, **Sun D**, Zhang N, Wang Y. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma. *International journal of pharmaceutics*. 2015 Apr 10;483(1-2):89-100. PMID: 25681730.
- 178 Wang Y, Yue D, Xiao M, Qi C, Chen Y, **Sun D**, Zhang N, Chen R. C1QBP Negatively Regulates the Activation of Oncoprotein YBX1 in the Renal Cell Carcinoma as Revealed by Interactomics Analysis. *J Proteome Res*. 2015 Feb 6;14(2):804-13. PMID: 25497084.
- 179 Friese CR, McArdle C, Zhao T, **Sun D**, Spasojevic I, Polovich M, McCullagh MC. Antineoplastic Drug Exposure in an Ambulatory Setting: A Pilot Study. *Cancer Nurs*. 2015;38(2):111-7. PMID: 24831047.
- 180 Kintzel PE, Zhao T, Wen B, **Sun D**. Stability of I.V. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection. *Am J Health Syst Pharm*. 2014 Dec, 71(23):2061-5.
- 181 Chen J, Jiang C, Levant B, Li X, Zhao T, Wen B, Luo R, **Sun D**, Wang S. Pramipexole derivatives as potent and selective dopamine D3 receptor agonists with improved human microsomal stability. *ChemMedChem*. 2014 Dec, 9(12):2653-2660.
- 182 Liu Y, Wang Y, Zhang C, Zhou P, Liu Y, An T, **Sun D**, Zhang N, Wang Y. Core-shell nanoparticles based on pullulan and poly(β -amino) ester for hepatoma-targeted codelivery of gene and chemotherapy agent. *ACS Applied Materials & Interfaces*. 2014 Nov, 6(21): 18712-18720.
- 183 Ren X, Chen H, Yang, V, **Sun D**. Iron oxide nanoparticle-based theranostics for cancer imaging and therapy. *Frontiers of Chemical Science and Engineering*. 2014 Sept, 8(3): 253-264.
- 184 Chen H, Zou H, Paholak HJ, Ito M, Qian W, Che Y, **Sun D**. Thiol-reactive amphiphilic block copolymer for coating gold nanoparticles with neutral and functional surfaces. *Polym Chem*. 2014 Apr 21;5(8):2768-2773. PMID: 24729795.
- 185 MJ Larsen, SD Larsen, A. Fribley, J. Grembecka, K. Homan, A. Mapp, Z. Nikolovska-Koleska, JA Stuckey, **D. Sun**, DH Sherman. The Role of HTS in Drug Discovery at the University of Michigan. *Comb Chem High Throughput Screen*. 2014 Mar, 17: 210.
- 186 Peng Zou, **Duxin Sun**, PLGA/liposome hybrid nanoparticles for short-chain ceramide delivery. *Pharm Res*, 2014 Mar, 31: 684.
- 187 Abulwerdi, F., Liao, C., Liu, M., Azmi, A.S., Aboukameel, A., Mady, A.S., Gulappa, T., Cierpicki, T., Owens, S., Zhang, T., **Sun, D.**, Stuckey, J.A., Mohammad, R.M., Nikolovska-Coleska, Z. A novel small-molecule inhibitor of Mcl-1 blocks pancreatic cancer growth in vitro

- and in vivo. *Mol Cancer Ther*, 2014 Mar, 13: 565.
- 188 Mancang Gu, Yanke Yu, G. M. Kamal B. Gunaherath, A. A. Leslie Gunatilaka, Dapeng Li, **Duxin Sun**. Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells. *Invest New Drugs*, 2014 Feb, 7. PMID: 23887853.
- 189 Hongwei Chen, Joseph Burnett, Fuxiang Zhang, Jiaming Zhang, Hayley Paholak, and **Duxin Sun**. Highly crystallized iron oxide nanoparticles as effective and biodegradable mediators for photothermal cancer therapy. *J. Mater. Chem. B*, 2014, 2(7): 757-765.
- 190 Jamie N. Connarn, Victoria A. Assimon, Rebecca A. Reed, Eric Tse, Daniel R. Southworth, Erik R. P. Zuiderweg, Jason E. Gestwicki, **Duxin Sun**. The Molecular Chaperone Hsp70 Activates Protein Phosphatase 5 (PP5) By Binding the Tetratricopeptide Repeat (TPR) Domain. *J Biol Chem*, 2014 Jan, 289: 2908.
- 191 Huang J, Zhang H, Yu Y, Chen Y, Wang D, Zhang G, Zhou G, Liu J, Sun Z, **Sun D**, Lu Y, Zhong Y. Biodegradable self-assembled nanoparticles of poly (D,L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer. *Biomaterials*. 2014 Jan; 35(1):550-66. PMID: 24135268.
- 192 L. Lin, B. Hutzen, HF Lee, Z. Peng, W. Wang, C. Zhao, HJ Lin, **D. Sun**, PK Li, C. Li, H. Korkaya, MS Wicha, J Lin, Evaluation of STAT3 Signaling in ALDH+ and ALDH+/CD44+/CD24-Subpopulations of Breast Cancer Cells, *PLoS One*, 2013, Dec. 23; 8 (12):e82821.
- 193 Li X, Srinivasan SR, Connarn J, Ahmad A, Young ZT, Kabza AM, Zuiderweg ER, **Sun D**, Gestwicki JE. Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents. *ACS Med Chem Lett*. 2013 Nov 14;4(11). PMID: 24312699.
- 194 Chen SL, Burnett J, **Sun D**, Wei X, Xie Z, Wang X. Photoacoustic microscopy: a potential new tool for evaluation of angiogenesis inhibitor. *Biomed Opt Express*. 2013 Oct 25;4(11):2657-66.
- 195 Zou, P., Chen, H., Paholak, H.J., **Sun, D.**, Noninvasive fluorescence resonance energy transfer imaging of in vivo premature drug release from polymeric nanoparticles, *Mol Pharm*, 2013 Nov, 10: 4185.
- 196 Zeller, J., Turbiak, A.J., Powelson, I.A., Lee, S., **Sun, D.**, Showalter, H.D., Fearon, E.R., Investigation of 3-aryl-pyrimido[5,4-e][1,2,4]triazine-5,7-diones as small molecule antagonists of β -catenin/TCF transcription, *Bioorg Med Chem Lett*. 2013 Nov, 23: 5814.
- 197 Hongwei Chen, Hayley Paholak, Masayuki Ito, Kanokwan Sansanaphongpricha, Wei Qian, Yong Che, **Duxin Sun**. Living PEGylation on gold nanoparticles to optimize cancer cell uptake by controlling targeting ligand and charge densities. *Nanotechnology*, 2013, 24(35):355101.
- 198 Yanyan Li, Tao Zhang, Xiaoqin Li, Peng Zou, Katlyn M. Soriano, Steven J. Schwartz, **Duxin Sun**. Kinetics of Sulforaphane in Mice after Consumption of Sulforaphane-Enriched Broccoli Sprout Preparation. *Molecular Nutrition & Food Research*, 2013 Dec, 57(12):2128-36. PMID: 23929742.
- 199 Wang D, Huang J, Wang X, Yu Y, Zhang H, Chen Y, Liu J, Sun Z, Zou H, **Sun D**, Zhou G, Zhang G, Lu Y, Zhong Y. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. *Biomaterials*. 2013 Oct, 34(31):7662-73.
- 200 Tao Zhang, Yanyan Li, Peng Zou, Jing-yu Yu, Donna McEachern, Shaomeng Wang, and **Duxin Sun**. Physiologically based pharmacokinetic and pharmacodynamics modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. *Biopharmaceutics & Drug Disposition*, 2013, 34:348-59. PMID: 23813446.

- 201 Peng Zou, Hong-Wei Chen, Hayley J Paholak, **Duxin Sun**. Burst Release of Lipophilic Drugs from Poly (Ethylene Oxide)-B-Polystyrene Micelles is not Caused by Micelle Disassembly. *J of Tumor*, 2013, 1 (2): 7.
- 202 Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, Shargary S, Bernard D, Li X, Zhao T, Zou P, **Sun D**, Wang S. A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice. *J Med Chem*. 2013, 56 (13):5553–61.
- 203 Y Zhao, W Sun, J Lu, D McEachern, X Li, S Yu, D Bernard, P. Ochsenbein, P, V Ferey, JC Carry, JR Deschamps, **D Sun**, S. Wang, Diastereomeric spirooxindoles as highly potent and efficacious MDM2, *J Am Chem Soc*, 2013, May 15; 135 (19):7223-34.
- 204 Y. Miyata, X. Li, U.K. Jinwal, S.R. Srinivasan, S.P. Sequin, Z.T. Young, J.L. Bodsky, C.A. Dickey, **D. Sun**, J.E. Gestwicki, Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. *ACS Chem Neurosci*, **2013**, 4(6):930–9 .(2012 IF: 3.676).
- 205 G. Zhou, Y. Lu, H. Zhang, Y. Chen, Y. Yu, J. Gao, **D. Sun**, G. Zhang, H. Zou, Y. Zhong. A novel pulsed drug-delivery system: polyelectrolyte layer-by-layer coating of chitosan-alginate microgels., *Int. J. Nanomedicine*, **2013**; 8:877-87.
- 206 Bryan D. Yestrepkyia, Yuanxi Xuc, 1, Meghan E. Breena, Xiaoqin Li, Walajapet G. Rajeswarana, Jenny G. Ryua, Roderick J. Sorensona, Yasuhiro Tsume, Michael W. Wilsona, Wenpeng Zhang, **Duxin Sun**, Hongmin Sunc, Scott D. Larsen. Novel Inhibitors of Bacterial Virulence: Development of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones for the Inhibition of Group A Streptococcal Streptokinase Expression. *Bioorganic & Medicinal Chemistry, Biorg Med Chem*, 2013 Apr 1; 21(7):1880-97.
- 207 Hongwei Chen, Peng Zou, Jamie Connarn, Hayley Paholak, **Duxin Sun**. Intracellular dissociation of a polymer coating from nanoparticles. *Nano Research*, 2012, 5: 815-825.
- 208 Bryan Newman, Yan Liu, Hsiu-Fang Lee, **Duxin Sun**, Yin Wang. HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. *Cancer Research*, 2012: 72(17):4551-61 (*co-corresponding authors).
- 209 Peng Zou, Nan Zheng, Yongsheng Yang, Lawrence X Yu, **Duxin Sun**. Prediction of Volume of Distribution at Steady-State in Humans: Comparison of Different Approaches. *Expert Opinion on Drug Metabolism and Toxicology*, 2012, 8: 855-72.
- 210 Peng Zou, Nan Zheng, Yanke Yu, Shanghai Yu, Wei Sun, Donna McEachern, Yongsheng Yang, Lawrence X. Yu, Shaomeng Wang, **Duxin Sun**. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics. *J Pharmacy Pharmaceutics Sciences*, 2012, 15: 265-80.
- 211 Joseph Burnett, Bryan Newman, **Duxin Sun**. Targeting Cancer Stem Cells with Natural Products. *Current Drug Targets*, 2012, 13: 1054-64.
- 212 Yu S, Zhang G, Zhang W, Luo H, Qiu L, Liu Q, **Sun D**, Wang PG, Wang F. Synthesis and biological activities of a 3'-azido analogue of Doxorubicin against drug-resistant cancer cells. *Int J Mol Sci*. 2012;13: 3671-84.
- 213 Li Y, Karagöz GE, Seo YH, Zhang T, Jiang Y, Yu Y, Duarte AM, Schwartz SJ, Boelens R, Carroll K, Rüdiger SG, **Sun D**. Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90. *J Nutr Biochem*. 2012, 23: 1617-26.
- 214 Zou P, Yu Y, Zheng N, Yang Y, Paholak HJ, Yu LX, **Sun D**. Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation. *AAPS J*. 2012; 14: 262-81.
- 215 Li Y, Zhang T, Schwartz SJ, **Sun D**. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function. *Nutr Cancer*. 2011, 63(7):1151-9.

- 216 Yu Y, Zick S, Li X, Zou P, Wright B, **Sun D**. Examination of the pharmacokinetics of active ingredients of ginger in humans. *AAPS J*. 2011, 13(3):417-26.
- 217 Sun H, Liu L, Lu J, Bai L, Li X, Nikolovska-Coleska Z, McEachern D, Yang CY, Qiu S, Yi H, **Sun D**, Wang S. Potent Bivalent Smac Mimetics: Effect of the Linker on Binding to Inhibitor of Apoptosis Proteins (IAPs) and Anticancer Activity. *J Med Chem*. 2011, 54: 3306-18.
- 218 Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, Liu L, Qiu S, Yang CY, Miller R, Yi H, Zhang T, **Sun D**, Kang S, Guo M, Leopold L, Yang D, Wang S. A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment. *J Med Chem*. 2011, 54:2714-26.
- 219 Li Y, Wicha MS, Schwartz SJ, **Sun D**. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. *J Nutr Biochem*. 2011, 22: 799-806.
- 220 Zheng N, Zou P, Wang S, **Sun D**. In Vitro Metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) in Human Liver Microsomes. *Drug Metab Dispos*. 2011, 39:627-35.
- 221 **Sun D**. Nanotheranostics: integration of imaging and targeted drug delivery. *Mol Pharm*. 2010, 7:1879.
- 222 Zou P, Yu Y, Wang YA, Zhong Y, Welton AR, Galbán C, Wang S, **Sun D**. Superparamagnetic iron oxide "nanotheranostics" for targeted cancer cell imaging and pH-dependent intracellular drug release. *Mol Pharm*. 2010, 7: 1974-84.
- 223 Zou P, Povoski SP, Hall NC, Carlton MM, Hinkle GH, Xu RX, Mojzisek CM, Johnson MA, Knopp MV, Martin EW Jr, **Sun D**. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. *World J Surg Oncol*. 2010; 8:65.
- 224 Zhang T, Li Y, Zhu Z, Gu M, Newman B, **Sun D**. MEK Inhibition Potentiates the Activity of Hsp90 Inhibitor 17-AAG against Pancreatic Cancer Cells. *Mol Pharm*. 2010, 7: 1576-84.
- 225 Liu Q, Zhang H, Zhou G, Xie S, Zou H, Yu Y, Li G, **Sun D**, Zhang G, Lu Y, Zhong Y. In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants. *Int J Pharm*. 2010, 397(1-2):122-9.
- 226 Zhu Z, Xu X, Yu Y, Graham M, Liu G, Prince ME, Carey TE, **Sun D**. Silencing Heat Shock Protein 27 (Hsp27) decreases metastatic behavior of human head and neck squamous cell cancer cells in vitro. *Mol Pharm*, 2010, 7(4):1283-90.
- 227 Yiqun Jiang, Denzil Bernard, Yanke Yu, Yehua Xie, Tao Zhang, Yanyan Li, Joseph Burnett, Xueqi Fu, Shaomeng Wang, and **Duxin Sun**. Split Renilla Luciferase Protein-Fragment-Assisted Complementation (SRL-PFAC) to Characterize Hsp90/Cdc37 Complex and Identify Critical Residues in Protein-Protein Interactions. *J Biol Chem*, 2010, 285:21023-36.
- 228 Yanyan Li, Tao Zhang, Hasan Korkaya, Suling Liu, Yanke Yu, Hsiu-Fang Lee, Bryan Newman, Shawn G. Clouthier, Steven J. Schwartz, Max S. Wicha, and **Duxin Sun**. Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells. *Clinical Cancer Research*, 2010,16: 2580-90.
- 229 Yanke Yu, Adel Hamza, Tao Zhang, Mancang Gu, Peng Zou, Bryan Newman, Yanyan Li, A. A. Leslie Gunatilaka, Chang-Guo Zhan, and **Duxin Sun**. Withaferin A Targets Heat Shock Protein 90 in Pancreatic Cancer Cells. *Biochemical Pharmacol*, 2010, 79: 542-51.
- 230 Yanke Yu, Lanyan Fang, **Duxin Sun**. Biodistribution of HuCC49 Δ CH2- β -galactosidase in colorectal cancer xenograft model. *International J Pharmaceutics*, 2010, 386: 208-15.
- 231 Yanke Yu and **Duxin Sun**. Superparamagnetic Iron Oxide nanoparticle (SPIO) "theranostics" for multimodality tumor imaging, gene delivery, targeted drug and prodrug delivery. *Expert Review of Clinical Pharmacology*, 2010, 3:117-30.
- 232 Tao Zhang, Yanyan Li, Yiqun Jiang, **Duxin Sun**. Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction. *J Biol Chem*, 2009, 284: 35381-9.

- 233 Ho-Chul Shin, Hye-Ryoung Kim, Hee-Jung Cho, Hee Yi, Soo-Min Cho, Dong-Goo Lee, A. M. Abd El-Aty, Jin-Suk Kim, **Duxin Sun** and Gordon L. Amidon. Comparative Gene Expression of Intestinal Metabolizing Enzymes. *Biopharm Drug Dispos*, 2009, 30: 411-21.
- 234 Yanyan Li, Tao Zhang, Yiqun Jiang, Hsiu-Fang Lee, Stephen J. Schwartz, **Duxin Sun**. Epigallocatechin-3-gallate Inhibits Hsp90 Function by Impairing Hsp90 Association with Co-chaperones in Pancreatic Cancer Cell Line Mia Paca-2. *Molecular Pharmaceutics*, 2009, 6, 1152-9.
- 235 Yanyan Li, Tao Zhang, Stephen J. Schwartz, **Duxin Sun**. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. *Drug Resistance Updates*, 2009, 12: 17-27.
- 236 Peng Zou, Songbo Xu, Stephen P Povoski, Anna Wang, Morgan A. Johnson, Edward W. Martin, Jr. Vish Subramaniam, Ronald Xu, **Duxin Sun**. Near-Infrared Fluorescence Labeled Anti-TAG-72 Monoclonal Antibodies for Tumor Imaging in Colorectal Cancer Xenograft Mice. *Molecular Pharmaceutics*, 2009, 6, 428-40.
- 237 Ronald X. Xu, Jiwei Huang, Jeff S. Xu, **Duxin Sun**, George H. Hinkle, Edward W. Martin, Jr., Stephen P. Povoski. Fabrication of indocyanine green encapsulated biodegradable microbubbles for structural and functional imaging of cancer. *Journal of Biomedical Optics*, 2009, 14, 034020.
- 238 Jie Shen, Robert Woodward, James Patrick Kedenburg, Xianwei Liu, Min Chen, Lanyan Fang, **Duxin Sun**, Peng George Wang. Histone Deacetylase Inhibitors through Click Chemistry. *Journal of Medicinal Chemistry*, 2008, 51: 7417-27.
- 239 Dongfeng Yin, Ying Lu, He Zhang, Guoqing Zhang, Hao Zou, **Duxin Sun**, Yanqiang Zhong. Preparation of glucagon-like peptide-1 loaded PLGA microspheres: characterizations, release studies and bioactivities in vitro/in vivo. *Chemical & Pharmaceutical Bulletin*, 2008, 56: 156-61.
- 240 He Zhang, Ying Lu, Guoqing Zhang, Shen Gao, **Duxin Sun**, Yanqiang Zhong. Bupivacaine-loaded biodegradable poly(lactic-co-glycolic) acid microspheres: I. Optimization of the drug incorporation into the polymer matrix and modelling of drug release. *International Journal of Pharmaceutics*, 2008, 351, 244-9.
- 241 Bei Wang, Stephen P Povoski, Xianhua Cao, **Duxin Sun**, Ronald X. Xu. Dynamic schema for near infrared detection of pressure-induced changes in solid tumors. *Applied Optics*, 2008, 47: 3053-63.
- 242 Lanyan Fang, **Duxin Sun**. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy. *Drug Metabolism and Disposition*, 2008, 36: 1153-65.
- 243 Tao Zhang, Adel Hamza, Xianhua Cao, Bing Wang, Shuwen Yu, Chang-Guo Zhan, **Duxin Sun**. A Novel Hsp90 inhibitor disrupts Hsp90-Cdc37 complex for pancreatic cancer therapy. *Molecular Cancer Therapeutics*, 2008, 7: 162-70.
- 244 Xianhua Cao, Mark Bloomston, Guang Jia, Wendy L. Frankel, Tao Zhang, Nathan Hall, Hao Cheng, Michael Knopp, and **Duxin Sun**. Simultaneously Targeting Hypoxic Cancer Cells by HSP90 Inhibitor and Glycolysis Inhibitor in Pancreatic Cancer Therapy. *Clinical Cancer Research*, 2008; 14: 1831-9.
- 245 Xianhua Cao, Bing Wang, Guang Jia, Ming Yang, Michael V. Knopp and **Duxin Sun**. Non-invasive tumor MRI imaging and synergistic anti-tumor effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. *Cancer Chemotherapy and Pharmacology*, 2008, 62: 985-94.
- 246 Huifei Cui, Jie Shen, Dongning Lu, Tao Zhang, Wenpeng Zhang, **Duxin Sun**, Peng George Wang. 4-Aryl-1,3,2-oxathiazolylum-5-olate: A novel GST Inhibitor to release JNK and activate c-Jun for cancer therapy. *Cancer Chemotherapy and Pharmacology*, 2008, 62: 509-

- 15.
- 247 Polli JE, Abrahamsson BS, Yu LX, Amidon GL, Baldoni JM, Cook JA, Fackler P, Hartauer K, Johnston G, Krill SL, Lipper RA, Malick WA, Shah VP, **Sun D**, Winkle HN, Wu Y, Zhang H. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. *AAPS J*, 2008, 10:373-9.
- 248 Ying Lu, Guoqing Zhang, **Duxin Sun**, Yanqiang Zhong. Preparation and evaluation of biodegradable flurbiprofen gelatin microspheres for intra-articular administration. *Journal of Microencapsulation*, 2007, 24, 515 .
- 249 **Duxin Sun**, Mark Bloomston, George Hinkle, Osama Habib Al-Saif, Nathan C. Hall, Stephen P. Povoski, Mark W. Arnold, Edward W. Martin Jr. Radioimmunoguided Surgery (RIGS), PET/CT Image-Guided Surgery, and Fluorescence Image-Guided Surgery: Past, Present, and Future. *Journal Surgical Oncology*, 2007, 96: 297.
- 250 Robert Battisti, Yanqiang Zhong, Lanyan Fang, Seth Gibbs, Jie Shen, Janos Nadas, Guisheng Zhang, **Duxin Sun**. Modifying the Sugar Moieties of Anthracyclines Overcomes P-gp-Mediated Multidrug Resistance. *Mol Pharm* 2007, 4: 140.
- 251 Lanyan Fang, Nicholas H. G. Holford, George Hinkle, Xianhua Cao, Mark P. Bloomston, Jim J Xiao, Seth Gibbs, Osama Habib Al Saif, James T. Dalton, Kenneth K. Chan, Jeffrey Schlom, Edward Martin, and **Duxin Sun**. Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49 Δ CH2 and Murine Antibody CC49 in Colorectal Cancer Patients. *J Clin Pharmacol* 2007 47: 227.
- 252 Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, Zheng X, Sadee W, **Sun D**. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. *Cancer Chemotherapy and Pharmacology*, 2007, 59: 495-505.
- 253 Hye-Ryoung Kim, Sung-Won Park, Hee-Jung Choa, Kyung-Ae Chaea, Ji-Min Sunga, Jin-Suk Kima, Christopher P. Landowski, **Duxin Sun**, A.M. Abd El-Aty, Gordon L. Amidon, Ho-Chul Shin. Comparative gene expression profiles of intestinal transporters in mice, rats and humans. *Pharmacological Research*, 2007, 56: 224-236.
- 254 Lanyan Fang, Guisheng Zhang, Chenglong Li, Xincheng Zheng, Lizhi Zhu, Jim J. Xiao, Gergely Szakacs, Janos Nadas, Kenneth K. Chan, Peng George Wang, and **Duxin Sun**. Discovery of a Daunorubicin Analogue That Exhibits Potent Antitumor Activity and Overcomes P-gp-Mediated Drug Resistance. *J Med Chem*, 2006; 49: 932-941.
- 255 Sherif I. Farag Badawy, David B. Gray, Fang Zhao, **Duxin Sun**, Alan E. Schuster, Munir A. Hussain Formulation of Solid Dosage Forms to Overcome Gastric pH Interaction of the Factor Xa Inhibitor, BMS-561389. *Pharm Res*, 2006, 23, 989.
- 256 Guisheng Zhang, Lanyan Fang, Lizhi Zhu, Yanqiang Zhong, George P. Wang, **Duxin Sun**. Syntheses and Biological Activities of 3'-Azido Disaccharide Daunorubicins against drug-resistant leukemia, *J Med Chem*, 2006 49(5); 1792-1799.
- 257 Janos Nadas and **Duxin Sun**. Anthracyclines as effective anticancer drugs. *Expert Opinion on Drug Discovery*, 2006, 1: 549.
- 258 Xianhua Cao, Seth T. Gibbs, Lanyan Fang, Heather A. Miller, Christopher P. Landowski, Ho-Chul Shin, Hans Lennernas, Yanqiang Zhong, Gordon L. Amidon, Lawrence X. Yu, and **Duxin Sun**. Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model. *Pharm Res*, 2006, 23: 1675.
- 259 Guisheng Zhang, Lanyan Fang, Lizhi Zhu, **Duxin Sun**, and Peng George Wang. Syntheses and Biological activities of Bisdaunorubicins. *Bioorganic and Medicinal Chemistry*, 2006, 14: 426-434.
- 260 Lanyan Fang, Robert F. Battisti, Hao Cheng, Philip Reigan, Yan Xin, Jie Shen, David Ross, Kenneth K. Chan, Edward W. Martin Jr, Peng George Wang, and **Duxin Sun**. Enzyme Specific Activation of Benzoquinone Ansamycin Prodrugs Using Humanized HuCC49CH2-

- alpha-Galactosidase Conjugates. *J Med Chem*, 2006, 49: 6290. PMID: 17034135.
- 261 Rong Zhou, Paul Moench, Christopher Heran, Xujin Lu, Neil Mathias, Teresa Faria, Doris A. Wall, Munir A. Hussain, Ronald L. Smith, and **Duxin Sun**. pH-Dependent Dissolution In Vitro and Absorption In Vivo of Weakly Basic Drugs: Development of a Canine Model. *Pharmaceutical Research*, 2005, 22: 188.
- 262 Jim Xiao, Sara Horst, George Hinkle, Xianhua Cao, Ergun Kocak, Jing Fang, Donn Young, M. Khazaeli, Doreen Agnese, **Duxin Sun**, and Edward Martin, Jr. Pharmacokinetics and Clinical Evaluation of ¹²⁵I-Radiolabeled Humanized CC49 Monoclonal Antibody (HuCC49deltaCH2) in Recurrent and Metastatic Colorectal Cancer Patients. *Cancer Biotherapy and Radiopharmaceuticals*, 2005, 20; 16.
- 263 Hao Cheng, Xianhua Cao, Ming Xian, Lanyan Fang, Tingwei Bill Cai, Jacqueline Jia Ji, Josefino B. Tunac, **Duxin Sun**, and Peng George Wang. Synthesis and Enzyme-Specific Activation of Carbohydrate-Geldanamycin Conjugates with Potent Anticancer Activity. *J Med Chem*, 2005, 48: 645.
- 264 Guisheng Zhang, Jie Shen, Hao Cheng, Lizhi Zhu, Lanyan Fang, Sanzhong Luo, Mark T. Muller, Gun Eui Lee, Lijun Wei, Yuguo Du, **Duxin Sun**, and Peng George Wang. Syntheses and Biological Activities of Rebeccamycin Analogues with Uncommon Sugars. *Journal of Medicinal Chemistry*, 2005, 48(7); 2600-261.
- 265 Guisheng Zhang, Lanyan Fang, Lizhi Zhu, Josephine E. Aimiwu, Jie Shen, Hao Cheng, Mark T. Muller, Gun Eui Lee, **Duxin Sun**, and Peng George Wang. Syntheses and Biological Activities of Disaccharide Daunorubicins. *Journal of Medicinal Chemistry*, 2005, 48, 5269-78.
- 266 Xianhua Cao, Lawrence X. Yu, Catalin Barbaciru, Christopher P. Landowski, Ho-Chul Shin, Seth Gibbs, Heather A. Miller, Gordon L. Amidon, and **Duxin Sun**. Permeability Dominates in vivo Intestinal Absorption of P-gp Substrate with High Solubility and High Permeability. *Molecular Pharmaceutics*, 2005, 2; 329-340.
- 267 Lizhi Zhu, Xianhua Cao, Wenlan Chen, Guisheng Zhang, **Duxin Sun**, Peng George Wang. Syntheses and Biological Activities of Daunomycin Analogs with Uncommon Sugars. *Bioorganic and Medicinal Chemistry*, 2005, 13: 6381-6387.
- 268 **Sun D**, Yu LX, M. Hussain, RL Smith, Amidon GL, and Smith RL. In vitro testing of drug absorption for drug "developability" assessment: Forming an interface between in vitro preclinical data and clinical outcome. *Current Opinion in Drug Discovery and Development* 2004, 7 (1); 75-85.
- 269 Landowski CP, Anderle P, **Sun D**, Sadee W, Amidon GL. Transporter and Ion Channel Gene Expression After Caco-2 Cell Differentiation Using 2 Different Microarray Technologies. *AAPS PharmSci*. 2004; 6 (3): art 21.
- 270 CP Landowski, **D Sun**, DR Foster, SS Menon, JL Barnett, LS Welage, C Ramachandra, GL Amidon. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. *J Pharmacol Exp Ther*, 2003, 306: 778-86.
- 271 Shin HC, Landowski CP, **Sun D**, Vig BS, Kim I, Mittal S, Lane M, Rosania G, Drach JC, and Amidon GL. Functional expression and characterization of a sodium-dependent nucleoside transporter hCNT2 cloned from human duodenum. *Biochem Biophys Res Commun* 2003, 307: 696-703.
- 272 Walters CL, Wang BC, Godfrey M, **Sun D**, Funk CD, and Blendy JA. Augmented response to morphine and cocaine in mice with a mutation in the 12-lipoxygenase gene. *Psychopharmacol* 2003, 170:124-31.
- 273 Qi X, Ackermann C, **Sun D**, Sheng Minli, Hou H. Physicochemical characterization and percutaneous delivery of 2,3,5,6-tetramethylpyrazine. *Int J Pharmaceutics* 2003, 253: 177-183.
- 274 Qi X, Liu R, **Sun D**, Ackermann C, Hou H. Convolution method to predict drug concentration

- profiles of 2,3,5,6-tetramethylpyrazine following transdermal application. *Int J Pharmaceutics* 2003, 259: 39-45.
- 275 **Sun D**, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD and Amidon GL. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequence tags and correlation with permeability of 26 drugs. *Pharm. Res.* 2002, 19: 1400-16.
- 276 Qi X, Ackermann C, **Sun D**, Liu R, Sheng M, and Hou H. The prediction of plasma and brain levels of 2,3,5,6-tetramethylpyrazine following transdermal applications. *AAPS Pharmasci* 2002, 4(4): 46.
- 277 **Sun D**, Landowski C, Chu X, Wallsten R, Komorowski TE, Fleisher D, and Amidon GL. Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein. *AAPS Pharmasci* 2001, 3: E2.
- 278 Bleich D, Chen S, Zipser B, **Sun D**, Funk CD, Nadler JL. Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. *J Clinical Investigation* 1999, 103: 1431.
- 279 Johnson EN, **Sun D**, Chen XS, and Funk CD. Lipoxygenase gene disruption studies. Status and applications. *Advances in Experimental Medicine & Biology* 1999, 447:63-73.
- 280 **Sun D**, McDonnell M, Chen XS, Funk CD. Human 12(R)-lipoxygenase and the mouse ortholog: molecular cloning, expression, and gene chromosomal assignment. *J Biol Chem* 1998, 273: 33540.
- 281 **Sun D**, Elesa SH, and Funk CD. Cloning of a human "epidermal-type" 12-lipoxygenase related gene and the chromosomal localization to 17p13. *Cytogenetics and Cell Genetics* 1998, 81:79.
- 282 **Sun D**, Funk CD. Disruption of 12/15-lipoxygenase expression in peritoneal macrophage: Enhanced utilization of 5-lipoxygenase pathway and diminished oxidation of low-density lipoprotein. *J Biol Chem* 1996, 271:24055-24062.
- 283 Hu JH, **Sun D**, Zeng GQ, Lin AY, Rui YC. Platelet adhesion to cultured bovine cerebral microvascular endothelial cells by stimulation of platelet activating factor and antagonism of drugs. *Acta Pharmacol Sin*, 1995, 16:318-321.
- 284 Hu JH, **Sun D**, Zeng GQ, Lin AY, Rui YC. Effects of calcimycin on platelet adhesion to cultured bovine cerebral microvascular endothelial cells and its antagonism by drugs. *Acta Pharmaceutica Sin*, 1994, 29:335-339.
- 285 Ji Y, Zeng GQ, **Sun D**. Drug antagonism of TNF induced proliferation of bovine cerebral microvascular smooth cells. *Acta Pharmaceutica Sin* 1994, 29:86-89.
- 286 **Sun D**, Huang TG, Zeng GQ, Rui YC. PAF production in bovine cerebral microvascular endothelial cells and its drug inhibition. *Acta Pharmcol Sin* 1993, 14:26-30.
- 287 **Sun D**, Zeng GQ, Rui YC. Platelet activating factor and cerebrovascular disorders. *Chin Pharmacol Bullet*, 1993, 9:90.
- 288 Zeng GQ, Ju DW, **Sun D**, Rui, YC. Dauricine and Anisodamine inhibited leukotrienes- and platelet activating factor induced DNA synthesis and proliferation of bovine cerebral microvascular smooth muscle cells in culture. *Acta Pharmacol Sin*, 1993: 14:329-331.
- 289 Zeng GQ, Rui YC, **Sun D**. Effects of imperatorin and isoimperatorin on rabbit platelet aggregation and TXB2, cAMP production. *Acad J Sec Mil Med Univ*, 1993, 14:369-70.
- 290 Zeng GQ, Wang XS, **Sun D**, Lin AY, Ji Y, Chu JX, Rui YC. Effects of 6-(α - α -diphenyl acetyl)piperazinyl) on rabbit platelet aggregation and TXB2, cAMP production. *Acta Pharmaceutica Sinica* 1993,28:256-259.
- 291 Zeng GQ, Ju DW, **Sun D**, Huang TG, Rui YC. Effects of dauricine and tetrandrine on 3H-WEB 2086 specific binding to bovine cerebral anterior arterial smooth muscle cells. *Acta Pharmaceutica Sin* 1993, 28:499-503.

- 292 **Sun D**, Rui YC, Zeng GQ. Cultivation of bovine cerebral micro-vascular smooth muscle cells and the production of platelet activating factor. *Chin J Anatomy* 1992, 15:27.
- 293 **Sun D**, Rui YC, Zeng GQ, Zhu J, Shen YA. Specific binding sites of platelet activating factor on intact bovine cerebral microvascular endothelial cells and antagonism of drugs. *Acta Pharmacol Sin* 1992, 13:326-329.
- 294 **Sun D**, Rui YC, Zeng GQ. Cultivation and characterization of bovine cerebral microvascular endothelial cells. *Acad J Sec Mil Med Univ* 1992,13: 178.
- 295 **Sun D**, Huang TG, Zeng GQ, Zhu J, Ju DW, Rui YC. Effects of platelet activating factor on the cerebrovascular permeability in rats and the protection by drug. *Acta Pharmaceutica Sin* 1992, 27(9): 651-655.
- 296 **Sun D**, Rui YC, Zeng GQ, Zhu J. Effect of SZ-1 on PAF induced arachidonic acid releases in cerebrovascular endothelial and smooth muscle cells. *Acad J Sec Mil Med Univ* 1992,13(4): 3.
- 297 Zeng GQ, Ju DW, **Sun D**, Rui YC. Effects of Dauricine and anisodamine on LTS and PAF induced DNA synthesis of bovine anterior arteries smooth muscle cells. *Acta Pharmaceutica Sin* 1992, 27:561-565.
- 298 Zeng GQ, Rui YC, **Sun D**. LTS and cerebrovascular disorders. *Pharmaceutical Information Bulletin*, 1992, 10:5.
- 299 Zeng GQ, Ju DW, **Sun D**, Rui YC. Inhibition of 3H-WEB 2086 specific binding to cultured bovine cerebromicrovascular smooth muscle cells by tetrandrine. *Chin J Physiol Sci* 1992, 8:375-79.
- 300 Zeng GQ, Rui YC, **Sun D**, Rui Y. Specific 3H-LTC₄ receptor on intact smooth muscle cells derived from bovine cerebral microvasculatures. *Acad J Sec Mil Med Univ*, 1992,13: 318.
- 301 Zeng GQ, Rui YC, **Sun D**, Shen YA. Leukotriene C₄ receptors in cultured smooth muscle cells from bovine anterior cerebral arteries and microcerebrovasculatures. *Acta Pharmacol Sin*, 1992, 13(6): 490-493.
- 302 Rui YC, **Sun D**, Lin AY. Effect of dazoxiben on the metabolism of arachidonic acid in isolated basilar arteries. *Acta Pharmacol Sin*. 1990, 11:261-264.
- 303 Rui YC, Zhang DZ, **Sun D**, Zeng GQ. Effect of silybin on production of oxygen free radical, lipoperoxide and leukotrienes in brain following ischemia and reperfusion. *Acta Pharmacol Sin*, 1990, 11:418-421.
- 304 Rui YC, **Sun D**, Long K. Effect of dazoxiben on cerebrovascular resistance in rabbit. *Acta Pharmacol Sin*, 1989, 10:342-345.
- 305 Rui YC, **Sun D**. Effect of silybin on histamine release in mast cells. *Commun Pharmacol Sin*, 1989, 5:33.

Book Chapters

- 1 Peng Zou, Sau Lee, Min Li, Lawrence Yu and Duxin Sun. A global perspective on first-in-man dose selection: Oncology and beyond. pp 39-58. *Pharmacokinetics in Drug Development: Problems and Challenges in Oncology*. Editors, Peter L. Bonate, Danny R. Howard, **2016**, Springer Science Business Media, New York, NY.
- 2 Alex Yu, Duxin Sun, Bing V. Li, Lawrence X. Yu. Bioequivalence History. pp1-27. *FDA Bioequivalence Standards*, **2014**, 13, Springer Science Business Media, New York, NY.
- 3 Yanyan Li, Steven J. Schwartz and Duxin Sun. Potential Application of Natural Dietary Components to Target Cancer Stem Cells. pp 407-430. *Cancer stem cells - the cutting edge*. Editor, Stanley Shostak. InTech, **2011**, ISBN 978-953-307-580-8.
- 4 Jarkko Rautio, Krista Laine-Lanyan Fang, Bing Han, Kristiina Huttunen, Duxin Sun. Enzyme-Activated Prodrug Strategies for Targeted Drug Action. *Targeted Delivery of Small and*

- Macromolecular Drugs*, **2010**, Taylor & Francis Group, CRC press.
- 5 Duxin Sun. Targeted drug delivery. *Encyclopedia of Cancer 2nd Edition*, Springer Verlag Gmbh Heidelberg, Germany, **2008**.
 - 6 Xianhua Cao, Lawrence Yu, and Duxin Sun. *Drug Absorption Principles*. Biopharmaceutics Applications in Drug Development, **2007**, Springer Science Business Media, Inc., New York, NY.
 - 7 Shin, Ho-Chul; Landowski, Christopher P.; Sun, Duxin; Amidon, Gordon L. Transporters in the GI tract. *Methods and Principles in Medicinal Chemistry*, **2003**, 18, 245-287.
 - 8 Funk CD, Sun D. Manipulations of the arachidonic acid cascade with lipoxygenase gene-inactivated mice. *Frontiers in Bioactive Lipids*. Edited by Vanderhoek, Plenum Press, New York, **1996**, p127-132.
 - 9 Sun D, Zeng, G, Rui YC. *Cerebrovascular disorders: Advance in basic and clinical research*. 1st edition. Published by Shan Dong Scientific and Technological Publishing House, **1993**.
 - 10 Sun D. Chemotherapy of parasitic infections. *Handbook of Clinical Therapeutic Drugs*. Jin Dun Publishing House, Beijing, China, **1992**.

Meeting Abstracts

- 1 Abdelnabi, M, Watts L, Singh P, Li R, Lkhagva A, Duan S, Liu S, Wen B, Baker J, Matvekas A, Chey W, Hasler W, Raofi S, Sun W, Boyce H, Kinjo M, Pai M, **Sun D**, Nojkov B. Gastrointestinal Intubation Using a Multi-Port Aspiration Catheter to Study Drug Release of Extended-Release Glipizide Drug Products in the GI Tract of Healthy Humans. Digestive Disease Week (DDW), Washington, D.C., May 18, 2024.
- 2 Tao J, Zhao H, Liu Z, Wen H, Li C, Li Q, He M, Wen B, Gao W, **Sun D**. A systemically administered non-nucleotide STING agonist in albumin nanoformulation with potent antitumor activity and low toxicity. 2024 AACR meeting in San Diego, CA, April 5-10, 2024.
- 3 Li C, Mao S, Zhao H, Mahamadou D, Liu Z, Wen H, He M, Wang M, Tao J, Wen B, Hoang T, Jacobovitz B, Wen F, Gao W, Sun D. Overcoming B regulatory cell induced STING resistance by dual functional albumin nanomedicine to prolong survival of pancreatic cancer. 2024 AACR meeting in San Diego, CA, April 5-10, 2024.
- 4 Hong-Yi Zhao, Zhongwei Liu, Shuai Mao, Meilin Wang, Miao He, Bo Wen, Wei Gao, **Duxin Sun**. Discovery of an oral tricyclic STING agonist with superior pharmacokinetic properties and potent in vivo efficacy. 2024 AACR meeting in San Diego, CA, April 5-10, 2024.
- 5 Chengyi Li, Wei Gao, **Duxin Sun**. Antigen-clustered nanovaccine achieves long-term tumor remission through promoting b cell immunity and tertiary lymphoid structures. 2023 NanoDDS, Boston, MA, September 16, 2023.
- 6 Wei Gao, Yudong Song, Luke Bugada, Ruiting Li, Hongxiang Hu, Luchen Zhang, Chengyi Li, Hebao Yuan, Krishani Kumari Rajanayake, Nathan A Truchan, Fei Wen and **Duxin Sun**. Modulating the Lymph Node and Tumor Immune Microenvironment with Nano-PI: A Revolutionary Approach to Treating Metastatic Breast Cancer. 2nd Global Summit – World Pharma, Virtual Event, March 20-23, 2023.
- 7 Lu Wang, Miao He, Hongxiang Hu, Bo Wen, Manjunath Pai, Hebao Yuan, and **Duxin Sun**. Using LC-MS/MS and MALDI-MSI to Study Long-Term Effects of Cyclosporine A on L-

- Carnitines and Its Derivatives in Mice Tissues. ASMS Conference in Minneapolis, MN, June 5-9, 2022.
- 8 Joseph Burnett, Garrett Johnson, Nathan Truchan, Michael Brooks, Max Wicha, **Duxin Sun**. Discovering epigenetic regulators of cells states in triple negative breast cancers. 2020 AACR meeting in Philadelphia, PA, April 27-28, 2020.
 - 9 Johanna Buschhaus, Ayse Muniz, Ming Luo, Joseph Burnett, Nathan Truchan, Michael Brooks, Brock Humphries, Kathy Luker, Joerg Lahann, **Duxin Sun**, Max Wicha, Gary Luker. Metabolic status and adaptability of breast cancer stem cells. 2020 AACR meeting in Philadelphia, PA, April 27-28, 2020.
 - 10 Yee Sun Tan, Blake R. Heath, Brett D. Hill, Xiaobo Luo, Syed M. Rizvi, Toktam Moghbeli, Hongxiang Hu, Erica Siismets, Haitao Wen, Yuying Xie, Duxin Sun, Simon Young, Weiping Zou, Fei Wen and Yu L. Lei. Resolving STING-mediated tumor immune microenvironment shift at single-cell resolution. AACR-AHNS Head and Neck Cancer Conference in Austin, TX, April 29-30, 2019.
 - 11 Nathan Truchan, Joseph Burnett, and **Duxin Sun**. Targeting intratumoral heterogeneity in TNBC with novel combinations of FDA-approved drugs. 2019 AACR meeting in Atlanta, GA, March 29-April 3, 2019.
 - 12 Hongwei Chen, Xin Luan, Haley Paholak, Joseph Burnett, Nicholas Stevers, Kanokwan Sansanaphongpricha, Miao He, Alfred Chang, Qiao Li, and **Duxin Sun**. Enhancing breast cancer immunotherapy via IONP-mediated photothermal therapy. 2019 AACR meeting in Atlanta, GA, March 29-April 3, 2019.
 - 13 Ming Luo, Michael Brooks, Joseph Burnett, Nathan Truchan, **Duxin Sun**, and Max S. Wicha. Tracing redox-regulated breast cancer stem cell state transition using a dual fluorescent reporter system. 2018 AACR meeting in Chicago, IL, April 14-18, 2018.
 - 14 Karson J. Kump, Jingshan Tong, Ahmed S. Mady, Lei Miao, Siwei Li, **Duxin Sun**, Jian Yu, Lin Zhang, and Zaneta Nikolovska-Coleska. Novel Mcl-1 inhibitor effectively restores *in vivo* regorafenib sensitivity in resistant colorectal cancer. 2018 AACR meeting in Chicago, IL, April 14-18, 2018.
 - 15 William L. Hasler, Jason Baker, Joseph Dickens, Mark Koenigs knecht, Ann Frances, Allen Lee, Kerby Shedden, Kimberly Harer, Gordon Amidon, **Duxin Sun**. Standardizing parameters of fasting duodenal manometry in healthy volunteers using clustered high-resolution pressure ports: Focus on migrating motor complex phase 2 contractions. *Gastroenterology*. 2018 May;154(6, Supplement 1):S-311.
 - 16 Nathan A. Truchan, Johann Buschhaus, Michael Brooks, Andre Halabu, Hongwei Guo, Hebao Yuan, Kathryn Luker, Max Wicha, **Duxin Sun**, Joseph P. Burnett. A novel CRISPR/Cas9 reporter system to monitor TNBC cancer stem cells in real time. 2018 AACR meeting in Chicago, IL, April 14-18, 2018.
 - 17 Chang-Ching Lin, Miao-Chia Lo, Rebecca Moody, Nicholas Stevers, Samantha Tinsley, Max Wicha, **Duxin Sun**. Identification of MLK4 as a novel regulator of cancer stem cells in triple-negative breast cancer. 2018 AACR meeting in Chicago, IL, April 14-18, 2018.

- 18 Lichao Sun, Chang-Ching Lin, Joseph Burnett, Hebao Yuan, **Duxin Sun**. Long non-coding RNA Linc00162, as a novel prognostic marker, modulates cancer stem cell properties in triple negative breast cancer. 2018 AACR meeting in Chicago, IL, April 14-18, 2018.
- 19 Mertz D, Li S, Luker K, Luker G, **Sun D**, Takayama S. Determining the mechanisms behind distribution variability in small molecule pharmaceuticals using 3D spheroid tissues. Drug Metab and Pharmacokinetics. 2018 Jan 12;33(1):S67.
- 20 Hertz DL, Kidwell KM, Vangipuram K, **Sun D**, Henry NL. Association of systemic paclitaxel concentrations with severity and progression of paclitaxel-induced peripheral neuropathy. San Antonio Breast Cancer Symposium, December 9, 2017.
- 21 Alex Yu, Trachette Jackson, Yasuhiro Tsume, Mark Koenigsknecht, Jason Baker, Ann Frances, Bo Wen, Manjunath Pai, Jeffrey Wysocki, Allen Lee, William Hasler, Gordon Amidon, **Duxin Sun**. Predicting human in vivo dissolution through mechanistic deconvolution of an oral absorption model. 2017 AAPS meeting in San Diego, CA, November 12-15, 2017.
- 22 Jinhui Liao, Jason Baker, Jeremy Felton, Miao He, Huixia Zhang, Michael Rice, William Hasler, Bo Wen, Manjunath Pai, **Duxin Sun**. Direct observation of drug disintegration and dissolution in the gastrointestinal tract. 2017 AAPS meeting in San Diego, CA, November 12-15, 2017.
- 23 Feng Li, Huixia Zhang, Miao He, Jinhui Liao, Nianhang Chen, Yan Li, Simon Zhou, Hebao Yuan, Manjunath Pai, **Duxin Sun**. Different nano formulations alter tissue distribution of paclitaxel correlating with distinct efficacy and safety profiles. 2017 AAPS meeting in San Diego, CA, November 12-15, 2017.
- 24 Bart Hens, Yasuhiro Tsume, Marival Bermejo, Paulo Paixão, Mark Koenigsknecht, Jason Baker, William Hasler, Robert Lionberger, Jianghong Fan, Joseph Dickens, Kerby Shedden, Bo Wen, Jeffrey Wysocki, Raimar Loebenberg, Allen Lee, Ann Frances, Greg Amidon, Alex Yu, Gail Benninghoff, Niloufar Salehi, Arjang Talattof, **Duxin Sun**, Gordon Amidon. Dynamic change in pH by low buffer capacity of gastrointestinal fluids along the human gastrointestinal tract: Implications for in vivo dissolution and absorption of ionizable compounds. 2017 AAPS meeting in San Diego, CA, November 12-15, 2017.
- 25 Paulo Paixao, Marival Bermejo, Miguel Hernandez, Yasuhiro Tsume, Mark Koenigsknecht, Jason Baker, Ann Fioritto, Bo Wen, Ting Zhao, Joseph Dickens, Alex Yu, Manjunath Pai, Barry Bleske, Jeffrey Wysocki, Kerby Shedden, Allen Lee, William Hasler, **Duxin Sun**, Gordon Amidon. Connecting gastrointestinal in vivo dissolution and systemic absorption of oral ibuprofen administered after a meal. 2017 AAPS meeting in San Diego, CA, November 12-15, 2017.
- 26 Marival Bermejo, Yasuhiro Tsume, Paulo Paixao, Mark Koenigsknecht, Bart Hens, Jason Baker, Ann Frances, Bo Wen, Ting Zhao, Joseph Dickens, Alex Yu, Manjunath Pai, Barry Bleske, Jeffrey Wysocki, Kerby Shedden, Allen Lee, William Hasler, **Duxin Sun**, Gordon Amidon. Linking gastrointestinal in vivo dissolution and ibuprofen systemic absorption. 2017 AAPS meeting in San Diego, CA, November 12-15, 2017.
- 27 Hongwei Chen, Hayley J. Paholak, Xin Luan, Joseph P. Burnett, Nicholas O. Stevers, Kanokwan Sansanaphongpricha, and **Duxin Sun**. Disrupting immunosuppressive tumor

- microenvironment via stealthy nanobombs to enhance T-cell anticancer efficacy. 2017 AACR meeting in Washington, D.C., April 1-5, 2017.
- 28 Hebao Yuan, Hongwei Guo, Feng Li, Joseph Burnett, Miao He, Nathan Truchan, Ila Myers, and **Duxin Sun**. Abraxane eliminates cancer stem cells in triple-negative breast cancers. 2017 AACR meeting in Washington, D.C., April 1-5, 2017.
- 29 Joseph P. Burnett, Shamileh Fouladdel, Nathan Truchan, Ebrahim Azizi, Max Wicha, **Duxin Sun**. Altering intratumoral heterogeneity in HER2+ breast cancers with PTEN inactivation and trastuzumab therapy. 2017 AACR meeting in Washington, D.C., April 1-5, 2017.
- 30 Nicholas O. Stevers, Samantha L. Tinsley, Rebecca Moody, Chang-Ching Lin, Jennifer Meagher, Jeanne A. Stuckey, Miao-Chia Lo, and **Duxin Sun**. Elucidating BCL11A's function in Triple Negative Breast Cancer. 2017 AACR meeting in Washington, D.C., April 1-5, 2017.
- 31 Chang-Ching Lin, Miao-Chia Lo, Rebecca Moody, Nicholas Stevers, Samantha Tinsley, Max Wicha, and **Duxin Sun**. Identifying CDCA7 as a novel regulator of tumor-initiating cells in triple-negative breast cancer. 2017 AACR meeting in Washington, D.C., April 1-5, 2017.
- 32 Rama Mahran, Pan Shu, **Duxin Sun**, and Dean E. Brenner. Cellular pharmacology of curcumin cellular pharmacology of curcumin±piperine. 2017 AACR meeting in Washington, D.C., April 1-5, 2017.
- 33 Tao Wu, Linda Kessler, Shuangwei Li, Trupta Purohit, Shisheng Li, Hongzhi Miao, Brian Linhares, Rasmus Hansen, Jeff Kucharski, Yi Wang, Ke Yu, Katarzyna Kempinska, Tess Ely, Szymon Klossowski, Ata Zariéh, Ulf Peters, Jun Feng, Yvonne Yao, Yuan Liu, Bo Wen, Francis Burrows, **Duxin Sun**, Jingchuan Zhang, Levan Darjania, Dana Hu-Lowe, Patrick Zarrinkar, Liansheng Li, Tomasz Cierpicki, Jolanta Grembecka, Pingda Ren, and Yi Liu. A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias. 2017 AACR meeting in Washington, D.C., April 1-5, 2017.
- 34 Ester Fernandez-Salas, Zhuo Chen, Mei Lin, Bing Zhou, Donna McEachern, Sally Przybranowski, Karson Kump, Luke F. Peterson, Malathi Kandarpa, Jiantao Hu, Fuming Xu, Liu Liu, Longchuan Bai, Bo Wen, **Duxin Sun**, Moshe Talpaz, Shaomeng Wang. A novel and highly efficacious small-molecule degrader of BET-BRD proteins for the treatment of acute leukemia. 2017 AACR meeting in Washington, D.C., April 1-5, 2017.
- 35 Alex Yu, Trachette L. Jackson, Gordon L. Amidon, Luca Marciani, and **Duxin Sun**. Modeling Dynamic Gastrointestinal Fluid Transit as a Basis for Dissolution and Absorption. 2016 AAPS meeting in Denver, CO, November 13-17, 2016.
- 36 Mark J. Koenigsknecht, Jason R. Baker, Ann F. Fioritto, Yasuhiro Tsume, Bo Wen, Ting Zhao, Joseph Dickens, Alex Yu, Jeffrey Wysocki, Kerby Shedden, Barry Bleske, Allen Lee, William L. Hasler, Gordon L. Amidon, and **Duxin Sun**. Regional *In Vivo* Dissolution of Immediate Release Ibuprofen in Human Gastrointestinal Tract and Its Relationship to Luminal pH, GI Motility, and Systemic Absorption. 2016 AAPS meeting in Denver, CO, November 13-17, 2016.
- 37 Siwei Li, Jing Lu, and **Duxin Sun**. New Software for Drug Metabolite Identification and Structural Characterization by Tandem Mass Spectrometry. 2016 AAPS meeting in Denver, CO, November 13-17, 2016.

- 38 Ann F. Fioritto, Alex Yu, Jason R. Baker, Kristen Collins, Bo Wen, Ying Wang, Ruijuan Luo, Siwei Li, Barry Bleske, Mark Johnson, Mark Koenigsknecht, William L. Hasler, and **Duxin Sun**. Direct Comparison of In Vivo Drug Release Profiles of Three Locally Acting Drug Products of Mesalamine in the Gastrointestinal Tract and Correlation With Systemic Exposure and Fecal Concentrations in Healthy Humans. 2016 Digestive Disease Week meeting in San Diego, CA, May 21-24, 2016.
- 39 Mari Gasparyan, Joseph P. Burnett, Lichao Sun, and **Duxin Sun**. Determining the functional and mechanistic role of homeobox transcription factor Meox1 in breast cancer and breast cancer stem cells. 2016 AACR meeting in New Orleans, LA, April 16-20, 2016.
- 40 Rebecca Reed, Miao-Chia Lo, Chang-Ching Lin, and **Duxin Sun**. Development and optimization of a fluorescence polarization-based assay for the discovery of inhibitors of the RBBP4/7-Histone H3 interaction. 2016 AACR meeting in New Orleans, LA, April 16-20, 2016.
- 41 Kanokwan Sansanaphongpricha, Hongwei Chen, Kai Sun, Bo Wen, and **Duxin Sun**. Janus nanostructures for magnetic resonance imaging and enhanced photothermal therapy for cancer treatment. 2016 AACR meeting in New Orleans, LA, April 16-20, 2016.
- 42 Chang-Ching Lin, Miao-Chia Lo, and **Duxin Sun**. Doxycycline inhibits breast tumor-initiating cells. 2016 AACR meeting in New Orleans, LA, April 16-20, 2016.
- 43 Hongwei Chen, Xin Luan, Nicholas Stevers, Kanokwan Sansanaphongpricha, Joseph Burnett, Hayley Paholak, and **Duxin Sun**. Boosting immunotherapy via stealthy nanoparticle-mediated photothermal therapy. 2016 AACR meeting in New Orleans, LA, April 16-20, 2016.
- 44 Longchuan Bai, Yujun Zhao, Liu Liu, Chao-Yie Yang, Donna McEachern, Jeanne Stuckey, Jennifer Meagher, Bo Wen, **Duxin Sun**, Shaomeng Wang. Antitumor activities of CD161, a structurally novel and orally bioavailable BET inhibitor, in leukemia and triple negative breast cancer cells *in vitro* and *in vivo*. 2016 AACR meeting in New Orleans, LA, April 16-20, 2016.
- 45 Jonathan Pollack, Dmitry Borkin, Kataryzna Kempinska, Trupta Purohit, Xiaoqin Li, Bo Wen, Ting Zhao, Hongzhi Miao, Shirish Shukla, Miao He, **Duxin Sun**, Tomasz Cierpicki, Jolanta Grembecka. Structure-based optimization of small molecule inhibitors of the protein-protein interaction between menin and mixed lineage leukemia (MLL). 2016 AACR meeting in New Orleans, LA, April 16-20, 2016.
- 46 Jamie Connarn, Yan Li, Simon Zhou, Xinyuan Zhang, Andrew Babiskin, Jianghong Fan, Thushi Amini, and **Duxin Sun**. Formulation Design Considerations and Pharmacokinetics Assessments of Bupropion Drug Products. 2015 AAPS meeting in Orlando, FL, October 25-29, 2015.
- 47 Huixia Zhang, Ting Zhao, Ruijuan Luo, Bo Wen, Ying Wang, Miao He, Siwei Li, Yang Liu, and **Duxin Sun**. Pharmacokinetics studies of echinomycin in a mouse xenograft model. 2015 AAPS meeting in Orlando, FL, October 25-29, 2015.
- 48 Ting Zhao, Bo Wen, Huixia Zhang, Ruijuan Luo, Siwei Li, Miao He, Christopher R. Friese, and **Duxin Sun**. A Sensitive and Selective LC-MS/MS Approach for Simultaneous Determination of 18 Cytotoxic Anticancer Agents in Human Plasma for the Assessment of Occupational Safety. 2015 AAPS meeting in Orlando, FL, October 25-29, 2015.

- 49 Siwei Li, Jing Lu, Ruijuan Luo, Bo Wen, Ting Zhao, Yujun Zhao, Bing Zhou, Donna McEachern, Miao He, Huixia Zhang, Shaomeng Wang, and **Duxin Sun**. QSPkR Regression Model to Predict Drug Distribution in Tumor of Anticancer Agents with Side Chain Modifications. 2015 AAPS meeting in Orlando, FL, October 25-29, 2015.
- 50 Alex Yu, Ann F. Fioritto, Jason R. Baker, Kristen Collins, Ying Wang, Ruijuan Luo, Bo Wen, Siwei Li, William L. Hasler, and **Duxin Sun**. Direct Measurement of Mesalamine Dissolution in Human Gastrointestinal Tract. 2015 AAPS meeting in Orlando, FL, October 25-29, 2015.
- 51 Ann F. Fioritto, Jason R. Baker, Kristen Collins, Bo Wen, Ying Wang, Ruijuan Luo, Barry Bleske, Mark Johnson, Mark Koenigsknecht, William L. Hasler, **Duxin Sun**. Contrasting Regional Availability of Different Mesalamine Products in the Gastrointestinal Tract in Healthy Humans Using a Novel Multi-Port Luminal Aspiration System and Correlation with Systemic Absorption. 2015 Digestive Disease Week meeting in Washington, DC, May 16-19, 2015.
- 52 Mark J. Koenigsknecht, Ann F. Fioritto, Jason R. Baker, Barry Bleske, Vincent B. Young, William L. Hasler, **Duxin Sun**. Novel Technique for Gastrointestinal Fluid Isolation and Microbiome Analysis Following Administration of Different Mesalamine Formulations in Healthy Volunteers. 2015 Digestive Disease Week meeting in Washington, DC, May 16-19, 2015
- 53 Hayley J. Paholak, Nicholas O. Stevers, Joseph P. Burnett, Hongwei Chen, Sean P. McDermott, Miao He, Tahra Luther, Shawn G. Clouthier, Max S. Wicha, and Duxin Sun. Epithelial-like breast cancer stem cells are preferentially sensitive to nanoparticle-mediated hyperthermia. 2015 AACR meeting in Philadelphia, PA, April 18-22, 2015
- 54 Hongwei Chen, Xiaoqing Ren, Hayley J. Paholak, Joseph P. Burnett, Feng Ni, **Duxin Sun**. Facile fabrication of MRI-capable and NIR-resonant core-satellite nanomediators for photothermal therapy. 2015 AACR meeting in Philadelphia, PA, April 18-22, 2015
- 55 Joseph P. Burnett, Ronack B. Shah, Hayley J. Paholak, Sean P. McDermott, Yasuhiro Tsume, Max S. Wicha, and **Duxin Sun**. Combination of docetaxel with sulforaphane synergistically inhibits triple negative breast cancer. 2015 AACR meeting in Philadelphia, PA, April 18-22, 2015
- 56 Rebecca Reed, Miao-Chia Lo, and **Duxin Sun**. Characterization of polycomb repressive complex 2 (PRC2) subunits retinoblastoma-binding protein 4 and 7 (RbBP4/7) in triple-negative breast cancer. 2015 AACR meeting in Philadelphia, PA, April 18-22, 2015
- 57 Jamie Connarn and **Duxin Sun**. Metabolic Kinetics of Bupropion in Human Liver and Intestinal Subcellular Fractions. 2014 AAPS meeting in San Diego, CA, November 2-6, 2014
- 58 Kanokwan Sansanaphongpricha, Hongwei Chen, Joseph Burnett, Fuxiang Zhang, Jiaming Zhang, Hayley Paholak, Patrick Sinko, and **Duxin Sun**. The Impact of Shapes and Crystal Lattice Orientation of Iron Oxide Nanoparticles on Photothermal Effect. 2014 AAPS meeting in San Diego, CA, November 2-6, 2014
- 59 Brown SW, Bly MJ, Baker J, Fioritto AF, Hasler WL, & **Sun D**. A novel method to investigate local concentrations of mesalamine in the gastrointestinal tract of healthy volunteers. *Gastroenterology*. 2014 May, 146(5, Supplement 1):S-367.

- 60 Hongwei Chen, Joseph Burnett, Xiaoqing Ren, Yi Wei, Hayley Paholak, and **Duxin Sun**. Near-Infrared-Resonant IONP/Au₂S Core/Satellites Hybrid Nanocomposite for Imaging Capable Photothermal Therapy. 2014 AACR meeting in San Diego, CA, April 5-9, 2014
- 61 Lichao Sun, Joseph P. Burnett, Mari Gasparyan, Hasan Korkaya, Hui Jiang, Yajing Liu, Jamie Connarn, Max Wicha, **Duxin Sun**. "MEOX-1 as a novel cancer stem cell target for treatment of trastuzumab-resistant Her2+ breast cancers" In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; San Diego, CA, Apr 5-9; 2014
- 62 Jamie Connarn, Xiaokai Li, Jason Gestwicki, **Duxin Sun**, A physiologically based pharmacokinetic model of an Hsp70 Inhibitor (JG48) for targeting neurodegenerative disease. 2013 AAPS Annual Meeting, San Antonio, TX, November 10-14, 2013.
- 63 Tao Zhang, Yanyan Li, Peng Zou, Jing-Yu Yu, Shaomeng Wang, **Duxin Sun**, Physiologically Based Pharmacokinetic and Pharmacodynamic (PBPK-PD) Modeling of an Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in a Mouse Xenograft Model of Human Breast Cancer, 2013 AAPS Annual Meeting, San Antonio, TX, November 10-14, 2013.
- 64 Joseph Burnett, Hasan Korkaya, Bryan Newman, Sarah Conley, Jamie Connarn, Lichao Sun, Hsiu-Fang Lee, Maria Ouzounova, Max Wicha, **Duxin Sun**. Natural Product Sulforaphane Selectively Inhibits Breast Cancer Stem Cell in Basal and Trastuzumab Resistant Her2+ Breast Cancer, 2013 AACR Annual Meeting, Washington, D.C., April 6-10, 2013.
- 65 Yasuhiro Tsume, Xinyuan Zhang, Robert A Lionberger, Xiaoqin Li, Lawrence Yu, and **Duxin Sun**. The Discrepancy of In Vitro Dissolution Rates and Predicted In Vivo Dissolution Rates of Different Mesalamine Formulations Through Simulation Software, 2012 AAPS Annual Meeting, Chicago, IL, October 14-18, 2012.
- 66 Hongwei Chen, Peng Zou, Hayley Paholak, **Duxin Sun**. Intracellular Dissociation of Polymer Coating from Nanoparticles. 2012 AACR Annual Meeting. Chicago. IL. March 31-April 4, 2012.
- 67 Peng Zou, Hongwei Chen, Hayley Smithkort, Andrew Wang, **Duxin Sun**. Stability of superparamagnetic iron oxide (SPIO)-loaded polymeric nanoparticles 2011 AAPS Annual Meeting. Washington DC, October 26, 2011.
- 68 Hsiu-Fang Lee, Bryan Newman, Suling Liu, Hasan Korkaya, Shawn G. Clouthier, Sean P McDermott, Max S. Wicha, and **Duxin Sun**. HDAC inhibitor SAHA suppressed breast cancer stem cells in vitro and in vivo. 2011 AACR Annual meeting, April 2-6, 2011. Orlando, FL.
- 69 Newman B, Zhang Q, Lu Y, Zhao J, Ding Y, Ma w, Fan H, Long J, Zhang H, Wang M, **Duxin Sun**. Analogue CY-9. 2011 AACR Annual meeting, April 2-6, 2011. Orlando, FL.
- 70 Y Li, Karagoz E, Seo Y, Zhagn T, Jiang Y, Yu Y, Schwartz S, Caroll K, Rudiger S, **Duxin Sun**. Sulforaphane inhibits Hsp90 by disrupting superchaperone complexes through direct interaction with specific residues of Hsp90/CDC37 in Pancreatic cancer cells. 2010 AAPS Annual Meeting, Nov 14-18, New Orleans, LA.
- 71 Hsiu-Fang Lee, Bryan Newman, Hasan Korkaya, Suling Liu, Shawn G. Clouthier, David Z. D'Argenio, Max S. Wicha, and **Duxin Sun**. Pharmacokinetic Analysis and Dose Optimization of 17AAG for Efficient Inhibition of Breast Cancer Stem Cells *In Vivo*. 2010 AAPS Annual Meeting, Nov 14-18, New Orleans, LA.
- 72 Tao Zhang, Peng Zou, Donna McEachern, Jing-yu (Jerry) Yu, Yanyan Li, David Z. D'Argenio, Shaomeng Wang, and **Duxin Sun**. Physiologically Based Pharmacokinetic Modeling for a Small Molecule Mimetic (AT-406) of Smac in Tumor-Bearing Mice after Oral Administration. 2010 AAPS Annual Meeting, Nov 14-18, New Orleans, LA.
- 73 Yanke Yu, Suzanna Zick, XiaoQin Li, Peng Zou, Duxin Sun. LC-MS/MS determination of 6-

- Gingerol, 8-Gingerol, 10-Gingerol and 6-Shogaol and their Pharmacokinetics in human clinical trial. 2010 AAPS Annual Meeting, Nov 14-18, New Orleans, LA.
- 74 Peng Zou, Nan Zheng, Yanke Yu, Shanghai Yu, Wei Sun, Shaomeng Wang, **Duxin Sun**. Prediction of clearance and volume of distribution in human of a novel MDM2 inhibitor (MI-219) using in vitro liver microsomal metabolism and in vivo pharmacokinetics in animals. 2010 AAPS Annual Meeting, Nov 14-18, New Orleans, LA.
- 75 Peng Zou, Yanke Yu, Y. Andrew Wang, Shaomeng Wang, **Duxin Sun**. Superparamagnetic iron oxide nanoparticle “theranostics” for targeted cancer cell imaging and pH-dependent intracellular drug release for targeted drug delivery. 2010 AAPS Annual Meeting, Nov 14-18, New Orleans, LA.
- 76 Yanke Yu, Zhenkun Zhu, Yiqun Jiang, Yanyan Li, Peng Zou, Tao Zhang, Jason E. Gestwicki, and **Duxin Sun**. Synergistic anticancer effect of Withaferin A and Myricetin in pancreatic cancer cells through inhibition of Hsp70. 2010 AAPS Annual Meeting, Nov 14-18, New Orleans, LA.
- 77 Peng Zou, Tao Zhang, Xiaoqin Li, Shanghai Yu, Wei Sun, Shaomeng Wang, **Duxin Sun**. Identification and inhibition of cytochrome P450 for metabolisms of a novel MDM2 inhibitor (MI-219). 2010 AAPS Annual Meeting, Nov 14-18, New Orleans, LA.
- 78 Yanyan Li, Tao Zhang, Hasan Korkaya, Suling Liu, Hsiu-Fang Lee, Bryan Newman, Yanke Yu, Shawn Clouthier, Steven Schwartz, Max Wicha, **Duxin Sun**. Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells. AACR 101 annual meeting, April 17-21, 2010, Washington DC.
- 79 Yiqun Jiang, Denzil Bernard, Yanke Yu, Tao Zhang, Yanyan LI, Xueqi Fu, Shaomeng Wang, **Duxin Sun**. Characterization of Hsp90/Cdc37 interaction and their critical residues using luciferase fragment complementation imaging. AACR 101 annual meeting, April 17-21, 2010, Washington DC.
- 80 Zhenkun Zhu, Xin Xu, Yanke Yu, Martin Graham, Gangli Liu, Mark Prince, Thomas Carey, **Duxin Sun**. Heat shock protein 27 increases metastasis of human head and neck squamous cancer cells *in vitro*. AACR 101 annual meeting, April 17-21, 2010, Washington DC.
- 81 Yanyan Li, Tao Zhang, Steven Schwartz, **Duxin Sun**. Sulforaphane sensitizes pancreatic cancer to 17-AAG by interfering with Hsp90/co-chaperone interaction. AAPS annual meeting, Nov 8-12, 2009, Los Angeles, CA
- 82 Tao Zhang, Yanyan Li, Peng Zou, Yabnke Yu, **Duxin Sun**. Characterization of celastrol to inhibit Hap90/Cdc37 interaction. AAPS annual meeting, Nov 8-12, 2009, Los Angeles, CA
- 83 Peng Zou, Michelle M. Carlton, George H. Hinkle, Nathan C. Hall, Stephen P. Povoski, Ronald X. Xu, Cathy M. Mojzisk , Morgan A. Johnson, Michael V. Knopp, Edward W. Martin, Jr, and **Duxin Sun**. Comparison of ¹²⁴I-HuCC49Δ_CH2 and ¹⁸FDG for PET imaging of colorectal cancer. AAPS annual meeting, Nov 8-12, 2009, Los Angeles, CA
- 84 Peng Zou, **Duxin Sun**. Metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) in Human and Rat Liver Microsomes by Liquid Chromatography Tandem Mass Spectrometry. AAPS annual meeting, Nov 8-12, 2009, Los Angeles, CA
- 85 Yanke Yu, Adel Hamza, Tao Zhang, Mancang Gu, Peng Zou, Bryan Newman, Yanyan Li, A. A. Leslie Gunatilaka, Chang-Guo Zhan, and **Duxin Sun**. Withaferin A Targets Heat Shock Protein 90 in Pancreatic Cancer Cells. AAPS annual meeting, Nov 8-12, 2009, Los Angeles, CA.
- 86 Hsiu-Fang Lee, B Newman, H. Korkaya, S. Liu, S. Clouthier, M Wicha, **D Sun**. HSP90 Inhibitor 17AAG Suppresses the Breast Cancer Stem/Progenitor Cell Population. AAPS annual meeting, Nov 8-12, 2009, Los Angeles, CA
- 87 B Newman, HF Lee, Y Liu, **D Sun**, Y Wang. 17AAG-mediated Hsp90 Inhibition is an Effective

- Means against Lymphoma Cancer Stem Cells. AAPS annual meeting, Nov 8-12, 2009, Los Angeles, CA
- 88 Yanyan Li, Tao Zhang, Steven J. Schwartz, and **Duxin Sun**. EGCG Inhibits Hsp90 Function by Impairing Hsp90 Association with Cochaperones in Pancreatic Cancer Cells. AACR Annual meeting , Denver, CO, April 2009
- 89 Tao Zhang, Yanyan Li, and **Duxin Sun**. Combination of Hsp90 inhibitors and MEK Inhibitors abrogates ERK Activation in Pancreatic Cancer Cells. AACR Annual meeting , Denver, CO, April 2009
- 90 Sears, R. Bryan; Turro, Claudia; Heremans, Joseph; **Sun, Duxin**; Martin, Edward. Development of An Intra-Operative Probe for near-IR Detection of Occult Tissue. Abstracts, 40th Central Regional Meeting of the American Chemical Society, Columbus, OH, United States, June 10-14 (2008), CRM-306.
- 91 Ronald Xu, Jeff Xu, Joseph Ewing, Bei Wang, **Duxin Sun**, Stephen Povoski, Edward Martin Jr. Development of indocyanine green encapsulated microbubbles for dynamic imaging of breast cancer. DOD Breast cancer program Era of Hope meeting, Baltimore, Maryland, June, 2008
- 92 Yanke Yu and **Duxin Sun**. Withaferin A that inhibits Hsp90 by disrupting Hsp90-Cdc37 interaction against pancreatic cancer cells. AAPS Annual Meeting, Atlanta, GA, November 2008
- 93 Peng Zou, Jeff Xu, Anna Wang, Stephen P. Povoski, Edward W Martin, Jr, Ronald Xu, and **Duxin Sun**. Near-Infrared Fluorescent Labeled Anti-TAG-72 Antibodies for Tumor Imaging in Colorectal Cancer Xenograft Mice. AAPS Annual Meeting, Atlanta, GA, November 2008
- 94 Jeff Xu, Peng Zou, **Duxin Sun**, Edward Martin, Stephen Povoski, Ronald Xu. Multimodal, intraoperative cancer imaging with microbubbles and antibody-fluorophore conjugates. BMES Annual Fall Meeting, St Louis, 2008
- 95 Chen, Wenlan; Zhang, Guisheng; Zhu, Lizhi; Fang, Lanyan; Cao, Xianhua; Kedenburg, James; Shen, Jie; **Sun, Duxin**; Wang, Peng George. Uncommon sugars and their conjugates to natural products. ACS Symposium Series (2007), 960(Frontiers in Modern Carbohydrate Chemistry), 15-33.
- 96 Tao Zhang, Adel Hamza, Xianhua Cao, Bing Wang, Shuwen Yu, Chang-Guo Zhan, **Duxin Sun**. A Novel Hsp90 inhibitor disrupts Hsp90-Cdc37 complex for pancreatic cancer therapy. AAPS Annual Meeting, San Diego, CA, November 2007
- 97 Lanyan Fang, Yanqiang Zhong, Ming Yang, Kenneth K. Chan, Edward T Martin Jr, and **Duxin Sun**. *In Vivo* Fluorescent Imaging for Antibody-Directed Enzyme Prodrug Therapy (ADEPT) and Tumor Detection Using HuCC49 Δ CH2- β -galactosidase Conjugate. AAPS Annual Meeting, San Diego, CA, November 2007
- 98 Xianhua Cao, Mark Bloomston, Guang Jia, Wendy L. Frankel, Tao Zhang, Nathan Hall, Hao Cheng, Michael Knopp, and **Duxin Sun**. Simultaneously Targeting Hypoxic Cancer Cells by HSP90 Inhibitor and Glycolysis Inhibitor in Pancreatic Cancer Therapy. AAPS Annual Meeting, San Diego, CA, November 2007
- 99 Xianhua Cao, Bing Wang, Guang Jia, Ming Yang, Michael V. Knopp and **Duxin Sun**. Non-invasive tumor MRI imaging and synergistic anti-tumor effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. AAPS Annual Meeting, San Diego, CA, November 2007
- 100 Lanyan Fang, **Duxin Sun**. Predictive physiological based pharmacokinetic (PBPK) analysis for antibody directed enzyme prodrug therapy (ADEPT). AAPS Annual Meeting, San Diego, CA, November 2007
- 101 Seth Gibbs, Changgong Liu, Mark Bloomston, Lanyan Fang, Peng George Wang, Carlo Croce, **Duxin Sun**. miR-221 and miR-222 regulation of Kit protein provides a novel

- mechanism for drug resistance in leukemia. AAPS Annual Meeting, San Diego, CA, November 2007
- 102 Guang Jia, Xianhua Cao, Peter Wassenaar, Ming Yang, Regina M Koch, Steffen Sammet, Hao Cheng, Tao Zhang, Petra Schmalbrock, **Duxin Sun**, Michael V Knopp. MR Imaging of Pancreatic Cancer in a Mouse Model using a Clinical 3T Scanner. ISMRM MR of Cancer Study Group Workshop: Frontiers in Metabolic, Molecular and Clinical Imaging. Oct 2006, Pocono Manor, PA, USA
- 103 Shen, Jie; Cao, Xianhua; **Sun, Duxin**; Wang, Peng George. Synthesis of geldanamycin (GA)-galactose ADEPT prodrug. 232nd ACS National Meeting, San Francisco, CA, United States, Sept. 10-14, 2006.
- 104 Abdul Rana, Xianhua Cao, **Duxin Sun**, Ronald Xu. Monitoring Oxygen Dynamics During Pressure Induced Ischemia on Cancer Xenograft Models. 31st International Conference on Infrared and Millimeter Waves and 14th International Conference on Terahertz Electronics. September 18-22, 2006, Shanghai ,China.
- 105 Bo Qiang, Xuehai Zhu, Xianhua Cao, Guanglong He, **Duxin Sun**, Ronald Xu. Development of a Multi-modal Sensor for in vivo Monitoring of Tumor Oxygen Dynamics. 31st International Conference on Infrared and Millimeter Waves and 14th International Conference on Terahertz Electronics. September 18-22, 2006, Shanghai, China.
- 106 L. Fang, R. Battisti, H. Cheng, E. Martin, K. Chan, P. Wang, **D. Sun**. Enzyme Specific Activation of Geldanamycin Prodrugs Using Humanized HuCC49deltaCH2-beta-galactosidase Conjugates. AAPS Annual Meeting, San Antonio, TX, October 2006.
- 107 L. Fang, N. Holford, X. Cao, G. Hinkle, J. Xiao, S. Gibbs, J. Dalton, K. Chan, E. Martin, **D. Sun**. Application of Bayesian Estimation to forecast time of Surgical Exploration using RadiolImmunoGuided Surgery (RIGS). AAPS Annual Meeting, San Antonio, TX, October 2006.
- 108 Xianhua Cao, Seth Gibbs, Lanyan Fang, Heather A. Miller, Christopher P. Landowski, Ho-Chul Shin, Hans Lennernas, Yanqing Zhong, Gordon L. Amidon, Lawrence X. Yu, and **Duxin Sun**. Why Is It Challenging to Predict Intestinal Drug Absorption And Oral Bioavailability In Human Using Rat Model. AAPS Annual Meeting, San Antonio, TX, October 2006.
- 109 Xianhua Cao, Lanyan Fang, Seth Gibbs, Ying Huang, Zunyan Dai, Ping Wen, Xincheng Zheng, Wolfgang Sadee, and **Duxin Sun**. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Gibbs S, AAPS Annual Meeting, San Antonio, TX, October 2006.
- 110 Seth Gibbs, Lawrence X Yu, and **Duxin Sun**. In vitro cell systems to evaluate and predict drug absorption from the pulmonary system. AAPS Annual Meeting, San Antonio, TX, October 2006.
- 111 Seth Gibbs, Jie Shen, Dongning Lu, Lanyan Fang, Guisheng Zhang, Peng G. Wang, **Duxin Sun**. Nitric oxide helps overcome p-gp-associated daunorubicin resistance. AAPS Annual Meeting, San Antonio, TX, October 2006.
- 112 Fang L Martin Jr. ED, **Sun D**. Population pharmacokinetics of HuCC49 Δ CH2, a novel monoclonal antibody for tumor targeting. AAPS Annual Meeting, Nashville, TN, November 2005.
- 113 Lanyan Fang, Guisheng Zhang, Xincheng Zheng, Jim J, Xiao, Peng George Wang, and **Duxin Sun**. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes MDR-mediated drug resistance. AAPS Annual Meeting, Nashville, TN, November 2005.
- 114 Xianhua Cao, Lawrence X. Yu, Catalin Barbaciru, Christopher P. Landowski, Ho-Chul Shin, Gordon L. Amidon, and **Duxin Sun**. Permeability Dominates In Vivo Intestinal Absorption of P-gp Substrate with High Solubility and High Permeability. AAPS Annual Meeting, Nashville,

- TN, November 2005.
- 115 Xianhua Cao, Ping Wen, Zunyan Dai, Ying Huang, Edward w. Martin Jr, Peng George Wang, Wolfgang Sadee, and **Duxin Sun**. Expression of GLUT1 in tumors promotes cancer cell survival. AACR Annual meeting, Anaheim, CA, April 2005
- 116 Jim J Xiao, Xianhua Cao, Jing Fang, George H Hinkle, Sara N Horst, Ergun Kocak, Donn Young, Doreen M Agnese, **Duxin Sun**, and Edward W Martin Jr. Pharmacokinetics and clinical evaluation of 125-I Radiolabeled Humanized CC49 Monoclonal Antibody (HuCC49DeltaCH2) in Recurrent and Metastatic Colorectal Cancer Patients. AACR Annual meeting, Anaheim, CA, April 2005
- 117 Cheng H, Cao, X, Xian M, Fang L, Cai TB, Tunac JB, **Sun D**, Wang GP. Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity. AACR Annual meeting, Anaheim, CA, April 2005
- 118 **Sun D**, Badawy S, Nyamweya N, Heran C, Moench P, Hussain M, Patel J, Schuster AE, Franchini M, Zhao F, Gray D, Wall D. pH-Dependent Absorption of a Factor Xa Inhibitor in Different Formulations. Pharmaceutical Research Institute Scientific Symposium, Wallingford, CT. May 2003.
- 119 **Sun D**, Wu Y, Heran C, Stetsko PI, Zhao F, Hollenbaugh F, Wall D. Establishment of a Canine Absorption Model and Application to Optimize CRF Antagonist Formulations. Pharmaceutical Research Institute Scientific Symposium, Wallingford, CT. May 2003.
- 120 Shin HC, Landowski CP, **Sun D** and Amidon GL. Molecular cloning and substrate recognition of the sodium-dependent nucleoside transporter hCNT2 from human intestine. Molecular Biopharmaceutics: A new era in drug absorption transport and delivery. 2nd International Congress on Drug Absorption Transport and Delivery, January 22-24, 2003. Hawaii, USA.
- 121 Foster D, Landowski CP, Streetman D, **Sun D**, Amidon GL, and Welage LS. Alterations in the expression of key intestinal transporters and metabolic enzymes in thermally injured rats. 2003 Spring Practice and Research Forum: 2003 Updates in Therapeutics: The Pharmacotherapy Preparatory Course. American College of Clinical Pharmacy. April 27-30, 2003. Palm Springs, CA, USA.
- 122 Landowski, CP, Neudeck BL, Foster D, Gonzales JP, **Sun D**, and Amidon GL, and Welage LS. Alterations in cephalixin transport and PEPT1 expression following thermal injury in rats. . Molecular Biopharmaceutics: A new era in drug absorption transport and delivery. 2nd International Congress on Drug Absorption Transport and Delivery, January 22-24, 2003. Hawaii, USA.
- 123 Landowski CP, **Sun D**, Menon SS, Ramachandran C, Barnet JL, Foster D, Welage LS, and Amidon GL. Gene expression in human intestine and correlation with oral valacyclovir pharmacokinetic parameters. *AAPS Annual Meeting and Exposition*, Nov 10-14, Toronto, Canada.
- 124 **Sun D**, Fleisher D, Lee KD, and Amidon GL. Regional and diet dependent drug intestinal absorption and gene expression by GeneChip analysis in rat. *The 29th International Symposium on Controlled Release of Bioactive Materials*. July 20-25, 2002. Seoul, Korea.
- 125 **Sun D**, Landowski CP, Welage LS, Neudeck BL, Foster D, Hsu C-P, Higaki K, Fleisher D, and Amidon, GL. Implication of intestinal transporter expression and in vitro/in vivo intestinal drug permeability correlation. *The 28th International Symposium on Controlled Release of Bioactive Materials*. June 24-27, 2001. San Diego, CA.
- 126 **Sun D**, Landowski, CP, Chu X, and Amidon GL. Drug uptake and hPepT1 localization using hPepT1-GFP fusion protein. *2000 AAPS annual meeting and Exposition*. Oct. 2000. Indianapolis, IN.
- 127 **Sun D**, Funk CD. Cloning of a human "epidermal-type"12-lipoxygenase related gene. *The 5th International Conference in Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation*

- and Related Diseases*. La Jalla, CA, September 17-20, 1997.
- 128 **Sun D**, Funk CD. The potential role of leukocyte-type lipoxigenase in atherogenesis. *First Annual Vascular Biology Retreat: Basic Science encounters Clinical Application*. March 21, 1997. Chestnut Hill, PA. p40.
- 129 **Sun D**, Funk CD. Disruption of 12/15-lipoxygenase expressions in peritoneal macrophage: Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of LDL. *Thirteenth Annual Student Symposium of University of Pennsylvania School of Medicine, Pharmacological Sciences*. October 1, 1996. Philadelphia, PA. p14.
- 130 **Sun D**, Funk CD. Disruption of the leukocyte-type 12/15-lipoxygenase in mice. *Frontiers in Bioactive Lipids'96. XVI Washington international spring symposium*. May 1996. Washington D.C.
- 131 Funk CD, **Sun D**, Johnson EN, Cheng XS. Arachidonate lipoxygenases molecular and gene knockout studies. *FASEB J* Apr. 30, 1996, P120.
- 132 **Sun D**, Rui YC. PAF and cerebrovascular endothelium injuries. *The First conference of basic and clinical research of cerebrovascular disorders*. September 1993. Shanghai, China. P178.
- 133 **Sun D**, Rui YC. The action of PAF on the cerebrovascular system. *The 8th international conference on prostaglandins and related compounds*. Montreal, Canada. July 1992, pp49.
- 134 **Sun D**, Rui YC. The specific binding sites of PAF on the cerebrovascular endothelial cells. *The 4th symposium of Chinese cardiovascular pharmacology*. August 1991. Shenyang, China. P253.
- 135 **Sun D**. The development of a PAF receptor antagonist and its pharmacological studies. *The First international conference of new drug development*. Oct. 1990. Beijing, China.

Invited Presentations

- 1 Measuring Glipizide Release from Two Different ER Formulations vs. Oral Solution In Situ Using Intubation in Humans. FDA/PQRI Workshop - Challenges and Opportunities for Modified Release Oral Drug Product Development-GBHI in Rockville, MD, April 18, 2024.
- 2 Advantages and Challenges of Partial AUC: Insights from GI Physiology, Pharmacokinetics, and Drug Dissolution in the GI Tract. PQRI/EUFEPS Global Bioequivalence Harmonisation Initiative (GBHI): 6th International Workshop – GBHI 2024 in Rockville, MD, April 16-17, 2024.
- 3 SARS-CoV-2 B Epitope-Guided Neoantigen Cancer Vaccine. Purdue University, Department of Industrial and Physical Pharmacy Seminar in West Lafayette, IN, March 27, 2024.
- 4 Why 95% of cancer drug development fails and how to improve it? Small Molecule Tissue Targeted Therapies at ACS National Meeting in New Orleans, LA, March 17-21, 2024.
- 5 Why 95% of cancer drug development fails and how to improve it? 8th International Conference on Cancer Research and Drug Development (Cancer R&D-2023) in Boston, MA, November 13-15, 2023.
- 6 Why 90% of drug development fails and how to improve this? Biochemistry, Microbiology, and Immunology Series at Wayne State University, Detroit, MI, September 26, 2023
- 7 Why 90% of drug development fails and how to improve it? MEDI Symposium at ACS National Meeting in San Francisco, CA, August 13-17, 2023.
- 8 Perspectives of Industry. Great Lakes Pharmacy Conference, Ann Arbor, MI. March 25, 2023.
- 9 Why Most AntiCancer NanoMedicines Failed to Show Superior Clinical Efficacy and How to Improve It to Achieve Long-Term Tumor Remission? The Targeted Delivery Interest Group, NIH, online. February 17, 2023.

- 10 Direct measurement of drug dissolution and bile salts in human GI tract for immediate- and modified-release drug products. Chicagoland Pharmaceutical Discussion, AAPS. Chicago, IL. November 10, 2022.
- 11 Why 90% Drug Development Fails and how to improve it? WenDaoShenNong Innovative Research Forum. Drug Clinical Trial Center, Peking University Third Hospital, online. November 23, 2022.
- 12 Improve Clinical Success of Anticancer NanoMedicine by Correcting Flawed Design. Nanoscience Approaches to Cancer, Brooklyn College Cancer Center, online. October 7, 2022.
- 13 Why 90% of clinical drug development fails and how to improve it? Gulf Coast Consortia Innovative Drug Discovery and Development Conference, Houston, TX. May 3, 2022.
- 14 What went wrong with anticancer nanomedicine design and how to make it right? The 8th International Symposium in Quantitative Pharmacology, online. December 6, 2021.
- 15 Overlooked Biopharmaceutics of Nanomedicines/Nanovaccines Impacts Clinical Dose/Efficacy/Safety. 5th FDA/PQRI Conference on Advancing Product Quality: Advancing Quality & Technology of Future Pharmaceuticals, online. December 1, 2021.
- 16 What went wrong with anticancer nanomedicine design and how to make it right. China Agriculture University, online. March 5, 2021.
- 17 Critical element PK PD, and what should physicians glean from PK PD clinically? Hematologic Malignancies Clinical Research Meeting, University of Michigan, online. October 20, 2020.
- 18 Visualize cancer cell heterogeneity and their response to therapy through cancer stem cell hierarchy. Hope College, Holland, MI. October 26, 2018.
- 19 From innovative medicine to drug development: new frontiers and challenges panel. Michigan China Biomedical Forum 2018 in Ypsilanti, MI. August 13, 2018.
- 20 Why most nanomedicines fail to improve efficacy, but only alter toxicity. National Taiwan University School of Pharmacy Research Day and International Conference in Taipei, Taiwan. June 2, 2018.
- 21 Real-time visualization of cancer stem cell plasticity, asymmetrical division, differentiation, and response to treatment to generate cancer cell heterogeneity. Cancer Center Grand Rounds at NCRC, University of Michigan, Ann Arbor, MI. March 19, 2018.
- 22 Measurement of gastrointestinal luminal and plasma drug concentrations. Oral Drug Delivery 2018 *in vivo* Predictive Dissolution, formulation Predictive Dissolution conference in Lake Tahoe, NV. March 5, 2018.
- 23 Development of GI sampling capsule. Oral Drug Delivery 2018 *in vivo* Predictive Dissolution, formulation Predictive Dissolution conference in Lake Tahoe, NV. March 5, 2018.
- 24 Nanomedicine eliminates cancer stem cells. 2017 Chinese Pharmaceutical Conference in Shanghai, China. October 29, 2017.
- 25 Broccoli as a functional food to eliminate cancer stem cells. 2017 Green Life Sciences Symposium, at the University of Michigan Ann Arbor, Michigan. October 21, 2017.
- 26 Strategies for assessing equivalence of complex injectable products. Development of Generics & 505(b)(2): Opportunities, Challenges and Solutions symposium in Somerset, NJ. September 21, 2017.
- 27 Direct measurement of *in vivo* dissolution of IR and MR drug products in human GI tract. AAPS Workshop on *In Vivo* Predictive Drug Dissolution/Simulation in Rockville, MD. September 11, 2017.
- 28 Direct measurement of drug dissolution in human GI tract *in vivo* using human intubation study for modified release and immediate release drug products. 2016 AAPS meeting in Denver, CO. November 17, 2016.

- 29 Modeling dynamic gastrointestinal fluid transit as a basis for dissolution and absorption. 2016 AAPS meeting in Denver, CO. November 16, 2016.
- 30 Drug discovery targeting PRC2 to alter epigenetics for therapeutics of triple-negative breast cancer. International Conference on Drug Discovery and Translational Medicines, Zhengzhou University. November 4-6, 2016.
- 31 Drug discovery targeting PRC2 to alter epigenetics for therapeutics of triple-negative breast cancer. 2016 China-US Translational Medicine Forum—University of Michigan Chapter, Guangxi Medical University, Nanning, China. October 29-November 1, 2016.
- 32 Drug discovery target PRC2 to alter epigenetics for therapeutics of triple-negative breast cancer. Qinghua University, Beijing, China. October 21, 2016.
- 33 Albumin paclitaxel nanoparticles inhibit cancer stem cells, enhance drug tissue penetration and cellular uptake, and alter elimination mechanism. 2016 International Forum on Leading Edge Technologies on Crystallization Engineering and Pharmaceuticals Development, Tianjin, China. October 14-16, 2016.
- 34 Potential new method to improve BE of modified release drug products supported by *in vivo* drug dissolution and metabolism studies. Food and Drug Administration, Washington, DC. May 20, 2016.
- 35 Natural products and nanomedicine to eliminate cancer stem cells. Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI. March 16, 2016.
- 36 Natural products and nanomedicine to eliminate cancer stem cells for cancer therapy. Fudan University, Shanghai, China. October 21, 2015.
- 37 Nanomedicine to eliminate cancer stem cells. Tianjin University, Tianjin, China. October 15, 2015.
- 38 Natural products to eliminate cancer stem cells for cancer therapy. Qingdao Agricultural University, Qingdao, China. October 12, 2015.
- 39 Elimination of cancer stem cells for cancer therapy. Zhejiang University, Hangzhou, China. October 8, 2015.
- 40 Nanomedicine and natural products for elimination of cancer stem cells. Second Annual Meeting of the International Ovarian Cancer Consortium, University of Oklahoma Health Sciences Center, Oklahoma City, OK. August 18, 2015.
- 41 *In vivo* drug dissolution in human GI tract for controlled release and locally acting drug products. Food and Drug Administration, Washington, DC, May 20, 2015.
- 42 Therapeutics of cancer stem cells using natural products. School of Medicine, University of Louisville, Louisville, KY. April 14, 2015.
- 43 Direct Measurement of *In Vivo* Drug Dissolution in Human GI Tract. Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI. August 5, 2014.
- 44 Direct Measurement and Computational Modeling of *In Vivo* Drug Dissolution in Human GI tract for Accurate BA/BE Study and Prediction of Generic Drugs. Food and Drug Administration, Washington DC, May 16, 2014.
- 45 Nano Satellite for Tumor Imaging and Photothermal Cancer Therapy. Tianjin Medical University, Tianjing, China. May 8, 2014.
- 46 Inhibition of Cancer Stem Cell Targets by Natural Products for Anticancer Therapy. Guangxi Medical University, Nanning, China. April 30, 2014.
- 47 Natural products to inhibit cancer stem cells for cancer therapy. Jinan University. Guangzhou, China. April 28, 2014.
- 48 Inhibition of Cancer Stem Cell Targets by Natural Products for Anticancer Therapy. Chinese Pharmaceutical University, Nanjing, China. April 23, 2014.
- 49 Small Molecules to Inhibit Cancer Stem Cell Targets and Protein-Protein Interactions for

- Cancer Therapy. University of Florida, Gainesville, FL. March 25, 2014.
- 50 Small Molecules to Inhibit Cancer Stem Cell Targets and Protein-Protein Interactions for Cancer Therapy. University of Iowa, Iowa City, Iowa. Feb 27, 2014.
- 51 Novel cancer stem cell target and therapeutics for Herceptin-resistant Her2+ breast cancer. Translational Oncology Program, University of Michigan, January 30, 2014.
- 52 Disruption of Protein-Protein Interactions in Hsp90 Complex for Cancer Therapy, Center for the Discovery of New Medicines, University of Michigan, September 13, 2013.
- 53 Antibody-Enzyme Conjugate for Prodrug Activation, AAPS Annual Meeting, October 14-18, 2012.
- 54 Therapeutic of Cancer Stem Cells Using Natural Products, University of Pittsburgh, Pittsburgh, PA. January 21-22, 2013.
- 55 Nanotheranostics for cancer imaging and targeted drug delivery. 47th Annual Arden Conference, March 11-14, 2012, West point, NY.
- 56 Targeting breast cancer stem cells. 2011 AAPS annual meeting, Washington DC, Oct 2011.
- 57 Nature products for therapeutics of cancer stem cells. 2011 International Symposium on Agricultural Biotechnology: Herbal Medicines for Immunity and Cancer. 10/20/2011, Taipei, China.
- 58 PET and Fluorescent Imaging to Study ADME of Tumor Targeting Antibody. AAPS webinar. August 2011.
- 59 Therapeutics of cancer stem cells using natural products. International Meeting on Natural Products and Cancer Targets: Progress and Promise. August 24-25th, 2011; Zhengzhou, China.
- 60 TCM and cancer stem cells. The Consortium for Globalization of Chinese Medicine (CGCM), Shanghai, China. August 26-28, 2011.
- 61 Drug discovery and natural products for therapeutics of cancer and cancer stem cells. Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. August 2011.
- 62 Biological factors influencing bioavailability and bioequivalence (BA/BE). International Workshop on Bioavailability and Bioequivalence, June 20-21, 2011. Suzhou, China.
- 63 Hsp90 inhibitors for therapeutics of cancer and cancer stem cells. Guangzhou Institutes of Biomedical and Health, Chinese Academy of Sciences, Guangzhou, China, June 2011.
- 64 PET and fluorescent imaging to study ADME of tumor targeting antibody. AAPS Annual Meeting, New Orleans, LA, November 2010.
- 65 Nanotheranostics for targeted drug delivery and tumor imaging. AAPS Annual Meeting, New Orleans, LA, November 2010.
- 66 Lead optimization and drug absorption prediction. Roche R&D Center (China) Ltd. June 17, 2010, Shanghai, China.
- 67 Novel Hsp90 Inhibitors That Disrupt Protein-Protein Interaction for Cancer Therapy. Roche R&D Center (China) Ltd. June 17, 2010, Shanghai, China.
- 68 New agents for therapeutics of cancer stem cells and nanotheranostics for tumor imaging and targeted drug delivery. Shanghai Pharmaceutical Association, June 9, 2010, Shanghai, China.
- 69 Biological factors that influence oral bioavailability. The second Asian Arden Conference and Annual Meeting of Pharmaceutics Committee of Chinese Pharmaceutical Association, June 11-13, Shenyang, China.
- 70 Lead optimization in drug discovery and development. The First International Research and Development of Innovative Drugs and Generic Drugs and the Assessment Process Forum, June 20-23, 2010, Guangdong, China.
- 71 Hsp90 inhibitors for cancer and cancer stem cells, June 6, 2010, College of Pharmacy, Shandong University, Jinnan, China.

- 72 Hsp90 inhibitors for cancer and cancer stem cells, June 12, 2010, College of Pharmacy, Nankai University, Tianjin, China.
- 73 Hsp90 Inhibitors for Therapeutics of Cancers and Cancer Stem Cells, Jan 21, 2010, College of Pharmacy, University of Wisconsin, Madison, WA.
- 74 pH-dependent solubility and absorption. 45th Annual Arden Conference, Feb 1-5, 2010, West point, NY.
- 75 Prediction of human hepatic metabolism and clearance from in vitro and in vivo animal experiments. AAPS annual meeting, Nov 8-12, 2009, Los Angeles, CA.
- 76 Targeted therapy and chemoprevention for cancer stem cells. AAPS annual meeting, Nov 8-12, 2009, Los Angeles, CA
- 77 Predict Oral Bioavailability in Human: Forming an Interface between Preclinical Data and Clinical Outcome. AAPS PPB workshop, Baltimore, MD, May 2009.
- 78 Antibody and FDG for PET Tumor Imaging and Targeted Drug Delivery, AAPS Annual Meeting, Atlanta, GA, November 2008.
- 79 P-gp and microRNA in Drug Resistance AAPS Annual Meeting, Atlanta, GA, November 2008.
- 80 An Integrated System for Tumor Detection and Targeted Drug Therapy Using ADEPT: Preclinical, Clinical Testing and Pharmacokinetic Modeling. IBC's Antibody Engineering. San Diego, CA, December 7 -11, 2008.
- 81 Novel Hsp90 inhibitors that disrupt Hsp90-Cdc37 interaction for the use of pancreatic cancer therapy. Poniard Pharmaceuticals Inc, San Francisco, June 2008.
- 82 Tumor detection and targeted drug therapy using monoclonal antibody and Hsp90 inhibitor in colorectal and pancreatic cancers. Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kansas, April 2008.
- 83 Chemical biology and microRNA to overcome drug resistance. Department of Pharmacology, The Ohio State University, February 2008.
- 84 Transporter, bioavailability prediction and BCS. BA/BE, BCS, and IVIVC symposium, Johnson & Johnson Pharmaceutical Research Development, New Jersey, October 2007.
- 85 Predict Oral Bioavailability in Human: Forming an Interface between Preclinical Data and Clinical Outcome. Pfizer Co. La Jolla, San Diego, CA, May 2007.
- 86 Pharmaceutical industry job application. The Society for Biological Engineering at OSU. Department of Chemical Engineering, College of Engineering, The Ohio State University, May 2007.
- 87 Tumor detection and targeted drug therapy using Hsp90 inhibitors in colorectal and pancreatic cancer. College of Pharmacy, University of Michigan, April 2007.
- 88 Tumor imaging and chemical biology in drug resistance. College of Biomedical Engineering, The Ohio State University. January 2007.
- 89 Cancer detection and targeted drug therapy. Biochemistry and Molecular Biology, The College of Wooster, Ohio. November 2006.
- 90 New strategies for anticancer drug development, College of Pharmacy, Shandong University, Jinan, China, August 2006.
- 91 Integrated system for tumor detection and targeted drug therapy for colorectal cancer. School of Pharmacy, Rutgers University, New Jersey, April 2006.
- 92 Integrated system for both tumor detection and targeted drug therapy of colorectal and pancreatic cancer. Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, 2006.
- 93 Prodrug design and targeted drug delivery. Department of Biochemistry and Chemistry, Ohio State University, 2005.
- 94 Nutrient transporter and Cancer development. Division of Pharmacology, College of

- Pharmacy, OSU. November 2004.
- 95 Drug transporter and drug development. Advances in biopharmaceutics and drug delivery. University of Michigan. June 2004.
 - 96 Drug transporter and drug absorption screening. Third 3rd annual Workshop on "Screening of Oral Drug Absorption" Kobe, Japan. December 2004.
 - 97 Transporter and targeted drug delivery. Faculty of Pharmaceutical Sciences, Setsunan University, Japan. December 2004
 - 98 Glucose transporters in cancer biology and targeted drug delivery. Department of Pathology, The Ohio State University, Columbus, HO 43210. February 2004.
 - 99 Glucose transporters and glycolysis enzymes in PET scan for cancer detection. Kettering Medical Center, Department of Medicine, Wright State University, Kettering, OH 45429. March 2004.
 - 100 In vivo/in vitro intestinal drug permeability correlation and implication of intestinal transporter expression by GeneChip analysis. The Cambridge Healthtech Institute's Fourth Annual Smarter Lead Optimization. Wyndham Franklin Plaza, Philadelphia, PA, USA. May 6-8, 2002.
 - 101 Pharmacy, Biopharmaceutics, Pharmacology, and Pharmacogenomics: From past to future. Biopharmaceutics and Genechip technology. Chinese Association of Pharmacy in Shanghai. Shanghai, China. September 2001.